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2. Abstract 
The OSTL gene is localized at the band q23 in the chromosome 6. Its localization corresponds 
to a translocation breakpoint between chromosomes 6 and 12, the t(6;12)(q23;p13), that was 
characterized in our group in an acute lymphoblastic leukemia cell line. This translocation 
involves the ETV6 (translocation ETs leukemia) gene localized in chromosome 12 with the 
STL (six twelve leukemia gene) gene localized in chromosome 6. The STL gene shares the 
first exon with a novel gene, that we named OSTL (opposite STL), but they are transcribed in 
opposite directions. Since the fusion gene ETV6/STL encodes only for a very small protein 
which lacks any known functional domain, we speculate that the main leukemogenic effect of 
this translocation is the deregulation of OSTL. OSTL has a RING-Finger motif that is highly 
conserved between species and has a significant homology with other genes in human as well 
as C. elegans, D. melanogaster, and S. cerevisiae. OSTL showed a very specific expression 
pattern during the mouse embryogenesis. The aim of this project was the functional 
characterization of OSTL, with special emphasis in normal hematopoiesis and 
leukemogenesis. Therefore we have sequenced the whole human and mouse OSTL cDNA by 
using OSTL cDNA clones from the RZPD (“Resource Zentrum Primäre Datenbank”) in 
Berlin. These sequences encode for a 307 (mouse) and a 275 (human) amino acids length 
protein. The protein length differences between human and mouse are explained because of 
the existence of alternative spliced exons. The homology between human and mouse sequence 
is 99% at the protein level. 
The expression of GFP-OSTL fusion protein in mouse fibroblast cell line enable us to observe 
the subcellular localization of OSTL protein. GFP-OSTL is localized mainly in the cytoplasm, 
showing small spots, probably in the mitochondrial region. In a mouse multiple tissue 
Northern blot, we could show that OSTL is expressed in testis, ovary and liver. In an human 
multiple tissue Northern, OSTL expression was observed in skeletal muscle, testis, ovary, 
heart, placenta, pancreas and prostate. Northern blotting with different human cell lines 
revealed expression of OSTL in three EBV (Epstein Barr Virus) transformed lymphoblastoid 
cell lines (LCL B, LCL D, and LCL R) and in one NHL (Non-Hodgkin Lymphoma) cell line 
(Karpas 422). In Reverse Transcriptase PCR experiments using B cell in different maturation 
stages, the expression of OSTL was observed in naive, memory B and plasma cells, and in 
leukemic patient samples, expression was observed in several AML and ALL cDNAs. 
Whole mount in situ hybridization experiments were performed to investigate the temporo-
spatial expression pattern of OSTL during mouse embryogenesis. There was distinct 
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expression of Ostl in the somites (myotome), first and second branchial arches, optic and otic 
vesicles, in the hair follicles of the vibrissae, and limb buds in mouse embryos of embryonal 
days 9.5 to 14.5. This expression pattern suggests an important role for Ostl in the early 
development of these structures. 
Aiming to find protein interaction partners of OSTL, we performed a Yeast Two Hybrid assay 
using a Hela cDNA library. Among others we found interaction of OSTL with the 
antiapoptotic protein, HAX-1 (HS1-associated protein X-1), that is involved in the regulation 
of B-cell signal transduction, and interaction with the pro-apoptotic protein, SIVA. SIVA was 
originally identified as an interaction partner of CD27 (TNFRSF7), a member of the TNF-
receptor superfamily, which is expressed in B cells. These interactions were confirmed by in 
vitro (cotransformation in yeast, CoIP) and in vivo (colocalization of these proteins in 
mammalian cells and CoIP) assays. 
Overexpression of Ostl in primary mouse hematopoietic cells followed by injection of the 
cells into lethally irradiated mice resulted in a T-Acute-Lymphoblastic-Leukemia (T-ALL) 
phenotype. 
In summary, our experiments could demonstrate that OSTL is important in B cell 
development and signaling and deregulation of this gene can contribute to the development of 
hematologic malignancies. 
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3. Zusammenfassung 
Das OSTL-Gen ist auf der Bande q23 von Chromosom 6 lokalisiert. Es liegt in unmittelbarer 
Nähe eines Translokationsbruchpunkts zwischen Chromosom 6 und Chromosom 12 
(t(6;12)(q23;p13)), der in unserer Arbeitsgruppe in einer akuten lymphoblastischen Leukämie 
Zellinie kloniert wurde. Bei dieser Translokation kommt es zu einer Fusion des ETV6-Gens 
von Chromosom 12 mit dem STL-Gen auf Chromosom 6. Das erste Exon von STL wird 
jedoch in entgegengesetzter Richtung von einem zweiten Gen abgelesen, welches wir OSTL 
nannten (OSTL = Opposite STL). Es ist nicht klar, ob das ETV6-STL Fusionsprotein eine 
Rolle bei der Leukämieentstehung spielt, da es nur für ein sehr kleines Protein codiert, das 
keine bekannten funktionellen Domänen aufweist. Wir vermuten daher, dass die Regulation 
von OSTL durch die Translokation gestört wird und dass dies hauptsächlich zur 
Leukämieentstehung beiträgt. OSTL hat ein charakteristisches RING-Finger Motif, das 
evolutionär hochkonserviert ist und signifikante Homologien zu anderen Genen des 
Menschen sowie von C. elegans, D. melanogaster und S. cerevisiae aufweist. OSTL hat ein 
zeitlich und räumlich sehr definiertes Expressionsmuster während der murinen 
Embryogenese. Es war das Ziel dieses Projektes, die Funktion von OSTL insbesondere im 
Hinblick auf die normale Hämatopoese und bei der Leukämieentstehung zu charakterisieren. 
An Hand von OSTL cDNA Klonen, die über das Ressourcen Zentrum Primäre Datenbank 
(RZPD) in Berlin bezogen wurden, konnten wir sowohl die Sequenz des menschlichen als 
auch des murinen OSTL-Gens ermittelt. Diese Sequenzen codieren ein 307 (Maus) bzw. 275 
(Mensch) Aminosäuren langes Protein. Der Unterschied in der Proteinlänge zwischen Mensch 
und Maus ist durch die Zusammensetzung aus alternativ gespleißten Exonen bedingt. Das 
murine und das menschlichen OSTL Protein weisen eine erstaunlich hohe Homologie von 
99% auf. 
Durch Expression eines GFP-OSTL Fusionsproteins in Mausfibroblastenzellen konnten erste 
Hinweise auf die subzelluläre Verteilung des OSTL-Proteins gewonnen werden. Es zeigte 
sich eine deutliche Aussparung des Kerns und eine Lokalisation des GFP-OSTL 
Fusionsproteins in diskreten kleinen Flecken im Zytoplasma, wahrscheinlich in den 
Mitochondrien. Expressionsanalysen mit Hilfe von Multiple Tissue Northern Blots zeigten, 
dass die verwendete OSTL-Sonde Transkripte unterschiedlicher Größe detektiert, bei der 
Maus in Testis, Ovar und Leber und beim Menschen in Muskeln, Testis, Ovar, Herz, 
Plazenta, Pankreas, und Prostata. Die Untersuchung der Expression in humanen Zell-Linien 
zeigte, dass sich mit der OSTL-Sonde bei drei Epstein Barr Virus-transformierten 
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lymphoblastoiden Zellinien (LCL B, LCL D und LCL R) und bei einer NHL Zell Linie 
(Karpas 422) Transkripte nachweisen lassen. Mithilfe von RT-PCR konnte gezeit werden, 
dass OSTL während unterschiedlicher Entwicklungsstadien von B-Lymphozyten (naive, 
memory B, and plasma Zellen) und außerdem bei Leukämie-Patienten (AML und ALL) 
exprimiert wird. 
Zur Analyse der räumlichen und zeitlichen Expression von OSTL während der 
Embryonalentwicklung der Maus wurden Embryonen der Entwicklungstage E9.5 bis 14.5 
mittels Whole Mount in situ Hybridisierung untersucht. Es zeigte sich eine spezifische 
Expression von OSTL unter anderem in den Somiten (wahrscheinlich im Myotom), an der 
hinteren Öffnung des Neuralrohrs, in den Extremitätenknospen, in den Kieferbögen, in den 
Ohr- und Augenanlagen, in den Anlagen der Schnurrbarthaare und in den Extremitäten 
(Hand- und Fußwurzeln) in Mausembryonen der Stadien 9.5 bis 14.5. Diese vorläufigen 
Ergebnisse zeigen ein sehr spezifisches Expressionsmuster von OSTL in der 
Embryonalentwicklung der Maus, was eine Rolle dieses Gens bei der frühen Entwicklung und 
Differenzierung bestimmter Gewebe und Strukturen (z.B. der Muskeln) nahe legt. 
Um Proteininteraktoren von OSTL zu identifizieren, wurde eine Hela cDNA Bank mittels 
Yeast Two Hybrid Screen durchsucht. Dabei fanden wir eine Interaktion von OSTL mit den 
Proteinen HAX1 (HS1-associated protein X-1), welches in der Signaltransduktion des B-
Zellrezeptors eine Rolle spielt, und mit dem pro-apoptotischen Protein SIVA. SIVA wurde als 
Interaktionspartner von CD27 (TNFRSF7), einem Mitglied der TNF-Rezeptoren 
Superfamilie, der auf B-Zellen exprimiert wird. Diese Interaktionen wurden mit Hilfe von in 
vitro (Kotransformation in Hefe, CoIP nach) und in vivo (Kolokalization in Säugetierzellen, 
CoIP) Methoden bestätigt. 
Durch Überexpression von OSTL in primären murinen Knochenmarkzellen, die in Mäuse 
transplantiert wurden, konnten wir eine T-ALL auslösen. 
Zusammengefasst zeigen unsere Experimente, dass OSTL eine wichtige Rolle bei der B-
Zellentwicklung spielt sowie dass eine deregulierte Expression von OSTL bösartige 
hämatologische Krankheiten verursachen kann. 
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4. Introduction 
4.1. Hematopoiesis and hematopoietic stem cells 
4.1.1. Yolk-sac hematopoiesis: the first blood cell of mouse and man 
The yolk sac is the first site of blood-cell production during murine and human ontogeny. In 
the adult, hematopoiesis is in a steady state as all blood cells are synthesized from multipotent 
precursor cells produced by hematopoietic stem cells in the bone marrow. In the fetus, the 
liver serves as the principal hematopoietic organ. However, the early mammalian embryo 
requires red cells for growth and survival prior to the development of the liver. Large 
primitive red cells are produced in blood islands of the yolk sac after implantation of the 
embryo (Palis & Yoder, 2001). Figure 4.1 illustrates the development of yolk sac islands in 
the mouse embryo. 
 
 
 
Figure 4.1: Development of yolk sac blood islands in the mouse embryo between E7.5 and E9.5. 
Yolk sac blood islands form between the single cell layer of endoderm cells (E) and mesothelial cells 
(open arrow). Blood islands develop from undifferentiated mesoderm cells (E7.5, closed arrow) that 
give rise to inner blood cells surrounded by an outer endothelial lining (E9.5, closed arrow) (figure 
from Palis, and Yoder, 2001). 
 
4.1.2. Ontogenic emergence of the hematopoietic stem cell (HSC) 
The developing tissues are supplied with oxygen and nutrients through the first hematopoietic 
cells that arise from extra-embryonic yolk sac, and circulate in the embryo. The primitive 
hematopoiesis, as the embryo develops is substituted by the definitive multilineage blood 
system. Pluripotent hematopoietic stem cells (HSC) sustained this definitive hematopoiesis 
and have the capacity of self-renewal, and are capable of long-term repopulation in 
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myeloablative recipients. The HSCs, in mouse embryos, appears beginning at mid-E10, in the 
yolk sac at E11, and at late-E11 in liver (Bonnet, 2003). In the zebrafish (Detrich, 1995) and 
frog (Turpen, 1997), both the ventral and dorsal mesoderm contribute to the initiation and 
perpetuation of hematopoiesis (Weissman, 2000). The human embryonic development 
significantly parallels mouse development, as shown schematically in figure 4.2 (Bonnet, 
2003). 
 
 
 
Figure 4.2: A and B Ontogenic emergence of the hematopoietic system in mouse and human. 
 
4.1.3. Hematopoiesis 
The human body produces, every day, billions of new white blood cells, red blood cells, and 
platelets to replace blood cells lost to normal cell turnover processes as well as to illness or 
trauma. A variety of homeostatic mechanisms allow blood cell production to respond quickly 
to stresses such as bleeding or infection and then return to normal levels when the stress is 
resolved. Hematopoiesis is the process of blood production and homeostasis. Alterations in 
the normal hematopoiesis can lead to several hematologic malignancies and other disorders 
such as leukemia, aplastic anemia, lymphoma, myelodysplasia, myeloproliferative disorders, 
and inborn errors of metabolism (Smith, 2003). 
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The complete number of mature blood cells in the body is derived from a relatively small 
number of hematopoietic stem cells and progenitors (Weissman, 2000; Lemischka, 2001). 
Murine models, particularly short- and long-term transplant studies, have provided a number 
of insights into the biology of HSCs and progenitors (Eaves, 1997; Jones, 1996). The results 
of these studies have demonstrated that HSCs are able to generate every lineage found in the 
hematopoietic system including red blood cells, platelets, and a variety of lymphoid and 
myeloid cells (Weissman, 2000; Lemischka, 2001; Eaves, 1997; Jones, 1996). Some of the 
most important lymphoid cells include natural killer (NK) cells, T cells, and B cells, while 
important myeloid cells include granulocytes, monocytes, macrophages, microglial cells, and 
dendritic cells (Akashi, 1999). Each of these cell types can be generated from a single HSC, 
and each HSC has an enormous capacity to generate large numbers of these cells over many 
years and perhaps even decades. In the mouse, a single HSC can reconstitute the entire 
hematopoietic system for the natural lifespan of the animal (Osawa, 1996). Murine HSCs are 
rare and are present at a frequency of 1/10.000 to 1/1.000.000 cells in the bone marrow 
depending on the species, age, and technical aspects of the model. 
While HSCs are primarily found in the bone marrow, they are present in a variety of other 
tissues including peripheral blood and umbilical cord blood, and are found at low numbers in 
the liver, spleen, and perhaps many other organs (Holyoake, 1999). 
These HSCs may have somewhat different properties, but they all have the ability to generate 
all the different blood lineages in large numbers for a prolonged period of time. 
HSCs generate the multiple hematopoietic lineages through a successive series of 
intermediate progenitors. These include common lymphoid progenitors (CLPs), which can 
generate only B, T, and NK cells, and common myeloid progenitors (CMPs), which can 
generate only red cells, platelets, granulocytes, and monocytes (Akashi, 2000; Kondo, 1997). 
Downstream of the CLPs and CMPs are more mature progenitors that are further restricted in 
the number and type of lineages that they can generate (Akashi, 2000). Ultimately, terminally 
differentiated cells are produced that cannot divide and undergo apoptosis after a period of 
time ranging from hours (for neutrophils) to decades (for some lymphocytes). When a bone 
marrow or blood stem cell transplant is performed, it appears that progenitors contribute to 
engraftment for only a short period of time, while long-term blood production is derived 
primarily from HSCs (Jordan, 1990). Figure 4.3 (Smith, 2003) shows a summary of the blood 
development process. 
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Figure 4.3: Process of blood development. ECM = extra-cellular matrix. 
 
4.1.4. B cell development and signalling 
The development of B lymphocytes from hematopoietic stem cells can be divided into distinct 
stages on the basis of the cytokine expression or loss of cell surface or intracellular proteins 
and of the rearrangement of the immunoglobulin (Ig) genes (Rolink, 1999; Hardy, 2000).  
The loss of long-term self-renewal capacity by the HSCs is accompanied by expression of the 
tyrosine kinase receptor Flt3 (also known as Flk2) in multipotent progenitors (MPP) cells 
(Adolfsson, 2001; Christensen, 2001). 
The Flt3+ MPPs subsequently differentiate to the earliest lymphocyte progenitors (ELP), 
which initiate RAG1 and RAG2 expression and start to undergo DH-JH rearrangements at the 
immunoglobulin heavy-chain (IgH) locus (Igarashi, 2002; Jumaa, 2005) (Figure 4.4 A). The 
ELP cell is likely to give rise to the recently identified early T-lineage progenitor (ETP) in the 
thymus (Allman, 2003) and to the CLP in the bone marrow, which is able to develop into four 
distinct cell types: B, T, NK, and DC cells (Kondo, 1997; Traver, 2003) (Figure 4.4 A). 
Subsequent expression of the B cell marker B220 coincides with differentiation to CLP-2 
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cells (Gounari, 2002; Martin, 2003), constituting a subset fraction A cells (Li, 1996; Tudor, 
2000) that enter the B cell pathway upon induction of CD19 expression and complete DH-JH 
rearrangements at the early pro-B cell stage (fraction B, figure 4.4 A) (Gounari, 2002; Hardy, 
1991; Li, 1993). Productive VH-DJH recombination in late pro-B cells (fraction C) results in 
cell surface expression of the Igµ proteins as part of the pre-B cell receptor (pre-BCR), which 
acts as a important checkpoint to control the transition from the pro-B to the pre-B cell stage. 
Signaling from the pre-BCR promotes allelic exclusion at the IgH locus, stimulates 
proliferative cell expansion, and induces differentiation to small pre-B cells, which start to 
recombine immunoglobulin light-chain genes (Meffre, 2000; Jumaa, 2005) (figure 4.4 B). 
Successful light-chain gene rearrangement leads to the emergence of immature IgM+ B cells 
that emigrate from the bone marrow to peripheral lymphoid organs (Meffre, 2000). 
Signaling via different transmembrane receptors is essential for guiding the differentiation of 
HSCs along the B cell pathway. Activation of the tyrosine kinase receptor c-Kit by its ligand 
SCF (stem cell factor) promotes the survival of long-term reconstituting HSCs in vitro 
(Adolfsson, 2001; Domen, 2000), although the absence of c-Kit does not affect the survival 
and engraftment of HSCs in vivo in a viable c-kitW/W (Vickid) mouse strain (Waskow, 2002). 
Similarly, signaling through the Flt3 receptor is required for efficient formation of the CLP 
and subsequent development of pro-B and pre-B cells, as these cell types are strongly reduced 
in the absence of the Flt3 ligand (FL) in the bone marrow of FL-/- mouse (Mckenna, 2000; 
Sitnicka, 2002). In contrast, normal numbers of the CLP are generated in γc-/- mice lacking 
functional IL-7 receptor, which is composed of the IL-7Rα protein and the signalling γc chain 
(Miller, 2002). Consistent with this early developmental block, the lymphoid cytokine IL-7 
not only signals pro-B cell survival, but also functions as a differentiation factor to induce B 
cell development of the CLP (Miller, 2002). Hence, the c-Kit, Flt3, and IL-7 signaling 
systems together account for the generation of all B-lymphocytes in the bone marrow of adult 
mice. 
In addition to cytokine signaling, a multitude of lineage-restricted transcription factors control 
B cell development from the HSC to immunoglobulin-secreting plasma cells (Schebesta, 
2002). 
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Figure 4.4: A and B) A scheme of B cell development. A) The expression of signaling receptors, the 
rearrangement status of immunoglobulin genes and the initiation of expression of characteristic cell 
surface proteins are indicated for successive progenitor cell stages of mouse B-lymphopoiesis (adapted 
from Busslinger, 2004). B) Productive rearrangement of the heavy chain (HC) gene locus in pro-B 
cells results in pre-BCR expression on pre-B cells. Productive rearrangement of one of the LC gene 
loci in small pre-B cells leads to BCR expression on immature B cells. Inactivation of the indicated 
genes results in specific maturation arrests during B cell development. GL = germline configuration of 
the Ig genes (adapted from Jumaa, 2005). 
 
4.1.5. Self-renewal of hematopoietic stem cells and leukemogenesis 
In the hematopoietic system, stem cells are heterogeneous with respect to their ability to self-
renew. Multipotent progenitors constitute 0.05% of mouse bone-marrow cells, and can be 
divided into three different populations: long-term self-renewing HSCs, short-term self-
renewing HSCs, and multipotent progenitors without detectable self-renewal potential 
Introduction 
 
15 
(Morrison, 1994; Morrison, 1997). These populations form a lineage in which the long-term 
HSCs give rise to short-term HSCs, which in turn give rise to multipotent progenitors 
(Morrison, 1997). As HSCs mature from the long-term self-renewing pool to multipotent 
progenitors, they progressively lose their potential to self-renew but become mitotically 
active. Whereas long-term HSCs give rise to mature hematopoietic cells for the lifetime of the 
mouse, short-term HSCs and multipotent progenitors reconstitute lethally irradiated mice for 
less than eight weeks. 
Because normal stem cells and cancer cells share the ability to self-renew, it seems reasonable 
to propose that newly arising cancer cells appropriate the machinery for self-renewing that is 
normally expressed in stem cells. Many pathways that are classically associated with cancer 
may also regulate normal stem cell development. For example the prevention of apoptosis by 
enforced expression of the oncogene bcl-2 results in increased numbers of HSC in vivo 
suggesting that cell death has a role in regulating the homeostasis of HSCs (Domen, 1998; 
Domen, 2000). 
Other signaling pathways associated with oncogenesis, such as the Notch, Sonic hedgehog 
(Shh) and Wnt signalling pathways, may also regulate stem cell self-renewal (Taipale, 2001) 
(Figure 4.5, adapted from Reya, 2001). 
If the signaling pathways that normally regulate stem cell self-renewal lead to tumorigenesis 
when dysregulated then are stem cells themselves the target of transformation in certain types 
of cancer (Sell, 1994; Sawyers, 1991). There are two reasons to think that this hypothesize 
may be correct: first, because stem cells have the machinery for self-renewal already 
activated, maintaining this activation may be simpler than turning it on de novo in a more 
differentiated cell; that is, fewer mutations may be required to maintain self-renewal than to 
activate it ectopically. Second, by self-renewing, stem cells often persist for long periods of 
time, instead of dying after short periods of time like many mature cells in highly proliferative 
tissues. This means that there is a much greater opportunity for mutations to accumulate in 
individual stem cells than in most mature cell types. Though the molecular mechanisms of 
stem cell self-renewal are poorly understood, several genes and gene families have been 
implicated in the process including the Hox (Buske, 2002; Antonchuk, 2001) and Wnt gene 
families (Reya, 2003). 
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Figure 4.5: Signalling pathways that regulates self-renewal mechanisms during normal stem cell 
development and during transformation. Wnt, Shh and Notch pathways have been shown to 
contribute to the self-renewal of stem cells and/or progenitors in a variety of organs, including the 
hematopoietic and nervous systems. When dysregulated, these pathways can contribute to 
oncogenesis. Mutations of these pathways have been associated with a number of human tumors, 
including colon carcinoma and epidermal tumors (Wnt), medulloblastoma and basal cell carcinoma 
(Shh), and T-cell leukemias (Notch). Though the molecular mechanisms of stem cell self-renewal are 
poorly understood, several genes and gene families have been implicated in the process including the 
Hox and Wnt gene families (adapted from Reya, 2001). 
 
4.2. Chromosomal translocations 
Recurring chromosomal abnormalities have been identified in a variety of cancers, but are 
most frequently associated with leukemias, lymphomas and sarcomas (Rabbitts, 1994; 
Rowley, 1999). At present, more than 500 recurring cytogenetic abnormalities have been 
reported in hematological malignancies. Three main cytogenetic changes have been detected 
in hematological malignancies: deletions, inversions and translocations. 
On the molecular level, there are two major mechanisms by which chromosomal 
translocations lead to malignant cell transformation: chromosomal breaks may occur within 
genes (usually within introns) and, if the reading frame is preserved, generate chimeric fusion 
genes with properties differing from those of the original ones or a chromosomal break may 
also occur near a cellular proto-oncogene that is then dysregulated in its pattern of expression 
(Rabbitts, 1994) (Figure 4.6 adapted from Burmeister, 2001). 
 
Introduction 
 
17 
 
 
Figure 4.6: Two major mechanisms by which chromosomal translocations can lead to oncogenic 
transformation. a) If the chromosomal breaks occur within introns of two genes and if the reading 
frame is preserved, two new chimeric genes result from the translocation. One of them may act as an 
oncogene. b) If a strong promoter or enhancer element is translocated near a proto-oncogene, this may 
consecutively be activated. 
 
4.2.1. Generation of fusion genes by chromosomal translocations 
The first identified chromosomal translocation generating a fusion gene was the fusion of the 
BCR (22q11) and c-ABL genes (9q34) on the Philadelphia chromosome (Novell, 1960; 
Bartram, 1983; de Klein, 1986). This fusion creates a tumor-specific marker and the 
functional consequence of the BCR-ABL fusion is constitutively active tyrosine kinase 
activity of ABL. The studies of the BCR-ABL fusion have paved the way for many more 
descriptions of fusion proteins, often involving transcription factors. 
There are at least seven different chromosomal translocations associated with 
myeloproliferative disease. These include the BCR/ABL, ETV6/ABL, ETV6/PDGFRB, 
HIP1/PDGFRB, H4/PDGFRB, RAB5E/PDGFRB, and ETV6/JAK2 fusions (Table 4.1 adapted 
from Dash, 2001). 
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Table 4.1: Chromosomal translocations involving tyrosine kinases 
Translocation Genes Major structures Disease 
t(9;22)(q34;q11) ABL1 BCR 
TK 
GRB2/SOS binding CML,ALL 
t(8;13)(p11;q12) FGFR1 ZNF198/FIM/RAMP 
TK 
Cysteine rich MYM MPD 
t(6;8)(q27;p11) FOP FGFR1 
Leucine rich 
TK MPD 
t(8;9)(p12;q33) FGFR1 CEP110 
TK 
LZ MPD 
t(5;7)(q33;q11.2) PDGFRB HIP1 
TK 
Huntingtin interaction CMML 
t(5;14)(q33;q32) PDGFRB CEV14 
TK 
LZ AML 
t(5;10)(q33;q21) PDGFRB H4/D10S170 
TK 
LZ MPD 
MPD = myeloproliferative disease 
 
Besides tyrosine kinases, transcription factors also play a crucial role in the development and 
maturation of blood cells. A coordinated action and timely expression of a whole set of 
transcription factors is necessary to insure the correct maturation of a progenitor cell into a 
fully functional cell of myeloid or lymphatic lineage. Inactivation of one transcription factor 
or alteration of its function or time-dependent expression pattern by a chromosomal break 
causing truncation and fusion with another gene may arrest the cell at a certain stage of 
differentiation. This immature differentiation-arrested cell may then undergo further genetic 
changes that ultimately result in malignant transformation and clonal outgrowth (Burmeister, 
2001). 
Approximately 20% of all cases of acute leukemia have chromosomal translocations 
involving the genes of the core-binding factor (CBF) family of transcription factor. 
Two members of the family are involved in human leukemias, CBFα2 (also known as 
AML1) and CBFβ. AML1 is disrupted by the t(8;21)(q22;q22) in approximately 20% of 
AML-M2 cases, where its N-terminal part is fused to a gene known as ETO (“eight twenty-
one”). In childhood but not adult ALL, the most frequent translocation (in some 20% of 
cases) is the cytogenetically invisible t(12;21)(p13;q22), leading to the fusion of the C-
terminal part of AML1 with a protein called ETV6 (Ets variant translocation 6; previously 
called TEL = “translocation ETS leukemia”; ETS: a family of transcription factors) (Golub, 
1995; Shurtleff, 1995). 
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Both translocations are associated with a remarkably favorable prognosis. Less frequently 
AML1 can also be found as a fusion partner with genes on 3q26 (EAP, MDS1, EVI1) in CML 
or myelodysplastic syndromes (Secker-Walker, 1995). 
Approximately 5-10% of all clonal translocations found in acute leukemias involve the MLL 
gene on 11q23. MLL (for “mixed lineage leukemia”) rearrangements have been 
indiscriminately found in myeloid, lymphatic, and biphenotypic leukemias, or as HTRX/HRX 
(due to its sequence homology to the Drosophila thithorax protein). There are more than 45 
different partner genes leading to a wide variety of different fusion proteins that have been 
described in leukemias (Waring, 1997). 
MLL rearrangements are particularly characteristic for infant ALL and therapy-related AML, 
where they can be found in 60-80% of cases (Hilden, 1997). The prognosis is usually poor in 
infants and therapy-related cases but has significantly improved in adults under intensified 
therapy regimens (Ludwig, 1998). 
It is also known that most cases of AML-M3 are cytogenetically characterized by a balanced 
translocation, t(15;17)(q22-24;q12-21). This chromosomal translocation disrupts two genes, 
the gene coding for the retinoic acid receptor α subunit on chromosome 17 and the PML (for 
promyelocytic leukemia) on chromosome 15 (Borrow, 1990; de The, 1990; Lemons, 1990). 
Two fusion genes result from the translocation, PML/RARα on chromosome 17 (expressed in 
nearly all cases) and RARα/PML on chromosome 15 (expressed in 80% of cases). 
PML/RARα is believed to mediate leukemogenesis, because it is not only expressed in nearly 
all cases but also retains the potentially important functional domains of both PML and 
RARα. The crucial event seems to be disruption of the RARα.  
 
4.2.2. Dysregulation of a proto-oncogene due to a nearby chromosomal break 
The term “proto-oncogene” refers to genes which play an important role in cell physiology, 
cell differentiation, regulation of cell growth, signaling cascades and others. If such a proto-
oncogene is altered by genetic changes such as point mutations or deletions or becomes 
dysregulated in its expression, it can convert into a real “oncogene” (a gene that promotes 
malignant growth or transformation). 
Many proto-oncogenes have first been detected in rapidly transforming animal retroviruses, 
where they were accidentally incorporated into the virus genome. The first example is ABL 
(from Adelson murine leukemia virus), second MYC (from avian myelocytomatosis), and 
third ERB (from murine erythroblastosis virus) (Burmeister, 2001).  
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The proto-oncogenes may be activated by a chromosomal break that relocates them near a 
strong enhancer element (Figure 4.6). 
A very common mechanism of proto-oncogene activation in human leukemias is translocation 
of a proto-oncogene to gene loci of the immunoglobulin (Ig) or T-cell receptor (TCR) family 
(Burmeister, 2001). T-cell acute leukemias (T-ALL) have a number of different recurring 
translocations, most involve putative transcription factors that are involved in differentiation 
and are not normally expressed in T cells. 
The HOX11 gene, located on chromosome 10, band q24, which is activated by translocation 
t(10;14)(q24;q11) and t(7;10)(q35;q24) in T-ALL is an example (Dube, 1991; Hatano, 1991; 
Kennedy, 1991; Lu, 1991). This gene encodes a homeodomain protein that can bind DNA and 
transactivate transcription (Dear, 1993). 
The TAL1/SCL gene, contains a b-HLH motif, is either involved in the t(1;14) or in up to 25% 
of childhood T-ALL cases (Baer, 1993). The chromosomal translocation probably causes 
ectopic TAL1 production, activating a specific set of target genes which are normally silent in 
T cells.  
Other T-ALL-associated protein activated by chromosomal translocation is the RBTN/Ttg 
proteins (Sanchez-Garcia, 1993). These are produced after translocations t(11;14)(p13;q11) or 
t(11;14)(p15;q11) and encodes proteins with a LIM motif (Boehm, 1990).  
The failure of certain fusion genes to induce leukemia on their own, in animal models, as well 
as the fact that more than 50% of acute myeloid leukemias do not have apparent cytogenetic 
abnormalities, point to the role of point mutations in or, alternatively, the aberrant expression 
of proto-oncogenes in the development of leukemia. These observations also suggest that the 
aberrant expression of proto-oncogenes might be more common than is generally believed. 
The sheer number of ETV6 fusions in AML allows for the study of a diverse group of 
leukemias in which more than one of the aforementioned mechanisms might be operating. 
The t(6;12) translocation is one of several that involve ETV6, in this case ETV6 is fused to 
STL gene in a B-cell ALL cell line. 
 
4.3. ETV6 
ETV6 is a member of the ets (E-26 transforming specific) family of transcription factors. All 
ets family proteins share a highly conserved protein domain of about 88 amino acids in length 
the so-called ets domain. The ets domain is a sequence specific DNA binding domain but is 
also mediates protein-protein interaction (Figure 4.7, modified from Slupsky, 1998), it is 
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evolutionarily highly conserved and found in invertebrates such as Drosophila and C. elegans 
(Oikawa, 2003; Wasylyk, 1993). 
The other evolutionarily conserved domain in the 652 amino acids of ETV6 is the N-
terminally located pointed or sterile alpha motif (SAM) domain (Figure 4.7). This domain is 
also called HLH domain and is even more highly conserved in evolution and found in many 
ets family member. It is found in yeast proteins and has been shown to be involved in homo 
and heterodimerization in transcription factors and in signal transducing proteins (e.g. of the 
MAPK pathway) (Grimshaw, 2004). ETV6 contains two alternative translational start codons 
(position 1 and position 43) leading to the expression of two isoforms of ETV6. 
 
 
 
Figure 4.7: ETV6 protein structure. The pointed domain is represented between Nt 38 and Nt 123; 
ETS domain is between Nt 338 and Nt 422 (modified from Slupsky, 1998). 
 
4.3.1. Role of ETV6 in hematopoiesis 
ETV6 is widely expressed throughout embryonic development and in the adult. Embryos with 
a conventional knockout (KO) of the Etv6 gene die by day 11 of embryonic development 
(E11) due to vascular abnormalities. Blood formation in the embryo is largely unperturbed 
(Wang, 1997). Yet, studies using chimeric mice from Etv6-deficient embryonic stem (ES) 
cells suggested a requirement of Etv6 in bone marrow hematopoiesis. Inducible and lineage-
specific gene disruption of Etv6 in adult hematopoiesis in mice suggests that it plays two 
important roles in hematopoietic differentiation. First, Etv6 controls the survival of HSCs so 
that its disruption indirectly affects the majority of all hematopoietic cells which have limited 
clonal life spans and eventually will extinguish without constant regeneration from HSCs. 
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Secondly, Etv6 is required late in the development of the megakaryocyte lineage, where it 
presumably acts in concert with transcriptional regulators previously implicated in 
megakaryopoiesis (Hock, 2004). 
 
4.3.2. ETV6 fusion partners 
Translocations involving the ETV6 gene contribute to leukemogenesis through at least 3 
different mechanisms. One mechanism is the activation of kinases. The second mechanism is 
the loss of function of critical transcription factors and/or the formation of aberrant 
transcription factors and the third mechanism is the induction of ectopic and aberrant 
expression of the proto-oncogene by the chromosomal translocation. Figure 4.8 shows the 
different breakpoints in the ETV6 gene with regard to the different fusion partners. 
 
 
 
Figure 4.8: Diagram of ETV6 with protein domain and breakpoints (indicated by arrows) representing 
different partner genes of ETV6 (indicated in closed boxes) (adapted from Bohlander, 2005). 
 
4.3.3. Protein tyrosine kinase fusion partners of ETV6 
The first identified fusion partner of ETV6 was a protein tyrosine kinase (PTK), the platelet-
derived growth factors receptor beta (PDGFRB) (Golub, 1994a). The fusion protein critical 
for the development of the chronic myelomonocytic leukemia is the ETV6/PDGFRB fusion, 
and not the reciprocal PDGFRB/ETV6 fusion. In the ETV6/PDGFRB fusion protein the N 
terminal portion of ETV6, which includes the pointed domain, is fused to the C-terminal two 
thirds of the PDGFRB protein, conserving the tyrosine kinase domain of PDGFRB. The 
fusion of the pointed domain of ETV6 in the N-terminal half with the tyrosine kinase domain 
in the C-terminal half of the fusion partner is characteristic of the class of ETV6/PTK fusions 
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and is found in the fusions of ETV6 with ABL1, ABL2, JAK2, NTRK3, FGFR3 and SYK 
(Table 4.2 adapted from Bohlander, 2005) (Papadopoulos, 1995; Cazzaniga, 1999; Kuno, 
2001). 
 
Table 4.2: Protein tyrosine kinase fusion partner of ETV6 
Fusion partner Translocation Breakpoint in  
ETV6 
Disease 
PDGFRB t(5;12)(q31;p13) Intron 4 CMMoL 
ABL1 t(9;12)(q34;p13) Introns 4 and 5 AML, ALL 
ABL2 t(1;12)(q25;p13) Intron 5 AML-M3, -M4, T-ALL 
JAK2 t(9;12)(p24;p13) Intron 4 or 5 Pre-B cell ALL, T-ALL 
NTRK3 t(12;15)(p13;q25) Intron 4 or 5 Congenital fibrosarcoma, 
mesoblastic nephroma,  
Secretory breast carcinoma, 
AML 
FGFR3 t(4;12)(p16;p13) Intron 5 Peripheral T cell lymphoma 
SYK t(9;12)(q22;p12) Intron 5 MDS 
 
4.3.4. Transcription factors and other fusion partners of ETV6 
The ETV6/RUNX1 (ETV6/AML1) fusion is the most common fusion gene in childhood acute 
B cell lymphoblastic leukemia (Shurtleff, 1995). Reporter gene assays showed that the 
ETV6/RUNX1 fusion protein acts as a repressor by binding to the promoter and enhancer 
regions of RUNX1 target genes. This repression function is dependent on the pointed and on 
the central domain of ETV6, which are both part of the ETV6 portion of the ETV6/RUNX1 
fusion protein (Fenrick, 1999). ETV6/ARNT and HLXB9/ETV6 chimeric proteins are other 
examples of this class of ETV6 fusions found in AML and the HLXB9/ETV6 hybrid is 
detected in up to 20% of pediatric cases with AML (Beverloo, 2001). A potential mechanism 
of transformation for these fusions is that the ETV6/ARNT and HLXB9/ETV6 proteins 
interact with the wild-type ETV6 through the pointed domain, thereby interfering with normal 
ETV6 function (Beverloo, 2001). 
 
4.3.5. Ectopic and aberrant expression of a proto-oncogene gene 
A number of ETV6 translocations including the ETV6-MDS1/EVI1 and the ETV6-CDX2 
fusion only contain the transcription/translation start of ETV6 (Peeters, 1997; Chase, 1999). In 
these cases ectopic expression of the transcription factors EVI1 and CDX2 was detected in 
addition to the expression of the fusion gene. 
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The potential importance of the ectopic expression of a proto-oncogene in this class of ETV6 
fusions was further underlined by observations that the ectopic expression of the proto-
oncogene also occurred when the fusion gene itself was not translated into a protein product: 
an example for this is the ectopic expression of the ParaHox gene GSH2 in patients with 
t(4;12) positive leukemia, even in cases, in which no protein expression of the CHIC2-ETV6 
fusion generated by the chromosomal translocation, could be detected. Furthermore, 
expression of IL-3 was observed in a CML case with a t(5;12), lacking the ETV6-ACS2 fusion 
protein. These results suggest that ectopic expression of GSH2 and IL-3 could be the key 
leukemogenic mechanism in these leukemias (Cools, 2002). 
 
 
 
Figure 4.9: ETV6 fusion partner genes are represented in a network and sub-grouped in clusters 
with regard to their functional similarity. Transcription factors and the sub-class of homeobox 
genes, tyrosine kinases and others ETV6 fusion partners with unclear function (adapted from 
Bohlander, 2005). 
 
There are some ETV6 fusion genes, such as MDS2 and STL which are predicted to code for 
small proteins with no significant homology to any protein in the database. It is therefore very 
likely, in these cases, that upregulation of a neighboring gene (like ID3, E2F2 or RPL11 in the 
case of MDS2; and OSTL in the case of STL gene) is critical in these cases (Bohlander, 2005). 
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4.4. The translocation t(6;12)(q23;p13) in a B-cell ALL cell line 
The translocation t(6;12)(q23;p13) was described by Zhang and coworkers in 1993 in the 
precursor B-cell ALL cell line SUB-B2 established from the leukemic cells from a 5-year-old 
boy with common ALL. The analysis of the balanced t(6;12)(q23;p13) led to the 
identification of ETV6/STL fusion gene (Suto, 1997). The ETV6/STL fusion gene codes for the 
first 54 amino acids of ETV6 and an additional 14 amino acids from the Six Twelve Leukemia 
(STL) gene. However, the four codons from the STL gene do not belong to a reading frame 
starting with an ATG. The reciprocal STL/ETV6 fusions are not in frame (Figure 4.10 adapted 
from Suto, 1997). The presumptive STL protein does not exhibit any homology to other 
proteins in the databases. Interestingly, the anti-sense strand of the first exon of STL is used to 
another gene which is transcribed in opposite direction. This gene was named OSTL 
(Opposite STL) by us. It codes for a 307 amino acid protein with two RING finger domains 
linked by an IBR (In Between RING fingers) or DRIL (Double RING fingers) motif. The 
OSTL protein is highly conserved (98% identity to its mouse and 86% to its Fugu homolog). 
OSTL interacts with several proteins involved in apoptotic signaling (Fontanari Krause, 
2003). This makes it very likely that the overexpression of the RING finger OSTL gene is the 
main pathogenic mechanism in this translocation. 
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Figure 4.10: A) Nucleotide sequence and putative amino acid sequence (continuation of ETV6 
reading frame) of ETV6/STL fusion. B) Nucleotide sequence and putative amino acid sequence (5’ 
continuation of ETV6 reading frame) of the three variant STL/ETV6 fusions. Note that only STL/ETV6 
has an in frame start codon 5’ of the ETV6 reading frame (double-underlined). C) Diagram of ETV6, 
ETV6/STL, and STL/ETV6 proteins (Suto, 1997). 
 
4.5. RING finger family of proteins 
Freemont and coworkers in 1991 have first described a third class of zinc finger family in the 
RING1 gene. The really interesting new gene (RING) is described as containing a cysteine-
rich motif. The structure of this RING domain revealed that it did not assemble classical zinc 
fingers, but utilized its Cys/His residues to bind two zinc atoms in a unique cross-brace 
fashion, where the first and third pair of metal ligating residues binds the first zinc and the 
second and fourth pair binds the second zinc (Figure 4.11). The RING domain is thought to 
provide interfaces for protein interactions (Freemont, 1993; Schmeichel & Beckerle, 1994; 
Schwabe & Klug, 1994; Saurin, 1996; Dawid, 1998). 
RING finger proteins may have either cytoplasmic or nuclear functions and are implicated in 
various processes such as cell lineage determination, oncogenesis, and embryogenesis 
(Freemont, 1993; Schwabe & Klug, 1994; Saurin, 1996; Dawid, 1998). The RING domain 
from KAP-1 is necessary for high-order oligomerization allowing KAP-1 to associate with 
the KRAB domain of KOX-1, thereby mediating transcriptional repression (Peng, 2000). The 
RING domains of PML and the viral protein Z directly bind eIF4E and alter its affinity for the 
5’ cap of mRNA. Thereby altering the mRNA transport and translational functions of eIF4E 
(Kentsis, 2001; Cohen, 2001). Finally, many RING domains function as E3 ubiquitin protein 
ligases in the ubiquitin conjugation pathway where they catalyze the transfer of an activated 
ubiquitin from an E2 ubiquitin conjugating enzyme to an intended substrate (Joazeiro, 2000; 
Fang, 2003). 
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Figure 4.11: PHD (Plant Homeo Domain) finger of KAP-1, which has a similar structure as a 
RING finger. A three dimensional cross brace system, represented by seven cysteines and a histidine 
(#5), which are able to coordinate two zinc atoms (modified from Capili, 2001). 
 
In 1999, Tyers and Willems after the biochemical characterization of the Skp1-Cdc53/CUL1-
F-box (SCF) and anaphase promoting complex (APC) ubiquitination complex suggested that 
RING fingers play a central role in the combinatorial set of protein interactions that determine 
substrate specificity in the ubiquitin pathway. This pathway targets protein for degradation 
through the 26S proteasome (Hershko & Ciechanover, 1998; Weissman, 2001). 
Ubiquitination can quantitatively regulate substrates such as cyclins, transcription factors, 
hormone nuclear receptors, and oncoproteins. Four types of enzymes are known to mediate 
ubiquitination: an ubiquitin-activating enzyme (E1 or Uba), an ubiquitin-conjugating enzyme 
(E2 or Ubc), an ubiquitin ligase (E3 or Ubr) (Hershko & Ciechanover, 1998; Weissman, 
2001), and a polyubiquitin ligase (E4) (Koegl, 1999). Ubiquitin conjugation occurs through 
the sequential action of these enzymes; first the E1 activates and forms a high-energy 
thioester bond with ubiquitin. Ubiquitin is then passed to the E2 by transthiolation and the E2, 
usually in cooperation with E3, transfers ubiquitin to a lysine side chain of the substrate. E3s 
specify the timing and substrate selection of ubiquitination reactions (Figure 4.12, adapted 
from Hicke & Dunn, 2003). 
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Figure 4.12: Regulation of protein transport by ubiquitin signals. a) Monoubiquitin and Lys63-
linked di-ubiquitin chains serve as regulated internalization signals that can be appended to a plasma 
membrane protein to trigger entry into primary endocytic vesicles budding from the plasma 
membrane. b) Monoubiquitin serves as a signal for the entry of transmembrane proteins into MVB 
(multivesicular body) vesicles. c) Ubiquitin, ubiquitin-binding proteins, and ubiquitin ligases are 
important for the budding of envelop viruses. d) (Poly)ubiquitination regulates the sorting of proteins 
at the trans-Golgi network to the lysosome/vacuole. e) Ubiquitin modifies and regulates components 
of the endocytic machinery. 
 
RING fingers are often found in conjunction with other cysteine-rich domains (Saurin, 1996). 
In the RING finger B-box coiled coil (RBCC) proteins, the RING fingers are linked to a 
specific cysteine-rich zinc-binding motif (B-Box) and a coiled coil domain (Reddy, 1992). 
Interstingly, the three RBCC proteins PML, TIF1, and Rfp were all identified as oncogenic 
products that are disrupted by chromosomal translocations (Saurin, 1996). 
In 1999, van der Reijden and coworkes identified a novel conserved cysteine-rich motif called 
DRIL (for Double RING finger linked). Two RING fingers and DRIL (TRIAD) motifs 
defined the conserved tripartite motif. 
The DRIL pattern differs from the consensus of the RING finger patterns with respect to the 
histidine location and the absence of length-variation in the C-terminal loop (Figure 4.13). 
Recently, Capili and coworkers described in the human homologue of the Drosophila Ariadne 
(HHARI) protein a novel zinc-binding domain called RING2, which is related to the C-
terminal RING of the protein family RING-IBR-RING (or TRIAD). Unlike classical RINGs, 
RING2 binds only a single zinc atom (Figure 4.14, adapted from Capili, 2004) and some 
conserved residues and metal binding ligands are charged. 
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C-x2-    C-x(17-19)-H-x2-   C-x2-     C-x2-C-x(16-20)-H-x2-C           LIM pattern 
C-x2-    C-x(9-39)- C-x(1-3)-H-x(2-3)-C-x2-C-x(4-48)-  C-x2-C           RING finger pattern 
C-x(1-2)-C-x(9-21)- C-x(2-4)-C-x(4-5)-H-x2-C-x(12-46)- C-x2-C           LAP/PHD pattern 
C-x4-    C-x(14-30)-C-x(1-4)-C-x4-    C-x2-C-x4-        H-x4-C          DRIL pattern 
 
Figure 4.13: DRIL pattern consists of seven regularly spaced cysteine and one histidine residues and 
closely resembles the LAP/PHD (Leukemia-Associated Protein/Plant Homeo Domain), LIM (for the 
proteins in which it was first discovered: Lin11, Isl1, and Mec3), and RING finger patterns. C = 
cysteine, H = histidine (bold), x = any amino acid. 
 
 
A) 
 
 
B) 
 
 
Figure 4.14: A) RING2 structure. B) Sequence of HHARI RING2 showing the residues used to bind 
the zinc atom (Capili, 2005). 
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4.6. Aim of this work 
Reciprocal translocations affecting band 12p13 are found as recurring chromosomal changes 
in myeloid and lymphoid malignancies. ETV6 is involved in most of these balanced 12p13 
translocations. The t(6;12)(q23;p13) translocation results in the fusion of ETV6 with STL in a 
childhood B-cell ALL. Since the ETV6/STL fusion gene encodes only for a small protein, 
which lacks any know functional domain and has no homology to other proteins, we 
hypothesize that the main leukemogenic effect of this translocation is the deregulation of 
OSTL. The aim of this project was the characterization of the OSTL gene. For this we have 
sequenced the whole mouse and human cDNA and looked for the expression pattern of this 
gene in normal tissues, normal and malignant cell lines and patient samples. To be able to 
define the role of OSTL in the cells we searched and identified the protein-interaction partners 
of OSTL. Finally, to analyze the role of Ostl in leukemogenesis and assay whether ectopic 
expression of this gene can lead to the development of ALL leukemia, we established a 
mouse model where Ostl was overexpressed in bone marrow cells. 
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5. Materials and Methods 
5.1. List of abbreviations and glossary 
AA = aa  Amino acids 
Ab Antibody 
AD Activation Domain 
AH 109 Yeast strain 
APC Allophycocyanin 
Aqua bidest. Water double deionized filtered trough Millipore filters 
Aqua dest. Water, deionized 
BD Binding Domain 
BM Bone Marrow 
bp Base pair(s) 
BSA Bovine Serum Albumin 
C Cysteine 
°C Degree Celsius 
cDNA Complementary DNA, synthetic DNA transcribed from a 
specific RNA through the action of the reverse transcriptase 
cfu Colony forming units 
Cys = C Cysteine 
dCTP Deoxycytosine triphosphate 
DEPC Diethyl pyrocarbonate 
dGTP Deoxyguanosine triphosphate 
DMEM Dulbecco’s Modified Eagle Medium 
DMF Dimethylformamide 
DMSO Dimethylsulfoxide 
DNA Deoxyribonucleic acid 
dNTP Deoxynucleotide triphosphate 
dTTP Deoxythymidine triphosphate 
DTT Dithiothreitol 
ECFP Enhanced Cyan Fluorescent Protein 
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EDTA Ethylenediaminetetraacetic acid 
EGFP Enhanced Green Fluorescent Protein 
EtBr Ethidium bromide 
EtOH Ethanol 
EYFP Enhanced yellow fluorescent protein 
FBS Fetal bovine serum 
FCS Fetal calf serum 
G Gram 
G Relative centrifugal acceleration 
G Glycine 
Gal Galactose 
GAL1 Yeast promoter 
Gal4 Yeast transcription factor 
Glc Glucose = dextrose 
Gly = G Glycine 
GST Glutathione S-transferase 
H Hour(s) 
HEPES N-(2-Hydroxythyl) piperazine-N’-2-ethan sulphuric acid 
His = H Histidine 
HRP Horse Radish Peroxidase 
IBR In Between RING fingers 
Ile = I Isoleucine 
IPTG Isopropyl-β-D-thio-galactopyranoside 
KAc Potassium acetate 
kb Kilobase(s) 
KCl Potassium chloride 
kDa Kilodalton 
KH2PO4 Potassium dihydrogenphosphate 
L Liter 
LB Luria-Bertani bacterial medium 
Leu = L Leucine 
LiAc Lithium acetate 
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Lys = K Lysine HCl 
m Meter 
M Molar 
MCS Multiple Cloning Site 
MCSV Murine Stem Cell Virus 
Met = M Methionine 
µg Microgram 
MgCl2 Magnesium chloride 
MgSO4 Magnesium sulfate 
mIL-3 
mIL-6 
Mouse Interleukine-3 
Mouse Interleukine-6 
min Minute(s) 
mix Mixture 
ml Milliliter 
µl Microliter 
mM Milimolar 
µM Micromolar 
µm Micrometer 
MOPS 3-N-Morpholine-propanesulfonic acid 
mRNA Messenger RNA 
M-SCF Recombinant Murine Stem Cell Factor 
msec Mili seconds 
MW Molecular weight 
NaAc Sodium acetate 
ng Nanogram 
NaH2PO4 Sodium dihydrogenphosphate 
Na2HPO4 Disodium hydrogenphosphate 
(NH4)2SO4 Ammonium sulfate 
nt Nucleotide 
N2 Nitrogen 
OD Optical density 
O/N Overnight 
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ORF Open reading frame 
PAGE Polyacrylamide gel electrophoresis 
PBS Phosphate buffered saline 
PCR Polymerase chain reaction 
PE Phycoerythrin 
PEG Polyethylene glycol 
Pen/Strep Penicillin/Streptomycin 
pg Picogram 
Phe = F Phenylalanine 
PMSF Phenylmethylsulfonyl fluoride 
R Adenine hemisulfate or Arginine HCl 
rh Recombinant human 
RING1 Really Interesting Protein 1 
RING2 Really Interesting Protein 2 
rm Recombinant mouse 
RNase Ribonuclease 
RNA Ribonucleic acid 
RPMI Roswell Park Memorial Institute culture medium 
rRNA Ribosomal RNA 
RT Room temperature 
RT Reverse transcription, or reverse transcriptase 
RT-PCR Method for amplifying cDNA from an RNA template 
SD Synthetic defined Dropout medium 
SDS Sodium dodecyl sulfate 
sec Second(s) 
SSC Saline-sodium citrate buffer 
Taq Thermus aquaticus (-Polymerase) 
TBS Tris-buffered saline 
TE Tris-EDTA buffer 
TEMED N,N,N’,N’-Tetramethylethylendiamine 
Thr = T Threonine 
Trp = W Tryptophan 
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Tris Trishydroxyaminomethan 
tRNA Transfer RNA 
Tyr = Y Tyrosine 
u Unit 
U Uracil 
UV Ultraviolet light 
Val = V Valine 
Vector Plasmid or phage chromosome used to carry cloned DNA 
segment 
vol Volume 
v/v Volume:volume ratio 
WB Western Blot 
w/v Weight:volume ratio 
X-gal 5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside 
YPD Yeast extract, peptone, dextrose 
 
5.2. Materials 
5.2.1. Chemicals, kits and materials 
1-kb-DNA molecular weight marker Life Technologies, Eggenstein, Germany 
1.5 ml microcentrifuge tube Eppendorf, Hamburg, Germany 
15 ml polypropylene conical tubes Becton Dickinson, Meylan, France 
50 ml polypropylene conical tubes Becton Dickinson, Meylan, France 
Acetic acid Merck, Darmstad, Germany 
Acrylamide/Bis solution Carl Roth, Karlsruhe, Germany 
Agar Carl Roth, Karlsruhe, Germany 
Agarose ICN Biomedicals Inc. 
Amino acids (yeast two hybrid) Sigma, Deisenhofen, Germany 
Ammonium Chloride solution CellSystems, Vancouver, Canada 
Ampicillin Pan Biotech, Aidenbach, Germany 
Amplify Fluorographic Reagent Amersham, UK 
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Ampuwa® H2O Fresenius, Bad Homburg, Germany 
Aprotinine Sigma, Deisenhofen, Germany 
Aqua bidest. Millipore, Eschborn, Germany 
BigDye terminator cycle sequencing v2.0 Applied Biosystems, Foster City, CA 
Blocking reagent  Roche diagnostics – Boehringer, Germany 
β-Mercaptoethanol Sigma, Deisenhofen, Germany 
Boehringer BM purple Ap substrate Boehringer, Germany 
Boric acid Carl Roth, Karlsruhe, Germany 
Bromophenol blue Carl Roth, Karlsruhe, Germany 
Bovine serum albumine Life Technologies, Eggenstein, Germany 
Cell culture medium DMEM Pan Biotech, Aidenbach, Germany 
Cell culture medium RPMI Pan Biotech, Aidenbach, Germany 
Chloroform Sigma, Deisenhofen, Germany 
Citric acid Merck, Darmstadt, Germany 
Coomassie® stain solution BioRad, Hercules, CA 
Cryotube vials Nalge Nunc Internacional, Denmark 
Deoxyribonuclease I, Amplification Grade Life Technologies, Eggenstein, Germany 
DEPC Carl Roth, Karlsruhe, Germany 
Dig antibody AP coupled Boehringer, Germany 
Dimethylsulfoxide (DMSF) Carl Roth, Karlsruhe, Germany 
DMF Carl Roth, Karlsruhe, Germany 
DMSO Sigma, Deisenhofen, Germany 
DNA Ligase buffer 10X NewEngland Biolabs, Schwalbach, 
Germany 
DNA polymerases (Taq, T4, Klenow) MBI Fermentas, St. Leon-Rot, Germany 
dNTP Set, PCR Grade Life Technologies, Eggenstein, Germany 
ECL™ Western Blot Detection reagents Amersham, Braunschweig, Germany 
EDTA Carl Roth, Karlsruhe, Germany 
Electroporation cuvettes PeqLab, Erlangen, Germany 
Eppendorf tubes Eppendorf, Germany 
Ethanol Merck, Darmstadt, Germany 
Ethidium bromide Carl Roth, Karlsruhe, Germany 
Falcon 14 Polystrene round-bottom tube Becton Dickinson, Meylan, France 
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Fetal Bovine Serum Gibco, Life Technologies, Paisley, Scotland 
Filter 0.22µm Millipore, Belford, USA 
Filterpaper (Gel-blotting-paper) Schleicher & Schuell, Dassel, Germany 
Fetal calf serum (FCS) Life Technologies, Eggenstein, Germany 
5-Fluorouracil Medac 
Formaldehyde 37% Carl Roth, Karlsruhe, Germany 
Formamide Carl Roth, Karlsruhe, Germany 
Genomed Plasmid Mega Kit Genomed, St. Louis, USA 
Giemsa, solution Merck, Darmstadt, Germany 
Glass beads (425-600 µ #G8772) Sigma, Deisenhofen, Germany 
Glutathione-Agarose (#G 4510) Sigma, Deisenhofen, Germany 
Gluthathione Sepharose™ 4B Pharmacia Biotech, Freiburg, Germany 
Glycerol Carl Roth, Karlsruhe, Germany 
Glycin Merck, Darmstadt, Germany 
Heparin Sigma, Deisenhofen, Germany 
HEPES Sigma, Deisenhofen, Germany 
Hybond™-P PVDF transfer membrane 0.45 µm Amersham, Buckinghamshire, UK 
Hydrochloridric acid 37% Merck, Darmstadt, Germany 
Hypercassete 18x24 cm Amersham, Buckinghamshire, UK 
Hyperfilm™ ECL chemiluminescence reagent Amersham, Buckinghamshire, UK 
Hyperfilm™ ECL high performance Amersham, Buckinghamshire, UK 
IPTG Roche Molecular Biochemicals Mannheim 
Isopropanol Carl Roth, Karlsruhe, Germany 
Kanamycin Pan Biotech, Aidenbach, Germany 
Klenow Fragment MBI Fermentas, St. Leon-Rot, Germany 
Lab-Tek II chambered coverglass w/cover Nalge Nunc International, Naperville, USA 
Leupeptine Sigma, Deisenhofen, Germany 
Levamisole Sigma, Deisenhofen, Germany 
Lithium acetate Sigma, Deisenhofen, Germany 
L-glutamine (cell culture) Pan Biotech, Aidenbach, Germany 
May-Grunwald’s eosin-methylene blue solution Merck, Darmstadt, Germany 
Megaprime™ DNA labeling system Pharmacia Biotech, Freiburg, Germany 
Methanol Merck, Darmstadt, Germany 
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Methocult™ GF M3434 CellSystems, Vancouver, Canada 
Methylene blue Merck, Darmstadt, Germany 
Microspin S-400 HR columns Amersham, UK 
mIL-3 Tebu-bio, USA 
mIL-6 Tebu-bio, USA 
Milk powder Carl Roth, Karlsruhe, Germany 
MOPS Life Technologies, Eggenstein, Germany 
M-SCF Tebu-bio, USA 
Nescofilm sealing film Carl Roth, Karlsruhe, Germany 
Nitrocellulose membrane (Hybond) Amersham, UK 
Oligo (dT)12-18 Primer Life Technologies, Eggenstein, Germany 
Paraformaldehyde Carl Roth, Karlsruhe, Germany 
PBS Pan Biotech, Aidenbach, Germany 
Penicillin/Streptomycin Pan Biotech, Aidenbach, Germany 
Pepstatine Sigma, Deisenhofen, Germany 
Pepton, meat pancreatic digested Merck, Darmstadt, Germany 
Pipette tips Carl Roth, Karlsruhe, Germany 
Polyethylenglycol (PEG) 4000 Merck, Darmstadt, Germany 
Phenol Sigma, Deisenhofen, Germany 
Phenol/Chloroform Life Technologies, Eggenstein, Germany 
Plastic cuvettes for OD Carl Roth, Karlsruhe, Germany 
Plastic material for cell culture 
 
“ 
“ 
Greiner Labortechnik, Frickenhausen, 
Germany  
Sarstedt, Nümbrecht, Germany  
Corning, USA 
Platinum® Taq DNA Polymerase 
“ 
 
“ 
Life Technologies, Eggenstein, Germany  
NewEngland Biolabs, Schwalbach, 
Germany  
Pan Biotech, Aidenbach, Germany 
PolyFect transfection reagent Qiagen, Hilden, Germany 
Propidium iodide Calbiochem, San Diego, USA 
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Protamine sulfate Sigma, Deisenhofen, Germany 
Proteinase inhibitor cocktail Sigma, Deisenhofen, Germany 
Protein Agarose-G beads Roche Molecular Biochemicals Mannheim 
Proteinase K Gibco, Life Technologies, Paisley, Scotland 
Qiagen® Plasmid Midi Kit Qiagen, Hilden, Germany 
Qiagen® Plasmid Maxi Kit Qiagen, Hilden, Germany 
Qiagen® Plasmid MaxiEndofree Kit Qiagen, Hilden, Germany 
Qiagen RNEasy Mini Kit Qiagen, Hilden, Germany 
Qiashredder™ columns Qiagen, Hilden, Germany 
Restriction enzymes 
“ 
“ 
MBI Fermentas, Germany 
NewEngland Biolabs, Schwalbach, 
Germany 
Ribonuclease A MBI Fermentas or Sigma, Germany 
RNase Away Carl Roth, Karlsruhe, Germany 
Rneasy™ mini kit Qiagen, Hilden, Germany 
RothFect transfection reagent Carl Roth, Karlsruhe, Germany 
SDS Carl Roth, Karlsruhe, Germany 
SeeBlue® Plus2 pre-stained standard Life Technologies, Eggenstein, Germany 
Shrimp alkaline Phosphatase MBI Fermentas, St. Leon-Rot, Germany 
SOC medium Sigma, Deisenhofen, Germany 
Sodium acetate Sigma, Deisenhofen, Germany 
Sodium chloride Merck, Darmstadt, Germany 
Sodium citrate Carl Roth, Karlsruhe-, Germany 
Sodium hydroxide Merck, Darmstadt, Germany 
SuperScript™ II RNase H- Reverse Transcriptase Life Technologies, Eggenstein 
Surgical blade Feather Safety Razor Co. Med. Div., Japan 
Syringe 10 ml Braun, Melsungen, Germany 
Syringe Driven Filter Unit Millex-GP 0.22 µm Millipore, Carrigtwohill, Ireland 
Syringe Driven Filter Unit Millex-HV 0.45 µm Millipore, Carrigtwohill, Ireland 
Syringe Driven Filter Unit Millex-LG 0.20 µm Millipore, Japan 
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T4 DNA Ligase NewEngland Biolabs, Schwalbach, 
Germany 
T4 DNA Ligase Life Technologies, Eggenstein, Germany 
T4 DNA Ligase Buffer NewEngland Biolabs, Schwalbach, 
Germany 
“ Life Technologies, Eggenstein, Germany 
T4 DNA Polymerase NewEngland Biolabs, Schwalbach, 
Germany 
TEMED Carl Roth, Karlsruhe, Germany 
Tris Carl Roth, Karlsruhe, Germany 
Triton X-100 Carl Roth, Karlsruhe, Germany 
Trypan blue Life Technologies, Eggenstein, Germany 
Trypsin-EDTA solution Biochrom AG, Berlin, Germany 
Tween® 20 Carl Roth, Karlsruhe, Germany 
Vektashield® mounting medium Vector laboratories, Burlingame, CA 
Yeast extract Sigma, Deisenhofen, Germany 
Yeast nitrogen base without aa Difco, Detroit MI, USA 
X - gal Clontech, Heidelberg, Germany 
 
5.2.2. Bacterial strains (E. coli) 
BL21 Clontech, Heildelberg, Germany 
XL1-Blue Clontech, Heildelberg, Germany 
 
5.2.3. Yeast strains (S. cerevisiae) 
CG 1945: 
MATa, ura3-52, his3-200, ade2-101, lys2-801, trp1-901, leu2-3, 112, gal4-542, gal80-538, 
cyhr2, LYS2::GAL1UAS-GAL1TATA-HIS3, URA3::GAL417-mers(x3)-CYC1TATA-lacZ (Clontech, 
Palo Alto, USA); Feilotter et al., 1994. 
 
AH 109: 
MATa, trp1-901, leu2-3, 112, ura3-52, his3-200, gal4Δ, gal80Δ, LYS2::GAL1UAS-GAL1TATA-
HIS3, GAL2UAS-GAL2TATA-ADE2, URA3::MEL1UAS-MEL1TATA-lacZ (Clontech, Palo Alto, 
USA); James et al., 1996. 
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5.2.4. Murine cell lines  
GP+ E86: 
Mouse fibroblast cell line  
 
NIH3T3: 
Swiss mouse embryo fibroblast cell; 
Aaronson et al., 1968; Jainchill et al., 1969; Copeland et al.,1979. 
 
5.2.5. Human cell lines 
DOHH2: 
Mature EBV- B cell derived from follicular B-NHL  
(provided by Dr. Martin Dreyling, GSF-CCG-Leukemia, Grosshadern, Munich); 
Kluin-Nelemans et al., 1991. 
 
Granta 519: 
Mature EBV+ B-cell line derived from B-NHL  
(provided by Dr. Martin Dreyling, GSF-CCG-Leukemia, Grosshadern, Munich); 
Rudolph et al., 2004; Jadayel et al.,1997. 
 
HBL2: 
Mature EBV- B cell line derived from B-NHL  
(provided by Dr. Martin Dreyling, GSF-CCG-Leukemia, Grosshadern, Munich). 
 
HBL4: 
B-NHL EBV+  
(provided by Dr. Martin Dreyling, GSF-CCG-Leukemia, Grosshadern, Munich). 
 
HEK293 T: 
Human embryonal kidney cell line;  
Graham et al., 1977. 
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Karpas 422: 
Mature B cell line derived from B-NHL  
(provided by Dr. Martin Dreyling, GSF-CCG-Leukemia, Grosshadern, Munich). 
Dyer et al., 1990. 
 
LCL B: 
Lymphoblastoid transformed cell  
(provided by Dr. Martin Schlee, GSF, Grosshadern, Munich). 
 
LCL D: 
Lymphoblastoid transformed cell  
(provided by Dr. Martin Schlee, GSF, Grosshadern, Munich). 
 
LCL R: 
Lymphoblastoid transformed cell  
(provided by Dr. Martin Schlee, GSF, Grosshadern, Munich). 
 
Nalm 6: 
Precursor B cell of type B-III; 
Hurwitz et al., 1979. 
 
NCEB-1: 
Mature EBV+ B cell derived from B-NHL  
(provided by Dr. Martin Dreyling, GSF-CCG-Leukemia, Grosshadern, Munich); 
Saltman et al., 1988. 
 
SEM: 
Precursor B cell of type B-I  
(provided by Dr. Georg Bornkamm, GSF, Grosshadern, Munich) 
Greil et al., 1994; Reichel et al., 1998. 
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Wsu-NHL: 
Mature EBV- B cell line derived from follicular B-NHL  
(provided by Dr. Martin Dreyling, GSF-CCG-Leukemia, Grosshadern, Munich); 
Mohamed et al., 1988. 
 
5.2.6. Mice 
Parental strain mice, for the bone marrow assays, and for the whole mount in situ 
hybridization assays (BALB/c mice) were bred and maintained at the GSF-Grosshadern, 
animal facility. Donors of primary BM cells were > 12-week-old (C57Bl/6Ly-Peb3b x 
C3H/HeJ) F1 (PebC3) mice and recipients were > 8 week old (C57Bl/6J x C3H/HeJ) F1 
(B6C3) mice.  
 
5.2.7. Antibodies 
The following antibodies were used for Western blot analysis and for flow cytometry: 
 
Anti-green fluorescent protein, rabbit IgG fraction (Molecular probes) 
Anti-HAX1, clone 52, mouse IgG1 (Clontech) 
Anti-SIVA, clone C-20, goat polyclonal IgG (Santa Cruz) 
B220, clone RA3-6B2, APC labeled (BD Pharmingen) 
CD4, clone GK1.5, PE labeled (BD Pharmingen) 
CD8, clone 53-6.7, APC labeled (BD Pharmingen) 
c-kit, clone 2B8, APC labeled (BD Pharmingen) 
c-myc, mouse monoclonal IgG1 (Clontech) 
Donkey anti-rabbit IgG-HRP (Santa Cruz) 
Donkey anti-goat IgG-HRP (Santa Cruz) 
Donkey anti-mouse IgG-HRP (Santa Cruz) 
Gr-1, clone RB6-8C5, PE labeled (BD Pharmingen) 
HA-tag, rabbit Ig polyclonal antibody (Clontech) 
Mac-1 (CD11b), clone M1/70, APC labeled (BD Pharmingen) 
Sca-1, clone D7, PE labeled (BD Pharmingen) 
Ter119, PE labeled (BD Pharmingen) 
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5.2.8. Plasmids 
The following mammalian expression plasmids pECFP/GFP/YFP, pcDNA6/V5-His A, and 
MCSV (MIG) were used for mouse cell transfections; the prokaryotic expression pGEX 4T-2 
vector was used to produce GST-fusion proteins; the pGEMT-easy was used to subclone PCR 
product; and the yeast shuttle plasmids pGBT9, pGBKT7 and pGADT7 were used in the 
yeast two hybrid screen. 
 
5.2.8.1. Mammalian expression plasmids  
pECFP/pEGFP/pEYFP-C1: 
pECFP/GFP/YFP vectors are used to generate fusion proteins for expression and localization 
studies. A gene of interest inserted into the MCS of these vectors will be expressed as a fusion 
to the C-terminus of the enhanced fluorescent protein (Cyane, Green or Yellow). The vectors 
carry a Kanamycin resistance gene for selection in bacteria (Clontech, Heidelberg). 
 
pcDNA6/V5-His A: 
The pcDNA6/V5-His A is used to express proteins with a V5 or HIS tag (Invitrogen). 
 
MSCV (MIG): 
For retroviral gene transfer into primary BM cells, the gene of interested was subcloned into 
the multiple cloning site of the modified murine stem cell virus (MSCV) 2.1 vector (Pineault 
et al., 2003) upstream of the internal ribosome entry site (IRES) and the enhanced GFP. 
 
5.2.8.2. Prokaryotic expression plasmids 
pGEX-4T2: 
This vector was used for inducible, high-level intracellular expression of genes as fusion with 
Schistosoma japonicum glutathione S-transferase (GST) under the control of a tac promoter 
(inducible with IPTG 1-5mM). The vector includes an internal lac Iq gene for use in any 
E.coli host and a coding region for factor Xa protease recognition site for cleaving the protein 
of interest from the GST protein (Pharmacia Biotech). 
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5.2.8.3. T-vector 
pGEM-T easy: 
The pGEM-T easy vector is used for the cloning of PCR products. It is provided ready for 
ligation with PCR products from the company. The vector contains T7 and SP6 RNA 
polymerase promoters flanking a multiple cloning region within the α-peptide coding region 
of the enzyme β-galactosidase (Promega, Madison, USA). 
 
5.2.8.4. Yeast two hybrid expression plasmids 
5.2.8.4.1. Bait-expression plasmids 
pGBT9: 
The vector pGBT9 is used for the expression of proteins of interest as fusions with the GAL4 
DNA-BD. The vector has the TRP1 gene for selection for tryptophan autotrophy in yeast and 
a beta-lactamase gene for selection with Ampicillin in bacteria (Clontech, Palo Alto, USA). 
 
PGBKT7: 
The vector pGBKT7 is used for the expression of proteins of interest as fusions with the 
GAL4 DNA-BD. The vector has the TRP1 gene for selection for tryptophan autotrophy in 
yeast and a beta-lactamase gene for selection with kanamycin in bacteria. 
It contains a c-Myc epitope that facilitates further in vitro assays, such as 
coimmunoprecipitation to confirm the interactions in yeast two hybrid system (Clontech, Palo 
Alto, USA). 
 
5.2.8.4.2. Prey-expression plasmids 
pGAD-GH: 
The vector pGAD-GH is used for the expression of library (prey) proteins as fusion with the 
GAL4 DNA-AD. The vector has the LEU2 gene for selection for leucine autotrophy in yeast 
and a beta-lactamase gene for selection with Ampicillin in bacteria (Clontech, Palo Alto, 
USA). 
 
PGADT7: 
The vector pGADT7 is used for the expression of library (prey) proteins as fusion with the 
GAL4 DNA-AD. The vector has the LEU2 gene for selection for leucine autothrophy in yeast 
and a beta-lactamase gene for selection with Ampicillin in bacteria. It contains a HA epitope 
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that facilitates further in vitro assays, such as coimmunoprecipitation to confirm the 
interactions in yeast two hybrid system (Clontech, Palo Alto, USA). 
 
5.2.8.5. Packaging plasmid 
Ecopac: 
The Ecopac is a packaging vector coding for the gag, pol, and env viral proteins. In this work 
it was used for transfection of HEK293T cells. 
 
5.2.9. Primers  
Oligonucleotides used for DNA amplification and sequence analysis (Table 2.1) were 
designed using the software program MacVector ™ 7.0 and were purchased from Metabion 
GmbH (Martinsried, München).  
 
Table 5.1: Oligonucleotides used in the project 
Oligoname Sequence Nucleotide position in 
cDNA sequence∗  
Ann 
°C 
OSTLEx1dATGXhoI 5’-CTACCTCGAGAGATGAAGGTACAACTTGGCC-3’ (235-246) Exon 1d 55 
OSTL58TxhoI 5’-CTACCTCGAGATATGCCCAGCCTGTTGGGAGC-3’ (58-77) Exon 1d 55 
OSTLE06205T 5’-GAGTGCCTCAAAGTCTACCTG-3’ (205-225) Exon 1 55 
OSTL983BpstI 5’-CATACTGCAGTGTTACCAGTGCATACCTGTCCG-3’ (983-961) Exon 6 55 
hGAPDHT 5’-GCACCACCAACTGCTTAGCACC-3’ (530-551) Exon 7 56 
hGAPDHB 5’-GTCTGAGTGTGGCAGGGACTC-3’ (1166-1146) Exon 9 56 
mGAPDHT 5’-CATCACCATCTTCCAGGAGC-3’ (271-291) 60 
mGAPDHB 5’-ATGACGTTGCCCACAGCCTT-3’ (714-695) 60 
pEGFP-C11240 5’-AAAGACCCCAACGAGAAGC-3’ (1240-1258) 55 
pGEX5’ 5’-GGGCTGGCAAGCCACGTTTGGTG-3’ Seq primer 55 
Seqf464OSTL 5’-CAAAATCCAGTGCCCTACC-3’ (464-482) Exon 3 55 
M13/pUCRevSeqP 5’-AGCGGATAACAATTTCACACAGG-3’ Seq primer 55 
J16-183T 5’-CTGCTCCGTGTACTGCGTGG-3’ (78-97) Exon 1d 55 
J16-251T 5’-AGTCCCCACCTCAAGCAC-3’ (146-163) Exon 1d 55 
G01-M13-295F 5’-AGTCTAAAAGGGAGTGGGC-3’ (295-568) Exon 2 55 
OSTL1431B 5’-CTCTTATCTTCTGAAAAGTGGC-3’ (1431-1410) Exon 6 55 
 
G01-295-468 5’-CAATCCAAGAAGGAGAAG-3’ (295-4680 Exon 2 55 
OSTL281B 5’-AAAACACTCTGTGATGGGG-3’ (282-264) Exon 2 55 
J16c-979T 5’-GACCACACATCAAACCTCAG-3’ (979-998) Exon 4 55 
J16T7-256T 5’-TCCTTACATAGACGGACCAG-3’ (256-275) Exon 1d 55 
J16-(390-414) 5’-CCATGAGGACTCTATCAAGTATAAG-3’ (557-582) Exon 2 55 
Y2H1 5’-TCATCGGAAGAGAGTAG-3’ (1155-1171) 55 
T7 5’-GTAATACGACTCACTATAGGGC-3’ Seq primer 55 
T3 5’-AATTAACCCTCACTAAAGGG-3’ Seq primer 55 
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Oligoname Sequence Nucleotide position in 
cDNA sequence∗ 
Ann 
°C 
SP6 5’-AGGTGACACTATAGAATAC-3’ Seq primer 55 
J16-836TEcoRI 5’-CATAGAATTCGGCAGAGAAATGCCCAGAAG-3’ (836-855) Exon 3 55 
J16-1218BXhoI 5’CAGCTCGAGTTACCAGTGCATACCTGT-3’- (1218-1197) Exon 6 55 
J16-982TEcoRI 5’-CATCGAATTCACACATCAAACCTCAGTAT-3’ (983-1001) Exon 4 55 
OSTLj16T302XhoI 5’-CAGCTCGAGGCCTATTAGGGGCTCCACCC-3’ (302-321) Exon 1d 55 
OSTLj16B1272XhoI 5’-CAGCTCGAGATCCTGCATGGCTCCTCCCG-3’ (1272-1253) Exon 6 55 
OSTLJ16B1217XhoI 5’-CAGCTCGAGCCAGTGCATACCTGTCCG-3’ (1217-1198) Exon 6 55 
mOSTLJ16364NcoI 5’-CAGCCATGGTGCTGATGTGCCGGGTG-3’ (364-384) Exon 1d 55 
Y2H3’AD 5’-AGATGGTGCACGATGCACAG-3’ (2078-2046) 55 
Y2H2-729-751 5’-CGTTTGGAATCACTACAGGGATG-3’ (729-751) 55 
J16-838TNcoI 5’-CATACCATGGGCAGAGAAATGCCCAGAAG-3’ (838-855) Exon 3 55 
J16-996BPstI 5’-CATACTGCAGGAGGTTTGATGTGTGGTC-3’ (996-978) Exon 4 55 
J16-949TNcoI 5’-CATACCATGGATGTGGAGAGAGATACCGC-3’ (942-960) Exon 4 55 
J16-295TNcoI 5’-CTATCCATGGCGTGCCTGGCCTATTAGGG-3’ (294-312) Exon 1d 55 
J16ATG1dNcoI 5’-CTACCCATGGTCAGGTACAACTTGGC-3’ (468-483) Exon 2 55 
J16-605BpstI 5’-CATACTGCAGTGGCTTGGTGCTGGAGTC-3’ (624-607) Exon 2 55 
J16-855BPstI 5’-CATCCTGCAGCTTCTGGGCATTTCTCTG-3’ (855-838) Exon 3 55 
HAX162TEcoRI 5’-CAGGAATTCATGAGCCTCTTTGATCTCTT-3’ (162-181) 55 
HAX976BEcoRI 5’-CAGGAATTCGGGACCGGAACCAACGTCCCA-3’ (996-976) 55 
SIVA33TEcoRI 5’-CAGGAATTCGCGGCCATGCCCAAGCGGAG-3’ (32-51) Exon 1 55 
SIVA562BXhoI 5’-CAGCTCGAGGGTCTCGAACATGGCACA-3’ (562-545) Exon 4 55 
OSTLJ16T358EcoRI 5’-GACGAATTCCCCTCATGGTGCTGATG-3’ (359-375) Exon 1d 55 
OSTLJ16T358BamHI 5’-GACGGATCCCCTCATGGTGCTGATG-3’ (359-375) Exon 1d 55 
E06OSTL601T 5’-AGAGGAATGCCCAGAAGTGTCC-3’ (602-623) Exon 3 57 
E06OSTL761B 5’-ACTGAGGTTTGATGTGTGGTCTCC-3’ (762-739) Exon 4 57 
E06OSTL196T 5’-TGTGCGAGGAGTGCCTCAAAG-3’ (197-217) Exon 1d 57 
E06OSTL381B 5’-TGGTGCTGGAATCAATACGGC-3’ (382-364) Exon 2 57 
E06OSTL374T 5’-CAGCACCAAGCCATGTCCTC-3’ (375-394) Exon 2 57 
E06OSTL501B 5’-AACACCAGACGAATTGGCAGG-3’ (502-482) Exon 3 57 
E06OSTL734B 5’-AAATCGGAGCTGGCGGTATC-3’ (735-761) Exon 4 57 
pMSCV-F 5’-CCCTTGAACCTCCTCGTTCGACC-3’ (1333-1355) 60 
A-pMSCV-F 5’-CAGCCCTCACTCCTTCTCTA-3’ (1378-1397) 58 
pMSCV-R 5’-CCTAGCAATGCTCGTCAAG-3’ (1498-1479) 58 
hTBP-F 5’-GCACAGGAGCCAAGAGTGAA-3’ (653-672)Exons 5 and 6 57 
hTBP-R 5’-TCACAGCTCCCCACCATGTT-3’ (779-760) Exon 6 57 
∗ GenBank acc. Nr.: BF165105 (mouse OSTL J16), AA992964 (human OSTL E06), NM_006118.2 (HAX1), NM_006427 
(SIVA 1), NM_021709 (SIVA 2); NM_001001303 (mouse GAPDH); NM_007583.11 (human TBP). 
 
5.2.10. Buffers and solutions 
All the solutions used for cell culture, bacterial and yeast work were sterilized (autoclaved or 
filtered with 0.22µm or 0.45 µm filters). 
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Ammonium Chloride Solution 
0.8% NH4Cl in sterile water 
0.1 mM EDTA 
Ampicillin stock 
100 mg/ml Ampicillin  
Aqua bidest. 
Sterilized by filtration. Aliquots 1 ml; stored -20°C 
Blotto A for Western Blot 
1 x TBS 
5% milk powder 
0.05% Tween 20 
Buffer E1 resuspension buffer  
50 mM Tris/HCl pH 8.0 
10 mM EDTA  
100 µg/ml RNAse A  
Buffer E2 lysis buffer  
200 mM NaOH  
1%SDS  
Buffer E3 neutralization buffer 
3 M Potassium acetate pH 5.5 
Buffer QBT equilibration buffer (Qiagen) 
750 mM NaCl  
50 mM MOPS  
15% EtOH 
0.15% Triton X-100 
Buffer QC wash buffer (Qiagen) 
50mM MOPS pH 7.0 
15% EtOH 
Buffer QF elution buffer (Qiagen) 
1.25M NaCl  
50mM Tris/HCl pH 8.5 
15% EtOH 
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Denhardt’s solution 50X 
1% BSA (fraction V) 
1% Ficoll (type 400) Polyvinylpyrrolidone 
1% Aqua bidest. 
Sterilized by filtration (0.45µm). Stored -20°C 
DEPC water 
0.1% diethylpyrocarbonate in bi-distilled water 
shacked vigorously and autoclaved 
Dithiothreitol (DTT) solution 
1M DTT 
0.01M Sodium acetate pH 5.2 
Sterilized by filtration (0.22µm). Aliquots 1mL; stored -20°C 
DNA loading buffer 
0.25% Bromophenol blue 
0.25% Xylencyanol FF 
15% Ficoll in Aqua bidest. 
Electrophoresis running buffer 
250 mM Tris HCl, pH 8,5 
2 M glycin 
1% SDS 
Electrophoresis sample (or loading) buffer 
125 mM Tris 
4% SDS 
20% glycerol 
10%β-Mercaptoethanol 
0.01% bromophenol blue 
FACS Buffer 
PBS 
2% FCS 
1 mg/l propidium iodide 
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Frozen Storage Buffer (FSB 1) for chemically competent cells 
Reagent Amount per liter Final concentration 
1 M potassium acetate (pH 7.5) 10 ml 10 mM 
MnCl2·4 H2O 8.91 g 45 mM 
CaCl2·2H2O 1.47 g 10 mM 
KCl 7.46 g 10 mM 
Glycerol 100 ml 10% (v/v) 
Bidest. H2O to 1 l  
Sterilized by filtration (0.45 µm). Aliquots 40 ml; stored -20°C 
Frozen Storage Buffer (FSB 2) for chemically competent cells 
Reagent Amount per liter Final concentration 
Na-MOPS 2.3 g 10 mM 
CaCl2·2H2O 11 g 75 mM 
KCl 0.75 g 10 mM 
Glycerol 150 g 15% (v/v) 
Bidest. H2O to 1 l  
Sterilized by filtration (0.45 µm). Aliquots 24 ml; stored -20°C 
Formaldehyde 3.7% 
3.7% Formaldehyde (stock 37%) 
in PBS 
Gel fixation solution 
20% methanol (v/v) 
10% acetic acid (v/v) 
IPTG 
0.2% w/v Isopropyl-β-D-thio-galactopyranoside  
Aqua bidest. 
Sterilized by filtration (0.2µm). Aliquots 1ml; stored at -20°C 
Kanamycin stock 
50mg/ml Kanamycin Aqua bidest. 
Sterilized by filtration. Aliquots 1 ml; stored at -20°C 
Lithium acetate stock solution 10X pH 7.5 
1M Lithium acetate  
pH 7.5 with diluted acetic acid 
autoclaved 
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Methocult™ GF M3434 
1% Methylcellulose in Iscove’s MDM 
15% Fetal Bovine Serum 
1% Bovine Serum Albumine 
10 µg/ml rh Insulin 
200 µg/ml Human Transferrin (iron-saturated) 
0.1 mM 2-Mercaptoethanol 
2 mM L-glutamine 
50 ng/ml rm SCF 
10 ng/ml rm IL-3 
10 ng/ml rh IL-6 
3 units/ml rh Erythropoietin 
10x MOPS electrophoresis buffer for Northern blot 
0.2 M MOPS pH 7.0 
20 mM sodium acetate 
10 mM EDTA pH 8.0 
Add water to 1l 
pH 7.0 with 2 N NaOH 
Na2HPO4 1M pH 7.2 
1M Na2HPO4 
Aqua bidest. 
Autoclaved 
Neutralization solution for Southern Blot 
1 M Tris HCl pH 7.4 
1.5 M NaCl 
50% PEG 4000 solution 
50% w/v PEG 4000  
Aqua bidest. 
Phosphate buffer saline (PBS) pH 7.4 
140 mM NaCl  
5.4 mM KCl  
9.7 mM Na2HPO4 x 2H2O 
2 mM KH2PO4 
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RIPA buffer (lysis buffer for Western blot) 
50 mM HEPES pH 7.5 (1 M stock) 
150 mM NaCl (5 M stock) 
1 mM EGTA (200 mM stock) 
10% Glycerol (50% stock) 
1% Triton X 100 
100 mM NaF 
10 mM Na4P2O7 x 10 H2O 
Protease inhibitors (freshly added): 
PMSF (stock 10 mg/ml diluted in isopropanol) 10 µl per 1 ml RIPA 
1:100 protease inhibitor cocktail stock (Sigma) in lysis buffer: 
104 mM AEBSF 
0.08 mM Aprotinin 
2 mM Leupeptin 
4 mM Bestatin 
1.5 mM Pepstatin A 
1.4 mM E-64 
Saline sodium citrate buffer (20xSSC)  
3 M NaCl  
0.3 M Sodium citrate pH 7.0 
DEPC-treated Aqua bidest. (for RNA experiments) 
Autoclaved 
Sample Buffer (for in vivo CoiP) 
150 mM Tris-HCl pH 8.0 
50 mM NaCl 
0.5% Triton X100 
SDS-electrophoresis running buffer 10x pH 8.3 
250 mM Tris Base  
1.92 M Glycin  
1% (w/v) SDS  
Aqua bidest. 
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SDS-protein running gel 10% (10 ml) 12% (10 ml) 
Tris/HCl (stock 1.5M pH 8.8) 2.5 ml 2.5 ml 
Acrylamide + Bisacrylamide (stock 30%) 3.3 ml 4.0 ml 
SDS (stock 10%) 0.1 ml 0.1 ml 
Aqua bidest 4.0 ml 3.3 ml 
TEMED 0.004 ml 0.004 ml 
APS (stock 10%) 0.1 ml  0.1 ml  
 
SDS-protein stacking gel 4.4% (8 ml) 
Tris/HCl (stock 1.5M pH 8.8) 1.0 ml 
Acrylamide + Bisacrylamide (stock 30%) 1.3 ml 
SDS (stock 10%) 0.08 ml 
Aqua bidest 5.5 ml 
TEMED 0.008 ml 
APS (stock 10%) 0.08 ml  
Separating electrophoresis gel buffer 
1.5 M Tris-HCl pH 8.8  
2% SDS 
Sodium dodecylsulfate (SDS) 10% 
10% (w/v) Sodium dodecyl sulfate  
Aqua bidest. 
Autoclaved 
Stacking Gel buffer 
1.5 M Tris-HCl pH 6.8 
2% SDS  
Stripping buffer for WB 
62.5mM Tris/HCl (stock 1M pH 6.7) 
2%SDS  
β-Mercaptoethanol 100mM 
Aqua bidest. 
Stripping buffer for Northern Blot 
0.1x SSC 
2% SDS 
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TBS-T wash buffer 5X pH 7.5 
250 mM Tris Base  
750 mM NaCl  
0.1% Tween 20 (1X) 
Aqua bidest. 
TE buffer 
10 mM Tris/HCl (stock 1M pH 8.0) 
1 mM EDTA 
Aqua bidest. 
Transfer buffer for Western Blot pH 8.8 
25 mM Tris Base 
20% Methanol 
1.44% (w/v) Glycin 
Aqua bidest. 
Triton X-100 cell lysis buffer 
0.5% Triton X-100 
in 1X PBS 
Trypan blue solution 
0.9% NaCl 
0.5% Trypan blue dyestuff 
Aqua bidest. 
X-gal 
2% 5-Bromo-4-chloro-3-indolyl-β-D-galactopyranoside 
in 100% N,N-dimethylformamide 
Stored in dark glass at -20°C 
 
5.2.11. Media 
5.2.11.1. Bacterial media 
E.coli bacteria were grown in Luria Bertani (LB) medium. Transfected bacteria containing the 
ampicillin resistance gene cells were grown in LB containing ampicillin (Amp) at the 
concentration of 100 µg/ml or transfected bacteria containing the kanamycin resistance gene 
cells were grown in LB containing kanamycin (Kan) at the concentration of 50 µg/ml. 
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LB medium pH 7.5 
1% w/vol Bacto-trypton  
0.5% w/vol Bacto-yeast extract  
0.5% w/vol NaCl 
Aqua bidest. 
Autoclaved 
LB agar plates 
LB medium 100 ml 
Bacto-agar 15 g 
Autoclaved 
Ampicillin 100 µg/ml or Kanamycin 50 µg/ml 
SOC medium 
Complete E.coli medium without selection (Sigma) 
950 ml dH2O 
20 g Tryptone 
5 g Yeast extract 
0.5 g NaCl 
250 mM KCl (10 ml to 1 liter) 
autoclaved and cooled to 60°C to add 20 mM glucose (1 M stock solution) 
Glycerol freezing solution 
1/3 Glycerol 
2/3 LB medium 
 
5.2.11.2. Yeast media 
Ingredients for liquid or solid media were dissolved in aqua bidest., mixed until completely 
dissolved and autoclaved in bottles (250-500-1000 ml). Amino acids (dropout solution) were 
prepared in water as 10X stock solution, autoclaved and added (50 ml/l) to medium without 
amino acids as required to obtain the desired SD medium. The dropout stock solution was 
prepared lacking the amino acids adenine, histidine, leucine, and tryptophan. 
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Dropout solution 
Amount in dropout powder 10x concentration (mg/ml) 
L-adenine hemisulfate salt∗ 200 
L-arginine HCl 200 
L-histidine HCl monohydrate∗ 200 
L-isoleucine 300 
L-leucine∗ 1000 
L-lysine HCl 300 
L-methionine 200 
L-phenylalanine 500 
L-threonine 2000 
L-tryptophan∗ 200 
L-tyrosine 300 
L-uracil 200 
L-valine 1500 
∗These amino acids were added separately for each selective Dropout medium  
(SD medium) 
 
YPD medium liquid 
1% w/v Yeast extract  
Peptone 2% 
Dextrose 2% 
For YPD plates 2% agar and 0.01% NaOH were added 
SD -T, -L plates 
6.7 g Yeast nitrogen base without aa 
20 g Agar 
850 ml Bidest. water 
100 ml sterile 10X –T, -L, -H, -A Dropout solution 
200 mg Adenine 
200 mg Histidine 
Autoclaved. Medium was allowed to cool to ~ 55°C before adding 2% glucose 
 
 
 
Materials and Methods 
 
 
57 
SD -T, -L, -H plates 
6.7 g Yeast nitrogen base without aa 
20 g Agar 
850 ml Bidest. water 
100 ml sterile 10X –T, -L, -H, -A Dropout solution 
200 mg Adenine 
Autoclaved. Medium was allowed to cool to ~ 55°C before adding 2% glucose 
SD -T, -L, -H, -A plates 
6.7 g Yeast nitrogen base without aa 
20 g Agar 
850 ml Bidest. water 
100 ml sterile 10X –T, -L, -H, -A Dropout solution 
Autoclaved. Medium was allowed to cool to ~ 55°C before adding 2% glucose 
SD -T, -L, -H, -A X-gal plates 
6.7 g Yeast nitrogen base without aa 
20 g Agar 
850 ml Bidest. water 
100 ml sterile 10X –T, -L, -H, -A Dropout solution 
Autoclaved. Medium was allowed to cool to ~ 55°C before adding 2% glucose and 20 
mg/ml X-α-gal solution in 1 ml DMF 
PEG/LiAc solution 
40% PEG 4000 
1X TE buffer 
1X LiAc 
Stock solutions (see 2.2.9) 
 
5.2.11.3. Cell culture media 
Complete RPMI or DMEM medium 
10% Fetal calf serum (heat-inactivated) 
1% penicillin/streptomycin solution (10.000 U/ml Penicillin, 10 mg/ml Streptomycin) 
RPMI1640 or DMEM to 500 ml volume 
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DMSO freezing medium 
10% DMSO sterile-filtered 
in filter sterilized and heat-inactivated FCS 
Roswell Park Memorial Institute culture medium (RPMI 1640) 
0.02 g/l L-Glutamine 
2.0 g/l NaHCO3 
Sterile filtered 
Dulbecco´s Modified Eagle medium (DMEM) 
4.5 g/l glucose 
0.5 g/l L-Glutamine 
0.1 g/l Sodium Pyruvate 
3.7 g NaHCO3 
Sterile filtered 
Penicillin/Streptomycin solution 
10,000 U/ml penicillin 
10 mg/ml streptomycin 
Trypsin/EDTA Solution 
0.05% Trypsin 
0.02% EDTA 
in PBS without Ca2+, Mg2+ 
 
5.2.12. Equipment  
Cytospin (Cytospin 2 Shandon) 
DNA Cross linker (GS Gene linker Bio-Rad) 
Flow Cytometry (BD FACS Calibur System) 
Fluorescence Activated cell sorting (BD FACSVantage SE System) 
Microscope (Zeiss Axiovert 200 M, Zeiss Axiovert 135) 
Sorvall RC SB Plus and RC-5 centrifuge (Kendro Laboratory Products) 
Microcentrifuge 5417 C (Eppendorf)) 
Spectrophotometer (Bio-Rad) 
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5.3. Molecular biology methods 
Many of the molecular biology procedures were performed as described (Sambrook and 
Russel, 2001). 
 
5.3.1. Plasmid DNA isolation from E. coli 
 
5.3.1.1. DNA Mini preparation 
This procedure, which rapidly isolates plasmid DNA from bacteria using the alkaline lysis 
method followed by Isopropanol precipitation, was used during the cloning process to isolate 
small amount of DNA from a large number of clones. 
Briefly, each single colony was inoculated into 3 ml of LB medium (plus 100 µg/ml Amp or 
50 µg/ml Kana) in plastic culture tubes and grown O/N at 37°C with vigorous shaking (260 
rpm). The next day 1.5 ml of the culture was transferred in Eppendorf tubes and bacterial cells 
were harvested by centrifugation at 14000 rpm for 2 min. 
The pellet was resuspended in 250 µl of cold Buffer E1 containing RNase (0.1 mg/ml) and 
250 µl of Buffer E2 were added, mixed gently, and the mixture was incubated at RT for 5 
min. 250 µl of Buffer E3 were added and mixed gently. The mixture was centrifuged at 14000 
rpm 15 min. The supernatant (~ 800 µl) was transferred to a new Eppendorf tube and 0.7 vol 
of isopropanol was added. The suspension was vortexed and incubated at -20°C for 10-20 min 
and then recentrifuged at 14000 rpm for 20 min. The pellet was washed with 500 µl of 70% 
ethanol, vortexed, and centrifuged 10 min at 14000 rpm, dried for 10-20 min and redissolved 
in 20 µl of sterile bidest. water. The DNA was stored at -20°C. 
 
5.3.1.2. DNA Maxi or MaxiEndofree preparation 
The plasmids used in the transfection experiments were prepared with the Qiagen maxi 
endofree kit, according to the manufacturer’s instructions. Qiagen plasmid purification 
protocols are based on a modified alkaline lysis procedure, followed by binding of plasmid 
DNA to Qiagen anion-exchange resin under appropriate salt and pH conditions. RNA, 
proteins, dyes, and low molecular weight impurities are removed by a medium salt wash. 
Plasmid DNA was eluted in a high salt buffer concentrated and desalted by isopropanol 
precipitation. Briefly, plasmids were prepared from E.coli XL-1 bacterial cultures grown in 
the presence of a selective antibiotic. 
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A single colony (or 50 µl of a glycerol stock) was inoculated into 5 ml of standard LB 
medium in the presence of ampicillin (50 µg/ml) or kanamycin (25 µg/ml), and grown for 6 h 
at 37°C with vigorous shaking (260 rpm). The preculture was diluted 1:100 into a larger 
volume of selective medium and grown to saturation (O/N) at 37°C with gently shaking (190 
rpm). 
The bacterial cells were harvested and centrifuged at 4000 rpm for 20 min at 4°C in Sorvall 
RC-5 with GS-3 rotor. The pellet was resuspended in 10 ml of Buffer P1 containing Rnase 
(0.1 mg/1ml) and transferred to non-glass tubes for the SS3H rotor. 10 ml of Buffer P2 was 
added, mixed by inversion, and the mixture was incubated at RT for 5 min. 10 ml of ice-cold 
Buffer P3 were added, mixed gently and the mixture incubated on ice for 20 min. The 
suspension was centrifuged at 16000 rpm 30 min at 4°C and the supernatant was transferred 
into new tube and recentrifuged at 16000 rpm for 15 min at 4°C. 
Qiagen column was equilibrated with 10 ml Buffer QBT. Subsequently, the supernatant from 
the cell lysate was applied to the column. Plasmid DNA bound to Qiagen anion-exchange 
resin was washed twice with 30 ml Buffer QC and eluted with 15 ml Buffer QF, collecting it 
in a 50 ml Falcon tube. The DNA was precipitated with 0.7 vol of isopropanol, incubated 10-
20 min at -20°C and centrifuged 5000 rpm for 30 min. The DNA pellet was washed with 15 
ml of 70% ethanol, vortexed, centrifuged 20 min at 5000 rpm, dried for 10-20 min and 
redissolved in 500 µl of sterile bidest. water. The DNA was stored at -20°C. 
 
5.3.2. Qualitative and quantitative DNA analysis 
To determine the quality and yield, the DNA was measured in an UV spectrophotometer 
(Pharmacia Biotech) at 260 and 280 nm, normally diluting 2 µl in 198 µl of sterile bidest. 
water. The DNA concentration was calculated by the spectrophotometric conversion 1A260 
unit of double-stranded DNA = 50 µg/ml (Sambrook, 1989). In addition, the ratio A260/A280 
was measured. Preparations with a DNA concentration of less than 0.2 µg/ml and a ratio 
below 1.5 were discarded. 
To ensure the correct preparation of the DNA plasmids, the DNAs were analyzed by one or 
more restriction enzyme digestions. 0.5 µg-1µg DNA (from maxiprep) or 1 µl DNA (from 20 
µl miniprep) were digested in 1.5 ml Eppendorf tubes in 20 µl of total volume containing: 
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1 µl of enzyme (10 U) 
2 µl of buffer (10X) 
x µl of sterile bidest. water up to 20 µl 
 
The mixture was spun down and incubates at 37°C (or recommended temperature) for 2-3 h. 
A 0.5-1.5% agarose gel in TBE 1X buffer with Ethidium bromide (final concentration 0.2 
µg/ml) was prepared. 1-2 µl of DNA loading buffer (10X) was added and mixed to each DNA 
sample and the complete content was loaded on the gel and run for 1 h at 60-100 V. An 
appropriate molecular weight marker (e.g. 1 kb DNA ladder from Life technologies) was 
used. 
 
5.3.3. DNA transformation into bacteria 
Two different protocols were used for bacterial transformation. The electroporation procedure 
was performed to transform electrocompetent Epicurian coli XL1-blue supercompetent cells 
(see 5.3.3.1) and the heat shock protocol was performed to transform chemically competent 
cells such as BL21 cells (see 5.3.3.3). 
 
5.3.3.1. Preparation of XL1 Blue electrocompetent cells 
A 40 µl aliquot of the frozen bacterial stock was inoculated in 5 ml of LB medium in a 50 ml 
Falcon tube and incubate O/N at 37°C with constant shaking (100 rpm). The next morning the 
O/N culture (5ml) was inoculated in 500 ml of LB medium in a 1 l Erlenmeyer glass flask and 
cells were grown for 2-3 h to reach OD600 ~ 0.5-0.6. Subsequently, the cells were transferred 
into Beckman centrifuge-tubes on ice and centrifuged 15 min at 4000 g in a precooled GS-3 
rotor at 4°C. Each cell pellet was washed twice in 100% vol with cold and sterile bidest. 
water, then in bidest. water 10% sterile glycerol. Cells were re-centrifuged 10 min at 4000 g, 
resuspended in 500 µl of cold bidest. water 10% glycerol, transferred to sterile Eppendorf 
tubes in 40 µl aliquots, shock frozen in liquid N2 and stored in -80°C freezer. 
 
5.3.3.2. Plasmid DNA transformation with electroporation 
For electroporation, XL1-Blue electrocompetent bacteria cells were thawed on ice. 1 µl of 
plasmid DNA (50-100 ng) or 5-10 µl of ligation reaction (from a 20 µl total ligation) were 
added to 40 µl thawed electrocompetent cells and mixed by pipetting. The cells were 
Materials and Methods 
 
 
62 
incubated on ice 1-2 min and then added to ice-cold electroporation cuvettes for bacteria. The 
cells were shocked by 1 pulse of 2.5 kV in 3-4 msec. immediately after each pulse, 1 ml of 
RT SOC medium was added and the suspension was transferred back to the original 
microtube, then incubated for 1 h at 37°C with shaking. After 15 sec of high speed 
centrifugation, 800-900 µl of medium was removed, the rest was resuspended and 100-200 µl 
of the suspension was plated on prewarmed LB/Amp or LB/Kana plates and incubated at 
37°C O/N. 
 
5.3.3.3. Preparation of BL21 chemically competent cells 
An aliquot of 100 µl from the frozen bacterial stock was inoculated in 20 ml LB medium in a 
100 ml Erlenmeyer glass flask and incubate O/N at 37°C shaking. The next morning the O/N 
culture (20 ml) was inoculated in 600 ml of LB medium in a 1 l Erlenmeyer glass flask and 
cells were grown for 2-3 h to reach OD600 ~ 0.5-0.7. Subsequently, the cells were transferred 
into Beckman centrifuge-tubes on ice and centrifuged for 10 min at 4000 rpm in a precooled 
GS-3 rotor at 4°C. Each cell pellet was resuspended in 240 ml sterile and cold FSB 1 (see 
5.2.9), then the suspension was incubated on ice 15 min. Cells were re-centrifuged for 10 min 
at 4000 rpm, resuspended in 24 ml of sterile and cold FSB 2 (see 5.2.9) solution, aliquoted in 
sterile Eppendorf tubes in 100 µl aliquots, shock frozen in liquid N2 and stored in -80°C 
freezer. 
 
5.3.3.4. Plasmid DNA transformation with chemically BL 21 competent cells 
For chemically transformation of XL1-Blue competent bacteria cells, 1 µl of plasmid DNA 
(50-100 ng) or 20 µl of ligation reaction (from a 20 µl total ligation) was added to 100 µl 
thawed competent cells and mixed by pipetting. The cells were incubated on ice 50 min. The 
cells were then incubated 90 sec at 42°C. After 15 sec of high speed centrifugation, 800-900 
µl of medium was removed, the rest was resuspended and 100-200 µl of the suspension was 
plated on prewarmed LB/Amp or LB/Kana plates and incubated at 37°C O/N. 
 
5.3.4. Cloning of PCR products 
The plasmids generated in this work were prepared by amplifying the desired DNA inserts by 
PCR with primers containing appropriate restriction sites at their 5’ termini. Then the PCR 
products were digested with the appropriate restriction enzymes and cloned into the recipient 
vector. 
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The strategy followed was: 
1) Design and synthesize 5’ and 3’-end PCR primers with the desired restriction sites; 
2) Perform the PCR with the appropriate primers and DNA template; 
3) Prepare the vector and insert for cloning (preparative gel/DNA purification or DNA 
ethanol precipitation); 
4) Ligate vector and insert DNAs; 
5) Transform the ligation products into E.coli electrocompetent cells or chemically 
competent cells; 
6) Plate on appropriate selection plates; 
7) Pick colonies and perform plasmid DNA minipreps; 
8) Restriction analysis to identify the clones containing the correct DNA insert; 
9) Sequence the insert or at least the cloning junction; 
10) Store the correct plasmid as DNA and bacteria glycerol stock at –20°C. 
 
5.3.4.1. Amplification of DNA by the polymerase chain reaction (PCR) 
To amplify DNA, the Platinum Taq DNA Polymerase (NewEngland Biolabs or Invitrogen) 
was used. The system is composed of the thermostable Taq DNA enzyme and the appropriate 
10X Taq DNA buffer, the NEB Taq DNA buffer already contains magnesium, the Invitrogen 
PCR kit provide the magnesium 50 mM to be added to the PCR mixture. The DNA 
amplification was performed according to the manufacturer’s instructions and some 
adjustments depending on the template and primer pairs. First, one master mix was prepared 
using sterile tubes, pipettes, and pipette tips (sterilized in the UV Stratalinker) with all 
reagents on ice as follows: 
 
PCR mix: 
 
10X PCR buffer 2.5 µl 
MnCl2 50 mM 0.6 µl 
dNTPs 2 mM 2.5 µl 
5’ Primer (10 µM) 0.5 µl 
3’ Primer (10 µM) 0.5 µl 
Bidest. water up to 19 µl 
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The reagent mix was pipetted into thin wall PCR tubes (0.2 ml), 1 µl of template (~ 100 ng) 
was added and the sample was placed immediately in the thermocycler and the PCR 
performed.  
Second, the cycle conditions in the Thermocycler (Perkin Elmer PCR System 2400 or PE 
Applied GenAmp PCR System 9700) were adjusted. 
Generally the PCR reaction used for PCR fragment with length up to 1.0 kb were performed 
with the following conditions: 
 
1. 95°C 2 min denaturation of template 
2. 94°C 30 sec denaturation 
3. 55-60°C (primer dependent) 
30 sec-1 min 
Annealing               20 cycles 
4. 72°C 1 min (template dependent) elongation 
5. 72°C 5 min finish elongation 
6. 4°C ∞ reaction end 
 
At the end of the PCR, 5 µl for each sample was analyzed on a 0.5-1% agarose gel.  
 
5.3.4.2. Vector and insert preparation 
In this work DNA was purified from agarose gels using the Qiagen gel purification kit, the 
procedure was performed according to the manufacturer’s instructions.  
Both vector (1-5 µg) and insert (1-5 µg) were digested with the compatible restriction 
enzymes in 20-50 µl reaction for 3 h to O/N: 
 
1-5 µg of DNA 
10-50 U of appropriate enzyme 
5-10 µl of enzyme buffer 5X 
x µl of sterile water up to 20 or 50 µl  
 
The cleavage reaction was pipetted in a 1.5 ml Eppendorf tube and incubated in a 
thermoblock at the optimal temperature as recommended for each enzyme. 
If the ends of the prepared vector were identical (e.g., following a single digestion), the vector 
DNA was treated for 30 min at RT with 1-2 µl of calf intestinal alkaline phosphatase (CAIP) 
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(Invitrogen) to remove the phosphate groups from the 5’ ends to prevent self-ligation of the 
vector. After 30 min incubation CAIP was inactivated for 15 min at 60°C. After digestion 
reaction the DNAs were precipitated for the ligation. 
 
 
DNA precipitation procedure: 
Add the following reagents to a 1.5 ml Eppendorf tube: 
1) 20 µl of digestion reaction 
2) 10% v/v 3 M NaAc 
3) 2.5 vol 100% ethanol 
4) mixed by vortexing 
5) incubated at -20°C for 10 min 
6) centrifuged 13000 rpm at 4°C for 20 min 
7) pellet was washed in 72 µl 70% ethanol 
8) centrifuged 13000 rpm at 4°C for 10 min 
9) the fluid was removed and the pellet dried at RT for 10-20 min 
10) DNA pellet was resuspended in 20 µl sterile water 
11) DNA was stored at -20°C 
 
5.3.4.3. Ligation of plasmid vector and insert DNAs 
After the vector and insert DNAs have been purified, the concentration of DNA was 
estimated by agarose gel electrophoresis in comparison to a molecular weight standard. The 
ligation was performed using T4 DNA Ligase (New England Biolabs) according to the 
manufacturer’s instructions. 
The typical ligation reaction was performed at RT for 2 h or at 16°C O/N, with 50-200 ng of 
vector and 50 to 200 ng of insert DNA (molar ratio of vector to insert 1:3) in 20 µl of final 
volume: 
 
1-2 µl of vector (50 to 200 ng) 
3-6 µl of insert  (1:1 to 1:3 molar ratio of vector to insert) 
2 µl of DNA Ligase buffer (5X) 
1 µl T4 DNA Ligase 
x µl of water up to 20 µl 
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To monitor the efficiency of ligation between vector and insert, the linear vector was 
transformed in the absence of the DNA insert. 
At the end of the reaction, the samples were placed on ice and 5-10 µl was transformed into 
electro-competent or chemically competent cells (E.coli XL1-blue competent cells). 
5.3.5. Analysis of RNA by Northern hybridization 
To analyze the size and the expression of the OSTL RNA, Northern analysis was performed. 
Total RNA was isolated from cells in cell culture or from mouse tissues, run on an agarose 
gel, transferred to nylon membranes and detected by hybridization with a radiolabeled DNA-
probe. To successfully isolate and analyze intact RNA some important precautions were used: 
effective disruption of cells, denaturation of nucleoprotein complexes, inactivation of 
endogenous ribonuclease (RNase) activity and purification of RNA away from contaminating 
DNA and protein (Sambrook, 1989). All disposable plastic ware were sterile. Many solutions 
as well as nondisposable plastic ware were pretreated with diethyl pyrocarbonate (DEPC) 
0.05% O/N before sterilization. 
 
5.3.5.1. Qiagen isolation of total RNA 
The isolation and purification of RNA from tissue culture cells or mouse tissues was 
performed using the Qiagen RNEasy mini kit according to the manufacturer’s instructions.  
Briefly, cells were washed with sterile PBS, trypsinized (adherent cells), diluted in the 
complete medium, counted and centrifuged at 1000 rpm for 5 min. 10 µl of β-
mercaptoethanol were added per 1 ml of RLT lysis buffer. 
Cell pellets or tissue pellets were resuspended in RLT buffer (350 µl for up to 5x106 cells or 
600 µl for up to 1x107 cells or 350 µl for up to 20 mg of tissues or 600 µl for up to 30 mg of 
tissues) and frozen at -80°C. Frozen lysates were thawed at 37°C for 10 min, transferred 
directly into QIAshreder columns sitting in 2 ml collection tubes and centrifuged at maximum 
speed for 2 min. Samples were collected into new tubes and 1 vol of 70% ethanol was added, 
creating conditions which promote selective binding of RNA to the RNEasy membrane. 700 
µl of sample were applied to RNEasy mini spin column sitting in 2 ml collection tubes and 
centrifuged at 13000 rpm for 15 sec to allow absorption of RNA to the membrane. If the 
volume of lysate cells exceeded 700 µl, the rest of the suspension was applied to the same 
RNEasy spin column, using the same collection tube but discarding the flow-through each 
time. 
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The columns were washed with 700 µl of RW buffer and centrifuged at 13000 rpm for 15 sec. 
After having transferred the RNEasy spin columns into new collection tubes, 500 µl of RPE 
buffer (containing ethanol) were added and centrifuged at 13000 rpm for 15 sec. reusing the 
collection tubes and discarding the flow-through, the columns were centrifuged at maximum 
speed to dry the membrane. The RNEasy spin columns were then transferred into 1.5 ml 
collection tubes and the RNA was eluted with two centrifugation steps at 13000 rpm for 1 min 
with 30 µl of DEPC-treated water and stored at -80°C. After this step all procedures were 
performed keeping RNA samples on ice. 
Yield and quality of the RNA were analyzed by UV spectrophotometer. The concentration of 
RNA was determined by the spectrophotometric conversion 1A260 unit of single-stranded 
RNA = 40 µg/ml. The absorbance ratio A260/A280 was determined and good RNA preparations 
were considered exhibiting a ratio A260/A280 grater than 1.8 (Sambrook, 1989). RNA (1.0 µl) 
was also analyzed by agarose gel electrophoresis and the 28S and 18S ribosomal bands were 
observed. 
 
5.3.5.2. Agarose gel electrophoresis (formaldehyde-agarose gel) 
To perform Northern analysis, a formaldehyde-agarose gel (Sambrook and Russel, 2001) was 
used. 
Two hours before starting, the electrophoresis chamber, combs and tray were washed with 
DEPC-treated Millipore water. 
To prepare 100 ml of a 1% agarose gel containing 2.2 M formaldehyde: 
 
1) 1 g of agarose was added to 74 ml DEPC-treated Millipore water; 
2) the agarose was dissolved by boiling in a microwave oven, 
3) the solution was cooled to 55°C; 
4) 10 ml of 10X MOPS electrophoresis buffer was added; 
5) 16 ml of deionized formaldehyde was added 
 
In a chemical fume hood, the agarose gel was poured using a 3-mm comb with at least four 
more wells than the number of RNA samples to be tested. These extra lanes were used for 
RNA size markers and running dyes. The gel was allowed to set for at least 1 hour at RT then 
wrapped with Saran Wrap until the samples were ready to be loaded. 
20 µg of total RNA were dried in a speed vac and resuspended in 18 µl of formaldehyde-
mixture, mixed well by pipetting and incubated for 1 h in a water bath at 50°C. 
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Formaldehyde mixture for RNA samples: 
2 µl of RNA (up to 20 µg) 
2 µl of 10X MOPS electrophoresis buffer (2.2.9) 
4 µl of formaldehyde 
10 µl of formamide 
1 µl of Ethidium bromide (200 µg/ml) 
____________________________ 
18 µl 
 
After 10 min incubation on ice, the samples were centrifuged for 5 sec to deposit all of the 
fluid in the bottom of the centrifuge tubes. 
2 µl of 10x formaldehyde gel-loading buffer were added to each sample and load them into 
the previously prepared 1% agarose gel. The electrophoresis was performed for 4-5 h at 80 V 
(in a 15 cm electrophoresis chamber) until the bromophenol blue had migrated 2/3 of the gel. 
 
10x formaldehyde gel-loading buffer: 
50% glycerol (diluted in DEPC-treated Millipore water) 
10 mM EDTA pH 8.0 
0.25% (w/v) bromophenol blue 
0.25% /(w/v) xylene cyanol FF 
 
5.3.5.3. Transfer of RNA to membrane 
At the end of the electrophoresis, the gel was rinsed in sterile DEPC-treated Millipore water 
to remove the formaldehyde. In the meanwhile twenty-eight pieces of Whatman 3MM paper 
and one piece of nylon membrane (Zeta-Probe GT blotting membrane, BioRad) were cut to 
the exact size of the gel, soaked first in sterile DEPC-treated Millipore water and then in 
20xSSC (prepared with DEPC-treated Millipore water and autoclaved). The transfer of the 
RNA to membrane was performed by capillary blotting O/N at RT (Sambrook, 1989). After 
the blotting, the RNA was fixed to the membrane using a UV-crosslinker (Bio-Rad) with the 
auto cross linker program. The membrane was marked under the UV-light with a special pen 
and stored in a plastic bag at 4°C until the hybridization. 
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5.3.5.4. Probe hybridization 
Before the hybridization step, the membrane was washed in 2xSSC at RT for 20-30 min, 
changing several times the buffer. 
The membrane was then placed in a glass tube and pre-hybridized for 3 h with rotation at 
65°C in 20 ml hybridization solution with 150 µl (10-15 µg) of denaturated Lacks DNA (to 
block unspecific ligations of the probe). The DNA probe was prepared (2.3.5.5.1), denatured 
at 100°C for 5 min, quick chilled on ice and added in 20 ml of fresh prepared and prewarmed 
hybridization solution at the final concentration of 106 cpm/ml. The membrane was 
hybridized with the radioactive probe with continuous rotation O/N at 65°C. 
After hybridization, the membrane was washed twice with 50 ml of wash buffer I at RT for 
10-20 min and twice with 50 ml of wash buffer II at 65°C for 10-20 min, and once with wash 
buffer III at 65°C for 5-10 min. The radioactive membrane was wrapped in plastic and 
autoradiography was performed. 
To reprobe the membrane, it was washed in a large volume of stripping buffer at 65°C for 2 h. 
As a positive control for RNA levels, the filter was re-hybridized with a GAPDH [α32P]- 
probe, using a PCR amplified GAPDH fragment (5’ primer: mGAPDHF and 3’ primer: 
mGADHR). 
 
Hybridization solution 
25% 20xSSC (see 2.2.10) 
10% 50xDenhardt’s solution (see 2.2.10) 
10% dextransulfat 
0.5% SDS 
Millipore water was added to final volume 
10% SDS 
10% w/v SDS powder in 1% DEPC-treated water 
Wash buffer I 
2xSSC 
Wash buffer II 
2xSSC 
0.1% w/v SDS 
Wash buffer III 
0.2xSSC 
0.1% w/v SDS 
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Stripping wash buffer 
1 M Tris HCl pH 8.0 
0.5 M EDTA pH8.0 
0.1xDenhardt’s solution 
 
For the human multiple tissue northern blot (hMTN blot), a commercial MTN blot (Clontech) 
was used. The hybridization was performed with the ExpressHyb™ hybridization solution at 
68°C. For the human B cells Northern, the same protocol as above was used. 
 
5.3.5.5. Radioactive labeling of DNA 
 
5.3.5.5.1. Megaprime DNA labeling system 
The Megaprime™ kit (Pharmacia), which uses random hexanucleotides to prime DNA 
synthesis on denatured template DNA, was used to label DNA. The Klenow fragment of 
DNA polymerase I is used in this kit. According to the manufacturer’s instructions, 25 ng of 
DNA was diluted in TE buffer pH 8.0 to a final volume of 34 µl in a 1.5 ml sterile centrifuge 
tube, heat denaturated at 95°C for 5 min and snap cooled on ice for 5 min. After a brief spin 
down, the denatured DNA was added to the Megaprime™ tube reaction. 5 µl of α[32P] dCTP 
were added, mixed by pipetting up and down about 12 times, and the reaction mixture was 
incubated at 37°C for 1 h. Then the DNA was denatured by heating to 95°C for 5 min and 
snap cooled on ice for 5 min. After a brief spin down, the radiolabeled DNA was purified 
using Bio-Spin Chromatography columns (BioRad) according to the manufacturer’s 
instructions.  
 
5.3.6. Analyzing OSTL expression by Reverse Transcriptase PCR (RT-PCR) 
5.3.6.1. RNA extraction from culture cells or frozen cells and from mouse tissues 
The RNA extraction was performed using a denaturing guanidine isothiocyanate-containing 
buffer for cell lysis and a silica-gel-based membrane for RNA isolation. The reagents and the 
protocol from the RNeasy Minikit (Qiagen) were used as described in 5.3.5.1.  
 
5.3.6.2. cDNA synthesis (Reverse Transcriptase Reaction) 
The reagents and protocols used for cDNA synthesis were from Invitrogen. To avoid DNA 
contamination, the RNA was treated with Deoxyribonuclease I before the cDNA synthesis. 
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For DNase I treatment, 1 µg RNA was mixed with 1 µl 10x DNase I reaction buffer (supplied 
in the kit), 1 µl DNase I (1 U/µl) in a total volume of 10 µl. The tube was incubated at RT for 
40 min and DNase I was inactivated by adding 1 µl of 25 mM EDTA to the reaction tube. 
After DNase treatment, a RNA aliquot was loaded on an agarose gel for quality control and to 
estimate the RNA concentration. 
For the Reverse Transcriptase reaction, 2 to 4 µl of RNA (approximately 2 µg) were pipetted 
into an 1.5 ml RNase-free Eppendorf tube together with 1 µl of Oligo (dT)12-18, 1 µl of 10 mM 
dNTP mix (containing 10 mM each dATP, dTTP, dCTP, dGTP at neutral pH) and sterile 
water to a total volume of 12 µl. The mixture was heated to 65°C for 5 min and quickly 
chilled on ice. To the tube contents, 4 µl of 5X First-Strand buffer, 2 µl of 0.1 M DTT, and 1 
µl of RNaseOUT™ were added. The tube contents was mixed and incubated at 42°C for 2 min. 
Afterwards, 1 µl of Superscript™ II Reverse Transcriptase was added, and the reaction was 
incubated at 42°C for 50 min. The reverse transcriptase was then heat-inactivated at 70°C for 
15 min.  
 
5.4. Identification of Protein-Protein Interactions with the Yeast Two Hybrid 
System 
 
5.4.1. Background 
To identify OSTL-interacting proteins the yeast two-hybrid system has been used (Fields and 
Song, 1989; Chien et al., 1991). This method is a useful sensitive approach to detect protein-
protein interactions that uses yeast as a test vehicle and transcriptional activation of a reporter 
system. The two-hybrid approach takes advantage of the modular domain structure of 
eukaryotic transcription factors. This modular structure consists at least of two distinct 
functional domains, one that directs binding to specific DNA sequences (BD) and one that 
activates transcription (AD). The DNA binding and activation domains need not be covalently 
attached to each other for activation; and they can be exchanged between transcriptional 
factors and retain their function. In this work the GAL 4 based two-hybrid system 3 
(Clontech) was used (Fig 5.1). To analyze the interaction of two different proteins X and Y, 
two constructs with encode separate fusion of protein X with GAL4 DBD and of Y with 
GAL4 AD domains are used. Our bait protein, OSTL, was cloned into the pGBKT7 vector 
(see 5.2.8.4.1), which then expressed a GAL4-DBD-OSTL fusion. A commercially available 
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Hela-cDNA-Library cloned into the pGAD-GH vector was used for screening (the “prey” 
proteins are expressed as GAL4-AD fusions). Interaction between bait and a prey plasmid in a 
single yeast clone can be scored by assaying the activation of reporter genes. 
The following reporter genes are present in the yeast strain AH109: His1, Mel1, Ade2. 
 
 
 
Figure 5.1: Scheme of the yeast two hybrid system 
 
Briefly, the main steps of the yeast two hybrid screen to identify OSTL-interacting proteins 
were: 
1) Construction of bait protein plasmids pGBT9-E06 (Ampicillin resistance) (used for 
expression and activity tests) and pGBKT7-E06 (used for the large transformation, 
because of the advantage in the selection (Kanamycin resistance); 
2) Transformation of yeast CG1945 cells with pGBT9;  
3) Characterization of bait protein expression and activity (spurious activation of 
reporters); 
4) Two Large scale transformation of yeast AH109 cells (AH109 cells have His1, Ade2, 
and Mel1 as reporter genes) with pGBKT7-E06 and with Hela S3-cDNA library 
plasmid (pGAD-GH); 
5) Collection of primary transformants in medium stringency (SD-T,L,H) plates (100 
cm) for the first transformation and in high stringency (SD-T,L,H,A) plates (100 cm) 
for the second one; 
6) X-α-Gal test (Mel1 reporter gene activity): 
Plate colonies from medium and high stringency transformants onto SD-T,L,H,A + X-
α-Gal plates. The blue clones (Mel1 reporter active) were selected; 
7) Isolation of plasmid-DNA from yeast clones and transformation in XL1-blue-bacteria; 
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8) Selection of colonies containing the prey plasmid by growth on Ampicillin plates; 
9) Isolation of plasmid-DNA by miniprep, restriction analysis; 
10) Sequence analysis of positive clones and DNA maxiprep of the relevant positive 
clones. 
 
5.4.2. Determination of yeast cell density 
The density of cells in culture was determined spectrophotometrically by measuring its optical 
density (OD) at 600 nm. For reliable measurements, cultures were diluted such that the OD600 
was < 1. In this range, each 0.1 OD600 unit correspond to ~ 3x106 cells/ml. 
 
5.4.3. DNA transformation into yeast cells using the lithium acetate procedure 
The lithium acetate method is based on the fact that alkali cations make yeast competent to 
take up DNA providing high transformation efficiency of 104 to 106 transformants/µg. 
One day before the experiment one or more AH 109 colonies (≤ 4 weeks old) were inoculated 
in 1 ml YPD medium with 2% of glucose and grown O/N to saturation at 30°C with vigorous 
shaking. 
On the next day the O/N culture was inoculated into 50 ml YPD with 2% glucose in a 500 ml 
flask and incubated until it reached an OD600 of 0.2-0.3 (~ 3x106 cells/ml). At this point, the 
cells were grown for another 1 to 2 generations (2 to 5 h) at 30°C. 
After that procedure, the yeast cells were harvested by centrifuging 10 min at 4000 rpm at RT 
in a Rotanata 46 R (Hettinge) centrifuge, resuspended in 25 ml of sterile water and 
recentrifuged 10 min at 4000 rpm at RT. Pelleted cells were resuspended in 1.5 ml buffered 
lithium acetate solution, freshly prepared as follows: 
 
1 vol 10x TE buffer, pH 7.5 
1 vol 10x lithium acetate stock solution 
8 vol sterile water 
 
For each transformation reaction, 0.1 mg freshly denaturated high-molecular-weight carrier 
DNA with 0.1 to 1.0 µg plasmid DNA were mixed in a sterile 1.5 ml microcentrifuge tube. 
Immediately, 100 µl of competent yeast cells and 600 µl of PEG/LiAc solution were added. 
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PEG/LiAc solution: 
1 vol 10x TE buffer, pH 7.5 
1 vol 10x lithium acetate stock solution 
8 vol 50% PEG 4000 
 
Cells were incubated for 30 min at 30°C; 70 µl of DMSO was added to each tube and gently 
mixed by inversion; the cells were then heat shocked 15 min at 42°C, chilled on ice and 
centrifuged for 5 sec at top speed in a microcentrifuge. Finally, the pellet was resuspended in 
1 ml of 1x TE buffer. 100-200 µl of the yeast suspension were plated on appropriate SD 
plates, and incubated at 30°C until colonies appeared (normally 2-7 days). 
 
5.4.4. Preparation and test of the bait protein 
Firstly, the pGBT9 bait plasmid expressing human OSTL (E06 clone) was constructed (for 
details see 6.6.1). In a second step, using the lithium acetate transformation protocol, pGBT9-
E06 and the empty pGBT9 as a control were transformed separately into yeast strain CG 
1945. The cells were plated on SD –W plates. Then the transformed yeast cells were replated 
on SD –W, -H. Growth on SD –W, -H plates would indicate activation of the HIS3 reporter 
gene through the bait protein alone. If this had been the case, the bait protein would have to be 
modified to remove any protein domains that happen to function as activation domains in this 
setting. 
To determine the degree of growth on –H plates, serial dilution plating was performed. This 
was done by dissolving a yeast colony in 500 µl sterile water. 100 µl of the suspension were 
diluted into 1 ml sterile water and a series of 1/20 dilutions were prepared to cover a 1000-
fold concentration range. 100 µl from each dilution (undiluted, 1/10, 1/100, 1/1000) were 
spread on 100 mm SD-T and SD-TRP, HIS dropout plates and then incubated at 30°C. The 
growth of the cells was monitored for several days. 
For the further yeast screens we have cloned E06 DNA into pGBKT7 vector, which has 
different selections in yeast and bacteria (see 5.2.8.4.1) and facilitates the selection for 
positive interactors and confirmation of these interactions. 
5.4.5. Large scale cDNA library transformation 
In order to obtain a high number of transformants expressing an individual library plasmid, a 
large scale transformation protocol was used. 
Materials and Methods 
 
 
75 
The DNA transformation into yeast cells AH109 was prepared in the same way as by 5.4.3. 
Selected transformed colonies (AH109-pGBKT7/OSTL) from SD –TRP yeast selection 
medium were prepared (see 5.4.3) in 2 ml of total volume and completely used for the 
transformation with the cDNA-Library. 
55 µg of plasmid DNA was used to obtain a maximal amount of transformation efficiency 
(this detail was checked before with series of pilot experiments to obtain the maximum 
number of colonies), that is this case was 4x104 transformants/µg DNA. 
After transformation the cells were incubated 1 h at 30°C with 22.5 ml of YPD yeast medium. 
The pellet was washed with 1X TE buffer and resuspended in 22.5 ml of the same buffer. 250 
µl of the transformed yeast cells was divided into 50 SD –TRP, LEU, HIS yeast selection 
plates and incubated at 30°C for 3 to 7 days (until the colonies appear). As a control, 2 µl of 
the transformation mixture was plated into SD –LEU and SD –TRP, LEU yeast selection 
plates and incubated in the same conditions.  
 
5.4.5.1. Selection of clones containing interacting prey proteins 
Through the selection, only the transformants that contain the DNA-BD/OSTL-fusion-protein 
interacting with an AD-fusion-protein must be examined. The yeast strain AH109 has three 
reporter genes (HIS3, ADE2, MEL1/lacZ) under control of the GAL4 DNA binding sites. This 
is a great advantage, because it reduces the number of false positives, if only those clones are 
analyzed that show activation of all three reporter genes. The colonies expressing HIS3, 
ADE2 have been selected through grown into SD –TRP, LEU, HIS, ADE yeast selection 
plates. These colonies were tested by expression of the MEL1-gene or through the activity of 
the α-Galactosidase. The primary transformants from 50 SD –TRP, LEU, HIS yeast selection 
plates were replated into ADE plates and finally into x-α-Gal plates. The selected colonies 
from the second screen (using high selective plates) were replated into x-α-Gal plates. After 4 
to 7 days incubation at 30°C, the positive colonies wee selected through it blue color. 
5.4.6. Rapid isolation of plasmid-DNA from yeast 
Plasmid DNA is released from yeast transformants together with chromosomal DNA in a 
rapid protocol by vortexing cells with glass beads in the presence of detergents, phenol, 
chloroform, and isoamyl alcohol. 
A single yeast colony was inoculated into 2 ml of medium in a sterile 14 ml falcon tube. The 
yeast cells were grown O/N at 30°C at 200 rpm. 1.5 ml of the O/N cultures was transferred 
into a microcentrifuge tube and spun 5 sec at high speed. The supernatant was removed and 
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the pellet was briefly vortexed. Cells were resuspended in 200 µl of breaking buffer (5.2.9). 
0.3 g of glass beads (0.45-0.52 mm acid-washed, ~ 200 µl) and 200 µl of 
phenol/chloroform/isoamyl (25:24:1) were added and vortexed for 2 min at high speed. The 
suspension was centrifuged 5 min at high speed at RT, and 50 µl of the aqueous layer was 
transferred in a new microcentrifuge tube and stored at -20°C. 
 
5.4.7. Transformation of plasmid DNA in E. coli 
Firstly E.coli XL1-blue were made electrocompetent and aliquoted at –80°C (5.3.3.1). To 
perform the electroporation with plasmid DNA isolated from the yeast clones, XL1-blue 
bacteria cells and DNA were thawed on ice. 
2 µl (1-2 µg) of plasmid DNA was added to the thawed bacteria, mixed, and the solution was 
transferred to ice-cold electroporation cuvettes (2 mm Equibio). After 1-2 min incubation, the 
cells were electroporated with a 2.5 mV in 3-4 msec pulse (Easyject-Equibio, 2500 V or 1800 
V, 6.125 kV/cm maximum field strength). Immediately after the pulse, 1 ml of SOC medium 
were added and the suspension was transferred back to the original microtube, then incubated 
1 hour at 37°C shaking. After 5 sec of centrifugation at high speed, 800 µl of medium was 
removed, the rest was resuspended and 100 µl of the suspension was spread on LB/Amp 
plates and incubated at 37°C O/N. 
 
5.4.8. Confirmation assays for specific interacting proteins 
5.4.8.1 Confirming potential interactions by co-transformation of bait and prey plasmid 
The specific interaction between two fusion proteins was first proved through 
cotransformation assay in yeast cells. The above candidates (pGAD-GH/cDNA-clone) were 
cotransformed with the DNA-BD-plasmid pGBKT7/OSTL into AH109 competent yeast cells 
(5.4.3).  
 
5.4.8.2. Transient cotransfection of mouse fibroblast cells (NIH3T3) 
Detailed procedure in section 5.5.1.1. 
 
5.4.8.3. In-vitro-expression and radioactive label of the interacting proteins for 
coimmunoprecipitation assay 
Radioactively labeled (35S-methionine incorporation) proteins were produced using an in 
vitro expression system: the TNT-reticulocyte-lysate system (Promega). The proteins to be 
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expressed were cloned into the vectors pGBKT7 or pGADT7 (see 5.2.7.4). These vectors 
contain a T7 promoter sequence 5’ of the multiple cloning site. Using T7-RNA-polymerase, 
cDNAs in these vectors can be transcribed at high copy numbers in the above mentioned 
reticulocyte lysate and the resulting RNA is translated into the appropriate proteins. Proteins 
translated from the pGBKT7 vector will have a Myc epitope tag at their N-termini, and 
proteins translated from the pGADT7 vector will have an HA epitope tag at their N-termini. 
The procedure was performed as follows: 
 
25 µl of TNT Rabbit Reticulocyte Lysate 
2 µl of Reaction buffer 
1 µl of T7 RNA Polymerase 
1 µl of amino acid, without Methionin (1mM) 
2 µl of [35S] Methionin (>1.000Ci/mmol at 10mCi/ml, Amersham) 
1 µl of RNasin Ribonuclease Inhibitor (40u/µl) 
2 µl of DNA Template(s) (0.5 µg/µl) 
Nuclease-Free Water up to 50 µl 
The reaction was incubated at 30°C for 90 min. 
 
In vitro co-immunoprecipitation assay 
The above amino acid methionine radioactive lysates (see 5.4.9.2) expressed in vitro were 
used for the CoiP assay. 
The procedure was performed as follows: 
 
10 µl of in vitro translated (35S-methionine-labeled) Myc-tagged bait protein 
10 µl of in vitro translated (35S-methionine-labeled) HA-tagged prey protein 
were mixed in an Eppendorf tube (the CoiP reaction). 
The reaction was incubated 1 h at RT on a rotating platform. Then 10 µl of a c-myc 
monoclonal antibody or a HA polyclonal antibody was added to the reaction and the 
incubation was continued for one more hour at RT. 
Meanwhile, protein A beads were prepared as follows: 
The beads were mixed by inverting the tube several times. A sufficient volume (∼ 10 µl) of 
beads were placed into a 1.5 ml microcentrifuge tube and washed twice with 200 µl of PBS. 
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The bead / PBS suspension was centrifuged at 7000 rpm for 30 sec and the supernatant was 
removed. Finally, the beads were resuspended in the original volume (∼ 10 µl) with PBS. 
3 µl of washed protein A beads were added the CoIP reaction and incubated for 1 h at RT, 
rotating. Then the reaction tube was centrifuged at 7000 rpm for 10 sec, the supernatant was 
discarded and the beads were washed five times with wash buffer 1 (supplied in the kit 
(Clontech). After each wash, the beads were centrifuged at 7000 rpm for 10 sec. Finally, the 
beads were washed twice with wash buffer 2 (supplied in the kit) (Clontech) and after 
centrifugation the beads were resuspended in 20 µl of SDS-PAGE loading buffer (see 5.2.9 
The sample was heated at 80°C for 5 min for denaturation, and 10 µl of the sample was 
loaded on a gradient 8-12% minigel (BioRad) following standard procedures. 
After electrophoresis, the gel was fixed with a gel fixation solution (see 5.2.10) at RT for 
10min, the fixation solution was changed once and the gel was incubated for 30 min at RT. 
After rinsing the gel with H2O, fluorographic amplification reagent (Amersham, CAT 
#NAMP100) was added according to manufacturer’s instructions, and incubated on a rotary 
shaker for 20 min at RT. The gel was placed onto pre-wetted 3 MM Whatman paper, covered 
with Saran wrap and dried at 80°C under constant vacuum. 
After the gel was dry, the Saran wrap was removed and the gel was exposed to an X-ray film 
(Kodak) O/N at RT. The film was developed using standard techniques. 
 
5.4.8.4. In-vivo-expression of the interacting proteins for coimmunoprecipitation assay 
The pECFP plasmid expressing OSTL (see 6.3) protein was cotransfected with pEYFP-HAX1 
or pEYFP-SIVA (see 6.6.5 – figure 6.32) to HEK293T cells by the lipofectamin method (see 
5.5.1). Cells were lysate 24 h post-transfection in a lyses buffer (see 5.2.10). Lysates from 
4.106 or 6.106 cells were precleared with protein G-Agarose beads (Roche). Total cell lysate 
(≅ 800 µg or 1400 µg) were divided and incubated with mouse anti-HAX1 clone 52 
(Clontech) or with polyclonal goat anti-Siva antibody clone C-20 (Santa Cruz) (reaction B) or 
control polyclonal mouse or goat IgG antibody (Santa Cruz) (reaction A) and protein G-
Agarose beads for 1:30 h. Then supernatant from reaction A was mixed with beads in reaction 
B and incubated for 5 h. The beads were washed twice with sample buffer (see 5.2.10). The 
immunoprecipitated proteins were analyzed by 10% SDS-PAGE (see 5.2.10), blotted, and 
probed with a rabbit anti-GFP antibody (Molecular Probes). Horseradish peroxidase-coupled 
rabbit anti-mouse IgG (Santa Cruz) was used with ECL detection system (Amersham 
Biosciences). 
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5.5. Cell Culture 
The cell culture procedures were carried out in a vertical laminar flow hood (BDK Luft- und 
Reinraumtechnick GmbH) to ensure sterile conditions required for mammalian cell culture. 
The cells were grown in commercially available cell culture flasks or dishes (5.2.1) and 
incubated at 37°C in a humid atmosphere containing 5% CO2. The cell culture medium used 
for adherent and suspension cells was commercial-available DMEM and RPMI, respectively, 
supplemented with 10% FCS and antibiotics (100 U penicillin and 100 ng streptomycin/ml 
medium). E 86 and bone marrow (BM) cells were grown with the described DMEM complete 
medium, supplemented with 15% FCS and 1.6 mg/ml cyprobay. The complete medium for 
BM cells grown was also supplemented with an growth factor cocktail, depending on the 
culture condition: for myeloid condition 6 ng/ml IL-3, 10 ng/ml IL-6, 10 ng/ml SCF, and for 
lymphoid condition 10 ng/ml IL-7, 10 ng/ml SCF, and 6 ng/ml Flt3 ligand. The cells were 
split according to the cell growth rate and density. 
In order preserve a the cell lines, ~ 6x106-1x107 healthy cells in the logarithmic growth phase 
were suspended in 1.5 ml of FCS with 10% DMSO in 1.8 ml cryotubes, the tubes were 
transferred to an -80°C freezer for 24 h and then stored permanently in liquid nitrogen. 
 
5.5.1. Transfection of adherent cells 
For co-localization and protein expression, mouse (NIH3T3) or human (HEK293 T) cell lines 
were transiently transected using cationic polymers from two commercial suppliers 
(RothFect transfection kit, Carl Roth or PolyFect transfection kit, Qiagen). 
The day before transfection, 35 mm 6 well culture dishes were seeded with 1-4x105 cells/well 
in 3 ml complete DMEM growth medium and grew O/N (12-18 h). For the transfection, 1.5 
µg of DNA was diluted in DMEM without serum and antibiotics to a final volume of 100 µl. 
10 µl of transfection reagent (PolyFect or RothFect) were added to the DNA sample and 
mixed by pipetting up and down for 5 times. 
The mixture was incubated at RT for 10 min to allow complex formation. While the complex 
formation took place, the DMEM medium was removed from the cells and the cells were 
washed once with 3 ml of PBS. 1.5 ml of fresh complete DMEM was added to the cells. 600 
µl of complete DMEM was added to the transfection complexes and mixed by pipetting. The 
transfection complexes were gently transferred to the 35 mm dishes and evenly distributed by 
gently swirling the dishes. Cells were grown O/N (12-24 h); after O/N incubation, cells were 
analyzed in a fluorescence microscope and prepared by fixation. 
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5.5.2. Fixation of cells 
Cells grown on cover slips were fixed in 3% formaldehyde solution in PBS as described by 
Dernburg and Sedat, 1998. Briefly, the cell culture medium was removed, the cells were 
washed twice with cold 1X PBS solution at RT for 3 min. 3% formaldehyde in PBS was 
added to the cells and they were incubated for 10 min at RT in the dark. The cells were 
washed twice with cold 1X PBS, then the coverslips were covered with Vektashield reagent, 
inverted, put on microscope slides and sealed with nail-varnish. 
 
5.5.3. Fluorescence microscopy 
After fixation, the cells were analyzed using an inverted fluorescence microscope (Zeiss 
Axiovert 200 M). Phase contrast (bright field) and fluorescent images of the cells were taken 
with 100X objectives with a greyscale CCD camera and appropriate filter settings (488 nm for 
GFP, 433-453 nm for pECFP and DAPI, 513 nm for YFP). The image data were directly 
transferred to a Macintosh computer (G4) running the Openlab 3.0 image acquisition 
program.  
5.6. Western Blot 
To analyze protein expression, SDS polyacrylamide gel electrophoresis (SDS-PAGE) 
followed by immunoblotting was performed. 
 
5.6.1. Sample preparation 
First, cellular protein extracts were prepared. Cell cultures were washed with cold sterile PBS, 
trypsinized, diluted in PBS, centrifuged at 1000 rpm for 5 min, rewashed in PBS, counted, 
centrifuged and resuspended in cellular lysis buffer (RIPA buffer – see 5.2.9) 150 µl / 5x107 
cells. The cells were incubated for 30 min at 4°C and mixed by inversion (Labinco machine). 
The sample was centrifuged at 14000 rpm for 30 min and the supernatant was transferred to a 
new Eppendorf tube, the protein concentration was determined by the Bradford method 
(5.5.6) and stored at -80°C. 
 
5.6.2. Total protein determination (Bradford-Bio-Rad) 
Protein concentrations were determined with the Bradford method. The assay is based on the 
observation that the absorbance maximum for an acidic solution of Coomassie Brilliant Blue 
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G-250 shifts from 465 nm to 595 nm when binding to protein occurs. Both hydrophobic and 
ionic interactions stabilize the anionic form of the dye, causing a visible color change. The 
extinction of a dye-albumin complex solution is proportional to the protein concentration over 
a 10-fold range (5-25 µg/ml). The protein concentration of the sample was determined by 
comparing the extinction of the sample to values obtained from a range of protein standards. 
The protein standard used was Bovine Serum Albumine (BSA). Six different amounts of 
albumine (2.5 µg, 5µg, 10 µg, 15 µg, 20 µg, and 25 µg) were diluted in distilled water to a 
final volume of 800 µl. 1 µl of cell lysate was diluted in distilled water for the measurement. 
200 µl of protein assay solution was added to the tubes. The tubes were incubated at RT for 
15 min. For the measurements, polystyrol spectrophotometer cuvettes (10x4x45 mm Sarstedt) 
were used. 
 
5.6.3. SDS polyacrylamide-gel electrophoresis (SDS-PAGE) 
Total cell extract (TCE) protein was separated on SDS-PAGE gels (see 5.2.10); some gels 
were purchased ready to use (BioRad). A 10-12% separation gel (tris-glycine buffer) and a 
5% stacking gel were used. 
 
5.6.4. Immunoblotting 
Proteins separated on SDS-PAGE were transferred to nitrocellulose membranes (BioRad) 
using a semi-dry-electroblotter (BioRad). Six pieces of Whatman 3MM paper and one piece 
of nitrocellulose membrane were cutted to the exact size of the gel, soaked first in water and 
afterwards in transfer buffer. The transfer occurred over 1-2 h at 150 mA (mA = cm2 
membrane x 0.8). Membranes were blocked in the presence of blotto A (5.2.9) at 4°C O/N. 
Membranes were then incubated with the respective antibodies diluted in blotto A (1:100-
1:3000) at RT for 1 h in continuous rotation, washed with TBS-T wash buffer once for 15 min 
and twice for 5 min in continuous rotation. Membranes were stained with the secondary anti-
mouse or anti-rabbit antibodies horseradish Peroxidase-conjugate (1:1000-1:6000) and finally 
proteins were detected using the enhanced chemiluminescence (ECL) assay (Amersham). 
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5.7. Preparation and purification of GST fusion proteins  
The coding region of proteins to be expressed as GST fusion protein was cloned into the 
pGEX-4T2 vector (5.2.7.2). BL21 E. coli cells were transformed with the pGEX constructs. 
Transformant cells were selected in LB/Amp plate and individual colonies were picked and 
diluted into 10 ml of LB/Amp medium and incubated O/N at 37°C. 
The next day 10 ml of the culture were diluted 1:10 in 100 ml of LB/Amp medium and 
incubated at 37°C for 1-3 h (OD600 ∼ 0.8). The expression of the fusion protein was induced 
by addition of IPTG (1 mM) for other 3-4 h. After induction, cells were centrifuged at 4000 
rpm and 4°C for 15 min. Cells were then resuspended in a freshly prepared lysis buffer, 
vortexed, and lysed by mild sonification. 
 
Lysis Buffer: 
1x PBS  
20% glycerol 
1% Triton 100 
1 mM DTT 
1 mM EDTA 
1 mM PMSF (diluted in isopropanol) 
10 µg Leupeptin (diluted in H2O) 
10 µg Pepstatin (diluted in DMSO) 
10 µg Aprotinin (diluted in H2O) 
 
After the sonification, the lysate was transferred to 1.5 ml microcentrifuge tubes and 
centrifuged at 14000 rpm for 5 min. The purification of the GST fusion protein was 
performed with glutathione Sepharose 4B (Pharmacia) according to the manufacturer’s 
instructions. Bacterial lysates was incubated with glutathione Sepharose 4B (500 µl / 50 ml 
lysate) and the GST fusion protein was eluted using a 15 mM glutathione solution in PBS. 
The purified proteins were examined on 12% SDS PAGE and Coomassie blue staining.  
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5.8. Whole mount in situ hybridization 
To analyze the expression pattern of OSTL during the mouse embryonic development, a 
whole mount in situ hybridization analysis using digoxigenin-labeled RNA OSTL probe was 
performed as described (Kispert et al., 1996; Lescher et al., 1998). 
An antisense-RNA-probe and as control a sense-RNA-probe were hybridized to mouse 
embryos of different developmental stages (9.5 until 14.5 mouse embryo days). 
This part of the work was performed in the Prof. Hrabé de Angelis laboratory at the GSF, 
Neuherberg, in collaboration with Dr. Gerhard Pzemeck. 
 
5.8.1. Preparation of RNA probe 
The DNA template used as probe was a PCR product from murine OSTL, which had been 
PCR amplified and subcloned into pGEMT-easy vector (see 5.2.7.3). Briefly, the steps of the 
procedure were as follows: 
 
1) 10 µg of DNA template was linearized with the restriction enzymes: NcoI for the 
sense-probe, and SalI for the antisense-probe; 
2) The reactions were incubated at 37°C for 2 h; 
3) The enzymes were inactivated by heating at 65°C for 15 min; 
4) Template DNAs were purified using a QIAquick spin column following the 
manufacturer’s instructions (Qiagen); 
5) The single-stranded RNA probes were synthesized using purified RNA polymerases 
(T7 for the antisense-probe, and SP6 for the sense-probe) to transcribe sequences 
downstream of the appropriate polymerase promoter site. This reaction was performed 
in a sterile microcentrifuge tubes on ice as follows: 
10 µl linearized DNA (10 µg) 
3 µl Ampuwa water 
2 µl TS-buffer 
2 µl rNTPs DigMix 
1 µl Rnase inhibitor 
2 µl RNA-polymerase (depends on DNA-template: T7 for antisense-probe) and sp6 
for sense-probe 
The reaction was incubated at 37°C for 2 h; 
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2 µl of DNase was added and the mixture incubated at 37°C for 15 min; 
6) The RNAs were precipitated with 400 µl of 100% EtOH, 1µl of tRNA (as a carrier), 
and 33 µl of 7.5 M NH4Ac, the reagents were gently mixed and incubated at -80°C for 
1 h; 
7) The RNA was pelleted at 4°C and 15000 rpm for 15 min; 
8) The RNA-pellets were resuspended in 100 µl of Ampuwa water, 1 µl of Rnase-
inhibitor was added and the pellets were stored at -20°C; 
9) The RNA synthesis quality was assayed by running 2 µl of RNA on a 1% agarose gel 
 
5.8.2. Preparation of mouse embryos 
Pregnant Balb-c female mice were obtained from the animal facilities GSF-Grosshadern. The 
mouse embryos from different development stages (9.5 until14.5 days) were collected using 
standard procedure (Kaufman, 2001). The embryos were prepared in PBS in DEPC-treated 
water (see 5.2.9). The embryos were fixed in a 4% paraformaldehyd solution diluted in PBS 
O/N at 4°C, rotating. After fixation the embryos were dehydrated (on ice) through 25%, 50%, 
and 75% MetOH diluted in PBS with DEPC-treated water for 10 min at each MetOH dilution. 
Afterwards the embryos were bleached with MetOH/H2O2 (6:1 v/v) for 1 h on ice. 
Finally, the embryos were dehydrated twice (on ice) with a large amount of 100% MetOH for 
5-10 min each time. They were stored in 100% MetOH at -20°C. 
 
5.8.3. Hybridization of probe to mouse embryos 
The embryos were rehydrated (on ice) through 75%, 50%, and 25% MetOH diluted in PBS 
(DEPC-treated water) for 10 min at each MetOH dilution with shaking. They were washed 
twice with PBT for 10 min on ice, and once for 5 min with shaking. For mouse embryos from 
10.5 until 14.5 days, a proteinase K treatment was performed. 10 µg/ml proteinase K was 
added and the embryos were incubated (10.5 days: 3 min, 11.5 days: 4 min, 12.5 days: 5 min, 
13.5 days: 6 min, and 14.5 days: 7 min) in proteinase K buffer at 37°C with shaking. Then 
washed twice with freshly prepared PBT/glycin for 5 min on ice, and twice with PBT on ice 
for 5 min with shaking. They were incubated in RIPA buffer on ice for 10 min, without 
shaking. Then, washed twice with PBT for 5 min on ice and fixed with freshly prepared 4% 
paraformaldehyd /0.2% glutaraldehyd in PBT for 20 min at RT, without shaking. 
Materials and Methods 
 
 
85 
After washing twice in PBT buffer for 5 min at RT, the embryos were incubated in 
hybridiyation buffer/PBT (1:1 mixture) for 10 min at RT, then washed with hybridization 
buffer for 10 min at RT. 
Prehybridization was performed as follows: hybridization buffer with 100 µg/ml tRNA at 
68°C for 3 h. The probes were denatured at 90°C for 3 min and hybridization was performed 
as follows: 1:100 diluted DIG labeled probe (0.25 µg/ml) with 100 µg/ml tRNA in 
hybridization buffer at 68°C O/N. 
The next day, the hybridization buffer with the probe was removed and the embryos were 
washed twice with heated hybridization buffer at 65°C for 30 min, then they were cooled to 
RT and washed once with hybridization buffer/RNAse solution (1:1 mixture). After wash 
once with RNAse solution for 5 min at RT, they were incubated with RNAse solution 
containing 100 µg/ml RNase A for 60 min at 37°C. Then a wash with RNase 
solution/SSC/FA/Tween 20 mixture for 5 min at RT was performed. Embryos were heated in 
SSC/FA/Tween 20 from RT to 65°C and washed twice with SSC/FA/Tween 20 for 5 min at 
65°C, then washed three times with SSC/FA/Tween solution for 10 min at 65°C and five 
times with SSC/FA/Tween solution for 30 min at the same temperature. Embryos were cooled 
down to RT and washed once with SSC/FA/Tween 20/1X TBST (1:1 mixture) for 5 min at 
RT, twice with 1X TBST for 10 min at RT and, finally, twice with MABT for 10 min at RT. 
Incubation with 10% blocking solution in MABT for 1 h at RT was performed. Meanwhile, 
DIG antibody was pre-adsorbed in 1% blocking solution/MABT (1:5000 dilution) for 1 h at 
4°C. Embryos were incubated in this antibody solution O/N at 4°C with shaking. To remove 
unbounded antibody, the embryos were washed three times with TBST for 5 min at RT, and 
about eight times with TBST for 1 h at RT. They were incubated in TBST for 72 hours at 4°C 
with shaking. 
 
5.8.4. Staining of probe and visualization 
The TBST solution was changed and the embryos were incubated with fresh TBST solution 
for 4 h at RT. Afterwards, washed twice with fresh made alkaline phosphatase buffer for 5 
min at RT, then stained in staining solution (solution was changed before it turned from 
yellow to pink) O/N at 4°C. 
Embryos were fixed in 4% paraformaldehyd in 1x PBS for 1 h at RT and photographed in 
30% sucrose in 1x PBS or in 0.8% agarose in PBS with a digital camera (JVC Ky-F70) on a 
Leica MZ APO microscope and images processed in Corel Photopaint and Adobe Photoshop. 
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5.8.5. Dissections of stained mouse embryos 
Stained whole embryo was incubated in 7.5% gelatine/30% sucrose in 1x PBS solution for 2 h 
at 42°C in a water bath. The gelatin solution with the embryos was poured in a 10 cm dish and 
kept at 4°C O/N. On a microscope the gelatin was cut in blocks of around 1 cm2 and frozen on 
dry ice. The blocks were incubated at -80°C at least O/N and then cut into 35 µm thick slice 
in a Cryotom (Kryostat Leica CM 1850). The Cryotom cuts were spread on glass slides with 
glycerin/gelatin and dried at RT. The glass slides were photographed with a digital camera 
(JVC Ky-F70) on a Zeiss Axiocan HRC microscope and images processed in Corel 
Photopaint and Adobe Photoshop. 
 
Solutions: 
All solutions used before and for in situ hybridization had to be absolutely Rnase-free. DEPC-
treated water was used for preparation of Rnase-free solutions and they were autoclaved. For 
Tris-buffer, DEPC-treated water is not sufficient; the solution was autoclaved twice. 
 
4% Paraformaldehyd/PBS 
4 g paraformaldehyd were added to 100 ml of 1x PBS  
Few drops of 10 N NaOH were added and the solution was heated to 55°C, until the 
paraformaldehyd was completely dissolved; 
Solution was cooled on ice and pH was adjusted to 7.0 with HCl (pH indicator paper was 
used). 
PBT 
PBS with 0.1% (v/v) of Tween 20 
tRNA 
10 µg/µl tRNA in DEPC-treated water 
stored in aliquots at -20°C 
Proteinase K buffer 
2% Tris-HCl (pH 7.0) 
0.2% 0.5 M EDTA 
water was added to complete 500 ml 
PBT/glycine 
2 mg/ml glycine in PBT 
Solution made fresh just before use 
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RIPA 
0.1% SDS 
150 mM NaCl 
1% NP40 
0.5% Sodium deoxycholate 
5 mM EDTA 
50 mM Tris-HCl ph 8.0 
DEPC water was added to 500 ml 
Hybridization buffer 
5 ml of deionized formamide 
2.5 ml of 20x SSC 
5 µl of heparin solution 
0.1% of Tween 20 
DEPC-treated water was added to 10 ml 
pH was adjusted to 6.0 with 1 M citric acid (4.5% 1 M citric acid was added) 
SSC/FA/Tween 20 
10 ml of 20X SSC 
25 ml of formamide 
0.5% Tween 20 
Water was added to 50 ml 
RNase solution 
500 mM NaCl 
10 mM Tris-HCl (pH 7.5) 
0.01% Tween 20 
Water was added to 10 ml 
RNase A 
10 µg/µl RNase A in 0.01 M NaAc (Sigma) (pH 5.2) 
The solution was heated to 100°C for 15 min, and slowly cooled to RT; 
The pH was adjusted by adding 0.1 vol of 1 M Tris-HCl pH 7.4; 
Aliquots were stored at -20°C 
MAB 
0.1 M maleic acid 
0.15 M NaCl 
pH was adjusted to 7.5 with solid NaOH; 
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Water was added to 1 l 
For MABT buffer:  
0.1% Tween 20 was added/l 
Blocking stock solution 
Blocking reagent (Roche) was dissolved in MAB buffer to 10% (w/v); 
Solution was mixed with shaking and heating in a microwave oven; 
Stock solution was autoclaved, then 0.1% Tween 20 was added to the solution; 
Aliquots were stored at -20°C 
Alkaline phosphate buffer 
The solution was freshly made just before use: 
500 mM NaCl 
50 mM MgCl2 
0.01% vol of Tween 20 
100 mM Tris-HCl (pH 9.5) 
2 mM Levamisol (diluted in TBST solution) 
Water was added to 50 ml final volume 
Staining solution 
Boehringer BM purple Ap substrate (Boehringer) 
2 mM of Levamisole 
0.1% vol of Tween 20 
Solution was centrifuged and only the supernatant was used 
 
5.9. Test for ubiquitination of a putative substrate protein 
The principle of this assay is based on a His-tagged version of ubiquitin, which is co-
expressed with the putative ubiquitin substrate. His-ubiquitin conjugates are recovered by 
precipitation on Ni-NTA beads and analyzed by Western blotting with antibodies directed 
against the putative substrate protein (modified from Treier et al., 1994). 
The procedure performed to test for ubiquitination of a putative substrate protein is as 
follows: 
 
1) One day before the transfection, 1.3 x 106 HEK293T cells were plated on 60 mm 
culture dish with 3 ml of complete DMEM culture medium; 
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2) At noon, the cells were co-transfected with the putative ubiquitin ligase (OSTL) as 
well as with the putative substrate proteins (HAX1 or SIVA) together with either the 
His-Ubiquitin or the HA-Ubiquitin expression vector (HA-Ubiquitin was used as 
negative control). 1 µg of DNA for each vector (His-Ubi and HA-Ubi) and 3 µg DNA 
for OSTL, HAX1 and/or SIVA (mOSTL in GFP and HAX1 and SIVA in YFP) in 1 
ml of Calcium-phosphate was used. 0.5 ml of the mixture has been added to the cells 
and they were incubated for 48 h; 
3) Four hours before the cells were lysed, 20 µM (final concentration) of the proteasome 
inhibitor MG132 in 1.5 ml DMEM was added to the cells; 
4) The cells were washed once with PBS and lysed in 0.8 ml of lysis buffer, the extracts 
were transferred to FACS-tubes; 
5) The cells were briefly sonicated (twice for 15 sec at low power to shear the DNA. 
After sonication the cells were transferred to 1.5 ml microcentrifuge tubes and 
centrifuged at 13000 rpm for 1 min at RT; 
6) 600 µl of supernatant was transferred to a new microcentrifuge tube (50 µl of the 
lysate was kept for TCA-precipitation (see below); 
7) The 550 µl remaining lysate was incubated with 15 µl of magnetic Ni-Agarose beads 
(Qiagen), vortexed and incubated O/N at RT, rotating; 
8) The tubes with the lysate were placed in a magnetic stand and the supernatants were 
removed with a 26G needle; 
9) 750 µl of wash buffer A was added to the beads, they were vortexed and rotated for 5 
min at RT; 
10) Steps 8 and 9 were repeated twice; 
11) The beads were washed three times with wash buffer B, and a final wash was 
performed with PBS; 
12) PBS has been removed and 60 µl of 1 x SDS-PAGE sample buffer was added, the 
beads were boiled for 10 min; 
13) 15 µl of the Ni-precipitate together with 15 µl of TCA precipitated extract (see below) 
were loaded on a 10% SDS-PAGE gel and analyzed by immunoblotting with anti 
HAX1 N17 antibody (sc-16636, Santa Cruz) diluted 1:1000 or anti SIVA antibody 
(sc-7250, Santa Cruz) diluted 1:1000. 
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TCA precipitation: 
50 µl of 10% TCA was added to the extract (approximately 5 µg ), the tubes were placed on 
ice and vortexed until a precipitate appeared (∼ 2 min) and then incubated on ice for 15 min. 
The supernatant was removed after high speed centrifugation for 15 min. The pellets were 
washed with 200 µl ice-cold ethanol by vortexing until they dissolved (∼ 2 min) and high 
speed centrifugation was performed for 15 min. The pellets were dried in the speed vac for 10 
min and resuspended in 50 µl sample buffer and boiled for 5 min. 
 
Lysis buffer 
6 M guanidine-HCl 
0.1 M NaH2PO4 
0.01 M Tris (pH 8.0 adjusted with NaOH) 
Wash buffer A 
8 M urea 
0.1 M NaH2PO4 
0.01 M Tris (pH 8.0) 
Wash buffer B 
8 M urea 
0.1 M NaH2PO4 
0.01 M Tris (pH 6.4) 
 
5.10. Overexpression of OSTL in primary hematopoietic cells 
5.10.1. cDNA constructs and retroviral vectors 
For retroviral gene transfer into primary bone marrow (BM) cells, the murine OSTL (clone 
J16) was subcloned into the multiple cloning site of the modified MSCV 2.1 vector 
(Pineault et al., 2003) upstream of the internal ribosomal entry site (IRES) and the enhanced 
green fluorescent protein (GFP) gene (2.2.7.1). As a control, the empty MSCV vector 
carrying was used.  
 
5.10.2. Retrovirus Production 
Retrovirus was produced with the constructs mentioned above by co-transfecting 30 µg of 
the construct plasmid DNA with equal amounts of Ecopac DNA into 293T cells using the 
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calcium phosphate precipitation method (Pineault et al., 2003). Virus conditioned medium 
(VCM) was collected 48h after transfection at time intervals of eight hours for forty-eight 
hours. Production of high-titer helper-free retrovirus was achieved by transducing the 
ecotropic packaging cell line GP+E86 (Pineault et al., 2003) with virus conditioned medium 
(VCM) from 293T transfected cells. Successfully transduced GP+E86 cells were sorted out 
by FACS using GFP as a marker 4 days after transduction using standard procedures 
(Pineault et al., 2003). 
 
5.10.3. Retroviral infection of primary BM cells 
Primary mouse bone marrow (BM) cells were transduced as previously described (Pineault 
et al., 2003). Briefly, BM cells were obtained by flushing both femurs and tibias of donor 
mice treated 4 days previously with 150 mg/kg 5-fluorouracil (myeloid condition) injected 
into the tail vein. Mice without 5-fluorouracil treatment (for lymphoid condition) were also 
used in this work. 5-flourouracil eliminates cycling cells hematopoietic cells from the 
animal, thus enriching the bone marrow for primitive hematopoietic progenitors, which are 
non-cycling or quiescent in nature (Reya, 2001). Cells were stimulated for 48 hrs in DMEM 
supplemented with 15% FBS, 10 ng/ml IL6, 6 ng/ml IL3 and 10 ng/ml mSCF. 
For lymphoid condition assays, cells were stimulated for 24 h in DMEM supplemented with 
15% FBS, 10 ng/ml IL7, 6 ng/ml mutant FLT3 and 10 ng/ml mSCF. 
For transduction, cells were co-cultured for 48h with irradiated (40 Gy) GP+E86 virus 
producing cells in the same medium with the addition of 5 µg/ml protamine sulfate. 
Protamine sulfate prevents aggregation of viral particles, thus increasing efficiency of 
transduction. Loosely adherent and non-adherent BM cells were harvested from the co-
culture 48h post transduction, BM cells were furtherer cultured in fresh medium with 
cytokine cocktail for 48 h or 24 h (myeloid or lymphoid condition) to allow expression of 
EGFP. Transduced BM cells were sorted by fluorescence activated cell sorting (FACS) 
using EGFP as a marker. 
 
5.10.4. In Vitro Assays 
5.10.4.1. Proliferation Assay 
To study the proliferative potential in vitro of BM cells transduced with OSTL expressing 
retroviruses, a proliferation assay was performed by plating successfully transduced bone 
marrow cells directly after sorting in DMEM supplemented with 15% FBS, 10 ng/ml mIL-
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6, 6 ng/ml mIL-3 and 100 ng/ml murine stem cell factor (SCF) (standard medium) (Tebu-
bio GmbH, Offenbach, Germany) at 37°C in a humidified 5% CO2 incubator. The cells 
were subjected to half-media change every 7 days and their proliferation assessed on the 
day of media change by counting viable cells after trypan exclusion. To generate IL-3 
dependent cell lines, successfully transduced bone marrow cells were cultured directly after 
sorting in DMEM, 15% FBS with IL-3 alone (6 ng/ml). A half-media change was done 
every 7 days. 
 
5.10.4.2. Colony Forming Cells Assay (CFC-assay) 
To analyze the differentiation and clonogenic potential of the transduced BM cells, we 
performed CFC assays by testing colony formation in methylcellulose. The CFC–assay was 
done by culture highly purified transduced cells (500/dish) in 35mm-diameter Petri dishes 
directly after sorting in 1ml methylcellulose supplemented with cytokines (Methocult 
M3434). 
Colonies were counted microscopically on 7 to 9 days after plating according to standard 
criteria (Schwaller, 1998). Re-plating capacity of clonogenic progenitors was assayed by re-
plating the primary colonies (500 cells/dish) on secondary methylcellulose dishes. Again 
colonies were counted at 7 to 9 days after the secondary re-plating. 
 
5.10.5. Cyto-Morphology 
Cyto-morphological analysis of bone marrow cells was done by transferring 5x104 to 1x105 
bone marrow cells on glass slide by centrifugation at 500 rpm for 10 minute using a Shandon 
Cytospin2 centrifuge. Slides were stained with May-Grunwald’s eosine-methylene blue and 
Giemsa solution using the standard protocol supplied by Merck. 
 
5.10.6. Immunophenotyping 
Cell differentiation was determined and lineage distribution was analyzed by 
immunophenotyping. 5x104 to 1x104 cells were rinsed with PBS and stained for 30 minutes 
on ice with an appropriate concentration of phycoerythrin (PE) conjugated antibody to Gr-
1, Sca-1, Ter-119, CD4, and allophycocyanin-conjugated antibody for lineage markers 
Mac-1, cKit, B220 or CD8 (all Pharmingen Heidelberg, Germany). The cells were then 
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washed with PBS and stained with propidium iodide, and viable cells were analyzed with 
the FACS Calibur system. 
 
5.10.7. BM transplantation and assessment of mice 
For the bone marrow transplantation procedures, 8–10 week old recipient F1 (B6C3) mice 
were irradiated with 850 cGy from a 137Cs γ-radiation source. FACS purified transduced 
BM cells or defined ratios of transduced and unpurified and untransduced cells were 
injected into the tail vein of irradiated recipient mice. 
PB or BM cell progeny of transduced cells were tracked using GFP fluorescence (Feuring 
Buske, 2002). Lineage distribution was determined by flow cytometric analysis as 
previously described (Pineault et al., 2003). 
For histological analyses, sections of selected organs were prepared and H&E stained at the 
Academic Pathology Laboratory, GSF, Munich, using standard protocols. The mice were 
under observation for early signs of leukemia. Aspiration of the blood and bone marrow 
was performed at 8 weeks and subsequently at four week intervals and assessed for 
engraftment of the mice with transduced cells and progression of disease. The early signs of 
disease (leukemia) development were paleness of the feet, limited mobility or lethargy, 
shortness of breaths or ruffled body hair. Moribund mice were sacrificed and analyzed as 
described. 
 
5.10.8. Analysis of sacrificed/dead experimental mice 
The PB, spleen and BM of sacrificed mice were analyzed carefully. PB was aspirated from 
heart with 1 ml insulin syringes; Heparin was used for anticoagulation. PB was used for 
blood smears on glass slides and RBC count. WBC count and immunophenotyping was 
performed after lysing the RBC with ammonium chloride. The spleen size was measured in 
diseased mice, and then homogenized for single cell suspension in DMEM medium, for 
further analysis by FACS, cytospin or ex vivo assays. BM cells were obtained by flushing 
both femurs and tibias and subjected to WBC count, cytospin and immunophenotyping. 
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5.10.9. Preparation for histopathology 
The four limbs, tail and head of mice were pinned to a cork plate with needles after sacrificing 
the animals for histological analyses. Then the skin from the chin to the anus and also the 
abdominal muscles were opened in the median and also pinned down (Fig.2.3). The mice 
were then bled by cut one of the renal arteries, and the blood was sucked out with a tissue 
paper. Then the diaphragm was carefully cut away to allow the fixing liquid to penetrate into 
the thorax. After this the whole mouse was placed into formalin (37%) over night, packed and 
sent to the department of pathology (PD. Dr. Leticia Quintanilla-Fend), where the organs 
were cut and stained for analyses. 
 
 
 
Fig 5.3: Schematic representation of an OSTL diseased mouse before fixation for the 
histopathologic analysis. 
 
5.11. Statistical analysis 
Data were evaluated using the t-test for dependent or independent samples (Microsoft Excel). 
Differences with p-values < 0.05 were considered statistically significant. 
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5.12. Computer programs 
Program Origin Application 
Adobe PhotoShop (Mac) Adobe Systems, USA Conversion of scanned files 
Macromedia Freehand 10.0 
(Mac) 
Freehand Systems, USA Graphics 
Mac VectorTM 7.0 Oxford Molecular Group Sequence analysis, primer 
design 
Microsoft Word 98 (Mac) Microsoft Corporation, USA Text processing 
Microsoft Excel 98 (Mac) Microsoft Corporation, USA Table calculations, diagrams 
Microsoft Internet Explorer 
5.2 (Mac) 
Microsoft Corporation, USA Internet search 
Microsoft Power Point 98 
(Mac) 
Microsoft Corporation, USA Graphics 
OpenLab 3.1 (Mac) OpenLab Systems, USA Microscopy pictures 
 
Analysis via the Internet www Address Application 
BLAST search 
(Basic Local Alignment 
Search Tool) 
http://www.ncbi.nlm.nih.gov/
BLAST/ 
DNA or protein sequence 
homology search 
PROSITE pattern search http://www2.ebi.ac.uk/ppsear
ch/ 
Protein motifs search 
PubMed http://www.ncbi.nlm.nih.gov/
entrez/query.fcgi?db=PubMed 
Scientific Literature 
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6. Results 
6.1. Identification of OSTL gene by sequencing 
The Opposite Six Twelve Leukemia gene (OSTL) was identified as overlapping with the Six 
Twelve Leukemia gene (STL), which was identified as a fusion partner of ETV6 in the SUP 
B2-ALL cell line (see 4.4). The ETV6-STL fusion gene encodes a very small protein, which 
lacks any known functional domains (Suto et al., 1997). Therefore we hypothesized that the 
main leukemogenic effect of this translocation might be the deregulation of the OSTL gene. 
OSTL is localized in the long arm of chromosome 6 band q23 (Figure 6.1) and shares the first 
exon with STL, but is transcribed in the opposite direction. To characterize this novel gene we 
completely sequenced the human and mouse OSTL cDNA. The OSTL gene used in all 
experiments was cloned from the human clone IMAGp998E064109Q2 (reference 
AA992964) and from the mouse clone IMAGp998J169272Q2 (reference BF165105). We 
have named the human OSTL as E06 and the mouse Ostl as J16. The human sequence (E06) 
has three alternative exons (1b, 1c, and 1d) instead of exon 1, exons 2 to exon 5, and a splice 
variant of exon 5 (5b), and the complete exon 6 (Figure 6.2 and tables 6.1, 6.3 and 6.4). The 
mouse sequence (J16) revealed the complete cDNA of Ostl (from exons 1 to 6) as observed in 
the figure 6.3, tables 6.2, 6.3, and 6.4. 
In the human OSTL cDNA sequence the second start codon (ATG, underlined) probably 
represents the true translational start site, because it contains a better Kozak sequence and it is 
homologous to the ATG in the mouse Ostl. The start (ATG) and stop (TAA) codons are in 
bold and underlined in both human and mouse OSTL cDNA sequences (Figures 6.2 and 6.3). 
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Figure 6.1: Diagram of the chromosomal localization of OSTL. OSTL and STL localize to the long 
arm of chromosome 6. They share the first exon, but are transcribed in opposite directions. ETV6 is 
located in the short arm of chromosome 12. In the chromosomes on the right side the ETV6-STL 
fusion is shown. 
 
1        GGCACGAGCGGCAGCATCGAGCTGGAGTTCTACCTGGCGCCCGAGCCGTTCTCCATGCCC      60 
                                                                M  P 
61       AGCCTGTTGGGAGCTCCACCCTACTCTGGCCTGGGCGGTGTAGGGGATCCCTATGTGCCC      121  
          S  L  L  G  A  P  P  Y  S  G  L  G  G  V  G  D  P  Y  V  P 
122      CTCATGGTGCTGATGTGCCGGGTGTGCCTGGAAGACAAGCCCATCAAGCCCCTGCCTTGC      182 
          L  M  V  L  M  C  R  V  C  L  E  D  K  P  I  K  P  L  P  C 
183      TGCAAGAAGGCCGTGTGCGAGGAGTGCCTCAAAGTCTACCTGAGCGCCCAGGTACAACTT      243 
          C  K  K  A  V  C  E  E  C  L  K  V  Y  L  S  A  Q  V  Q  L 
244      GGCCAAGTAGAAATCAAATGCCCCATCACAGAGTGTTTTGAATTCTTGGAAGAAACAACT      304 
          G  Q  V  E  I  K  C  P  I  T  E  C  F  E  F  L  E  E  T  T 
305      GTTGTCTATAACTTAACGCATGAAGACTCCATCAAGTATAAGTACTTCTTGGAACTTGGC      365 
          V  V  Y  N  L  T  H  E  D  S  I  K  Y  K  Y  F  L  E  L  G 
366      CGTATTGATTCCAGCACCAAGCCATGTCCTCAGTGCAAGCACTTTACAACCTTCAAGAAA      426 
          R  I  D  S  S  T  K  P  C  P  Q  C  K  H  F  T  T  F  K  K  
427      AAAGGACATATTCCCACCCCTTCCAGATCAGAAAGCAAATACAAAATCCAGTGCCCTACC      487 
          K  G  H  I  P  T  P  S  R  S  E  S  K  Y  K  I  Q  C  P  T 
488      TGCCAATTCGTCTGGTGTTTTAAGTGCCACTCTCCTTGGCATGAAGGTGTTAACTGCAAG      548 
          C  Q  F  V  W  C  F  K  C  H  S  P  W  H  E  G  V  N  C  K 
549      GAGTACAAAAAAGGAGACAAATTGTTGCGTCACTGGGCCAGCGAAATTGAGCATGGGCAG      609 
          E  Y  K  K  G  D  K  L  L  R  H  W  A  S  E  I  E  H  G  Q 
610      AGGAATGCCCAGAAGTGTCCAAAGTGCAAGATCCACATCCAGCGAACTGAAGGATGTGAC      670 
          R  N  A  Q  K  C  P  K  C  K  I  H  I  Q  R  T  E  G  C  D 
671      CATATGACCTGCTCACAATGTAACACTAATTTTTGTTACCGATGTGGTGAGAGATACCGC      731 
          H  M  T  C  S  Q  C  N  T  N  F  C  Y  R  C  G  E  R  Y  R 
732      CAGCTCCGATTTTTTGGAGACCACACATCAAACCTCAGTATATTTGGATGCAAATATCGC      792 
          Q  L  R  F  F  G  D  H  T  S  N  L  S  I  F  G  C  K  Y  R 
793      TACCTCCCAGAGAGACCTCATTTAAGGAGATTAGTGCGAGGGTCAGTCTGTGCTGGAAAA      853 
          Y  L  P  E  R  P  H  L  R  R  L  V  R  G  S  V  C  A  G  K 
854      TTATTCATTGCACCTCTAATTATGGTTTTGGGATTGGCACTAGGGGCCATAGCGGTTGTA      914 
          L  F  I  A  P  L  I  M  V  L  G  L  A  L  G  A  I  A  V  V 
915      ATCGGTTTATTTGTATTTCCTATCTATTGCCTTTGTAAAAAACAGAGAAAACGATCACGG      975 
          I  G  L  F  V  F  P  I  Y  C  L  C  K  K  Q  R  K  R  S  R 
976      ACAGGTATGCACTGGTAACATGCAGATGATTTCATCCAGCTAAGCTGGTTGGAGTAGGAG      1036 
          T  G  M  H  W  *    
1037     CGATACCAAAGGGTACACCCATCTGTGAGTCACATCTTGAAAAACACTGAGAGGAACCTT      1097 
1098     CTACCATCTCATCTCCCAGTGATTCTCCGTGGGCCACAATGCCTCTAGCTATGGTGCACT      1158 
1159     CCCAACATGGTATCCTGTCCTTTCCCTAAACAAATTGCTGCTGCTTTTAAAAAATGGTCA      1219 
1220     CTTTCATAAACTATAAACATCTATATCATAACTCTGACCTTTGTGGTTCTTGGAAGAAGA      1280 
1281     TATTTTAAGAACCAGTTATCCTAAGAATTCTGAGCACGCCTCTTCTGAGAATTGCTTGGA      1341 
1342     CTGTCTTTGAACTCTGCACCTCCTCCAGGCCATCTTGTGAGACTTGGTGTTAATAGCTGA      1402 
1403     AGTCCTATCTGTACCAACAAGCAAGGCCACTTTTCAGAAGATAAGAGTTCACTGAATGCA      1463 
1464     CCTATTATAATCTGTGGCCCCAGCAGTATAATTCTTTTATCTTTCAAATGTTATAATTGC      1524 
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1525     AAAAAATCTCAATGTCCAAAAGGGAATGAGTGAAACTAAATTAATGAGAAGAATATTAAG      1585 
1586     TTACTGAAGTGTATATGCGTAGGGGCGTGAATGTGTGTGTATATAAATATGTATTAAAAC      1640 
1641     TAGGCCCAGTAACCTTGTACTTACCCAGTTCCATGCCGCTACACTATTTTTCCACATTTT      1701 
1702     CATAGACCTATTGAAAGATGATGGCTCCTTTGTGGACATAATTTAGCAATGTATTAAATT      1762 
1763     AAAGTCAATGTAGACAACAGGCCATTTCGATACTGAACTTTTCTATTTCTTGCTCTTTCT      1823 
1824     TTTTGTCACACAAACACAGAAATTTGTGCAACGTCACCCCAAGGAGTATTAAGCTTTGTA      1884 
1885     AACTGACAAAACTGGCTGCTTTTAGGAAATTCTCAAGACACAAATATTCAGTCTTTTTAA      1945 
1946     AATTCTTACATTTTGGAAAACATGCTTCACTCTATAGATAGATCCTTCACATTGGGATTA      2006 
2007     TTTAATCCCAAAAACAAGTTTGCTGTAGACAACTGCTTAAGCCTTTAAAAAATTCCTATT      2067 
2068     CTGCTAATTTTTTAACCAACTTGTAATTATAGATAATTCTGCTTTAGGTCAAGGTCTTAC      2128 
2129     ATCATTTAATATCCTAACCTTGTTATCTCTTGCCTCCTCCTC                        2170 
Figure 6.2: cDNA sequence of human OSTL (E06) from exon 1b to exon 6. The start and stop 
codons are shown in bold and underlined. 
 
1        GGCCAGCAGCCCCCCGACGGTCTGCTCCTGGACGTGCTGGCCCAGCGACACCCGCCCCCC      60 
61       GCCAAGCCGCAAGTCCTCTGCTCCGTGTACTGCGTGGAGAGCGACTTGCCCGAGGCCCCC      121 
122      TCCGCCGAGTCCCCGTCGCCGTCGGAGTCCCCACCTCAAGCACCGCTGGGGCCGATTCCC      182 
183      GCCAGCCCGCCGCCCTCCTTCCCCAGCTCCCCGCTGTCGCTCCCGGCTGACCCCCTTTCC      243 
244      CCCGACGGCGGCAGCATCGAGCTGGAGTTCTACCTGGCTCCGGAGCCCTTCTCCGTGCCT      304 
305      GGCCTATTAGGGGCTCCACCCTACTCTGGCCTGGGGGGAGTAGGGGACCCCTATGCGCCC      365 
366      CTCATGGTGCTGATGTGCCGGGTGTGCCTGGAAGACAAACCCATCAAGCCCCTGCCCTGC      426 
             M  V  L  M  C  R  V  C  L  E  D  K  P  I  K  P  L  P  C 
427      TGCAAGAAGGCGGTGTGCGAGGAGTGCCTCAAAATCTACCTGAGCTCTCAGGTACAACTT      487 
          C  K  K  A  V  C  E  E  C  L  K  I  Y  L  S  S  Q  V  Q  L 
488      GGCCAAGTAGAAATCAAATGCCCAGTCACAGAGTGTTTCGAATTCCTGGAGGAAACAACT      548 
          G  Q  V  E  I  K  C  P  V  T  E  C  F  E  F  L  E  E  T  T 
549      GTTGTCTACAATTTAACCCATGAGGACTCTATCAAGTATAAGTACTTCTTGGAACTTGGC      609 
          V  V  Y  N  L  T  H  E  D  S  I  K  Y  K  Y  F  L  E  L  G 
610      CGAATTGACTCCAGCACCAAGCCATGTCCTCAATGCAAACACTTCACAACCTTTAAGAAA      670 
          R  I  D  S  S  T  K  P  C  P  Q  C  K  H  F  T  T  F  K  K 
671      AAAGGACATATCCCCACTCCTTCCAGATCAGAAAGCAGATACAAAATCCAGTGTCCCACT      731 
          K  G  H  I  P  T  P  S  R  S  E  S  R  Y  K  I  Q  C  P  T 
732      TGCCAATTGATCTGGTGTTTTAAGTGCCACTCTCCTTGGCATGAAGGTGTTAACTGCAAG      792 
          C  Q  L  I  W  C  F  Q  C  H  S  P  W  H  E  G  V  N  C  K 
793      GAGTACAAAAAAGGAGACAAGTTACTGCGTCACTGGGCCAGTGAGATTGAGCACGGGCAG      853 
          E  Y  K  K  G  D  K  L  L  R  H  W  A  S  E  I  E  H  G  Q 
854      AGAAATGCCCAGAAGTGTCCAAAGTGCAAGATCCATATCCAGAGAACAGAAGGGTGTGAC      914 
          R  N  A  Q  K  C  P  K  C  K  I  H  I  Q  R  T  E  G  C  D 
915      CATATGACTTGTTCACAGTGTAACACTAATTTTTGCTATCGATGTGGAGAGAGATACCGC      975 
          H  M  T  C  S  Q  C  N  T  N  F  C  Y  R  C  G  E  R  Y  R 
976      CAGCTCCGATTTTTCGGAGACCACACATCAAACCTCAGTATATTTGGATGCAAATATCGC      1036 
          Q  L  R  F  F  G  D  H  T  S  N  L  S  I  F  G  C  K  Y  R 
1037     TACCTCCCAGAGAGACCTCATTTAAGAAGATTAGTTCGAGGGTCAGTCTGTGCTGGAAAG      1097 
          Y  L  P  E  R  P  H  L  R  R  L  V  R  G  S  V  C  A  G  K 
1098     CTCTTCATTGCGCCTCTCATCCTGGTTTTGGGATTGGCACTAGGGGCCATAGCAGTTGTA      1158 
          L  F  I  A  P  L  I  L  V  L  G  L  A  L  G  A  I  A  V  V 
1159     ATCGGTTTATTTGTATTTCCTATATATTGCCTTTGTAAAAAACAGAGAAAGCGATCACGG      1219 
          I  G  L  F  V  F  P  I  Y  C  L  C  K  K  Q  R  K  R  S  R 
1220     ACAGGTATGCACTGGTAATCCACAGAGGATTTCACATGATGTCAGCCGGTACCGGGAGGA      1280 
          T  G  M  H  W  * 
1281     GCCATGCAGGATGGTGCACTTGTCTGTGAGTTGGATCCTTAAAACTACCTAGAGGAACTT      1341 
1342     CTGCCATCTTGTCTCCTGTGGTTCTCTGCAGACCACAGTGCCTCTAGCTACGGTGCACTC      1402 
1403     TCAACATGGCATCCTGTCCTTTCCTTAAGCAGATTGCTGCTTTTTAAAAAAATGGTCACT      1463 
1464     TTCGTTAACTATATACATTTATATAGTAACTCTCACCTTTGTGGTTCTTGGAAGAAAATA      1524 
1525     TTTTGAGAACAGGATATCCTCAGATGTCTTTTGAGGATACCTCACCTGGAGTGTTATTTG      1585 
1586     GATTGTCTGAACCTTGTGCTTCCCCCGGGCTGTCTCTGAGACATGGTATGCATAGCTGAA      1640 
1641     TCCGGCCTGTCTCAACAAACAAGGCCACTTTTCAGAAGATAAATCAAGTTCACCAAATGT      1701 
1702     ACCTAATTGTCCTCTGTAACCCAAATGGTATCATCGTTTTGTTTTTTGGATACTGTAATT      1762 
1763     GCTTTAAAAAAAAAGTGTCAGCACCCAGAGGGAATTAATGAAACTAAATTAATGAAAAGA      1823 
1824     ACCATGAGTTACTGGTCCGTCTATGTAAGGATGTGAATGTGTGTATATAAACACGTATTA      1884 
1885     AACCAGGCTCCATAACCATGTGCTTGCCTATTTCCATGTCTATTTTCATAGAACCTTTCA      1945 
1946     GGCCTTGATGGTTATTTTTGTGGGCCTAACTTGGTAATGTACTGAATTAAAGCCAATGTC      2006 
2007     AACAACAAAAAAAAAA                                                  2022 
Figure 6.3: cDNA sequence of mouse Ostl (J16). The whole mouse Ostl sequence from exon 1 to 
exon 6. The start and stop codons are shown in bold and underlined. 
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6.1.1. Characterization of the OSTL protein  
We searched the protein databases for homologous protein sequences using the OSTL protein. 
After sequence analysis and comparison with known proteins in the database, we were able to 
identify the OSTL protein domains. 
As represented in figure 6.4, we could identify three domains, one at the N terminal region 
from aa 5 until aa 51 (46 aa), representing a variant RING finger domain, a second domain, 
from aa 88 until aa 138 (50 aa) representing an in-between-RING finger domain (IBR) also 
known as double RING finger linked motif (DRIL) and a consensus RING finger was found 
in the C terminal region from aa 165 until aa 194 (29 aa).  
In the variant N terminal RING finger of OSTL, there is a lysine (K) instead of an histidine 
(H) in the 4th position. 
We searched the Fugu rubripes database for homologous sequences using segments of the 
human and mouse OSTL protein. Fugu genome is the smallest vertebrate genome and has 
proved to be a valuable reference genome for identifying genes.  
There are two possible start codons in the human OSTL as commented in 6.1. In our studies, 
we used the second ATG (Figure 6.2 and 6.3), which was homology in the human and mouse 
OSTL sequence and is embedded in a better Kozak sequence. The ORFs (open reading 
frames) obtained encoded a 275 aa protein for human OSTL and a 307 aa protein for mouse 
Ostl as shown in table 6.1. 
Human and mouse protein show 98% identity over their amino acid sequence, there are only 
8 aa that are not identical (underlined in figure 6.5). The homology between human OSTL 
and Fugu Ostl is 86%, indicating that OSTL is highly conserved between species. The three 
domains of OSTL are 100% conserved in Fugu, human and mouse. The domains of OSTL are 
color-coded in figures 6.4 and 6.5. 
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Figure 6.4: OSTL protein domains and comparison with consensus motifs. The three domains are 
schematically represented in color (pink: variant RING 1; blue: IBR; yellow: RING 2), the amino 
acids correspond to the human OSTL protein. 
 
 
Figure 6.5: Domains of OSTL protein and comparison between Fugu, human and mouse 
sequences. The differences between human and mouse aa sequences are underlined. The color bars 
represent the three protein domains of OSTL (pink: variant RING finger 1; blue: IBR or DRIL; 
yellow: RING finger 2). The aa without grey background are different between human, mouse, and 
fugu OSTL protein. 
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6.1.2. Genomic map of the STL/OSTL loci 
The STL and OSTL genes share the first exon (as represented in figures 6.1 and 6.6), but they 
are transcribed in the opposite directions (striped bar in figure 6.6). Comparison of genomic 
and cDNA sequences suggested that the cDNA fragment of human clone AA992964 (E06) 
comprises exons 1b (nt 138710 to 138810 from EST AL355296), 1c (nt 140938 to 141125 
from EST AL355296), 1d (nt 141657 to 141765 from AL355296), 2 (nt 18684 to 18917 from 
AL136128), 3 (nt 31415 to 31579 from AL136128), 4 (nt 50130 to 50331 from AL136128), 5 
(nt 54909 to 54980 from AL136128), 5b (nt 55922 to 56036 from AL136128), and 6 (nt 
56337 to 57575 from AL136128), and the cDNA sequence of mouse clone BF165105 (J16) 
corresponds to human exons 1 (nt95694 to 95912 from AL355296), 2, 3, 4, 5, and 6 as 
observed in figure 6.6, and tables 6.1, 6.2 and 6.4. 
OSTL is composed for six exons, with a total cDNA length of 2125 bp and several splice 
variants (see 6.1.3). The exon-intron boundaries of human and mouse OSTL are listed in 
tables 6.1 and 6.2. 
There are only two nucleotides in the splice donors not identical in both sequences (human 
and mouse OSTL), shown in the table 6.2 (in bold), in the intron 1 (were a guanine and a 
cystosine in the human sequence are replaced by thymidines in the mouse sequence). 
 
 
 
Figure 6.6: Map of STL/OSTL loci and position in the genomic sequence. The 6 STL exons are 
shown in pink bars, the exons and splice variants of OSTL from exon 1 (1b, 1c, and 1d) and from exon 
5 (5b) are represented with red bars. The genomic sequences AL355296 and AL136128 and respective 
position in the map are represented in the lower black bars. 
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Table 6.1: Exon-intron boundaries of hOSTL 
Intron Splice acceptor Exon Splice donor 
  Exon 1 (218 bp) AGCGCCCAGgtaacttcac 
Intron 1 (77kbp) ccatcatgcagGTACAACTT Exon 2 (233 bp) AAATACAAAgtaagcattt 
Intron 2 (12kbp) ttcttacacagATCCAGTGC Exon 3 (164 bp) AAGTGCAAGgtgagataac 
Intron 3 (18kbp) tgctgatacagATCCACATC Exon 4 (201 bp) CAGTCTGTGgtgagtgtct 
Intron 4 (4 kbp) ttgttttccagCTGGAAAAT Exon 5 (71 bp) TTGTAATCGgtaagaaacac 
Intron 5 (1 kbp) cttatccctagGTTTATTTG Exon 6 (1238 bp)  
 
Table 6.2: Exon-intron boundaries of mOstl 
Intron Splice acceptor Exon Splice donor 
  Exon 1 (218 bp) AGCTCTCAGgtaacttcac 
Intron 1 (77kbp) ccatcatgcagGTACAACTT Exon 2 (233 bp) AAATACAAAgtaagcattt 
Intron 2 (12kbp) ttcttacacagATCCAGTGC Exon 3 (164 bp) AAGTGCAAGgtgagataac 
Intron 3 (18kbp) tgctgatacagATCCACATC Exon 4 (201 bp) CAGTCTGTGgtgagtgtct 
Intron 4 (4 kbp) ttgttttccagCTGGAAAGC Exon 5 (71 bp) TTGTAATCGgtaagaaacac 
Intron 5 (1 kbp) cttatccctagGTTTATTTG Exon 6 (1238 bp)  
 
6.1.3. Identification of splice variants of the OSTL gene  
In order to characterize and identify other possible splice variant of OSTL, we analyzed the 
EST clones AW859482, AA776581, AA373303. The exons contained in these EST clones 
and the proteins encoded by each clone are shown in the table 6.3, together with mouse (J16) 
and human (E06) OSTL clones. For a complete overview of the OSTL splice variant forms we 
included in our analysis the data obtained from the RT-PCR experiments of OSTL during B 
cell development (Figure 6.12). The RT-PCRs were performed in Markus Müschen's 
Laboratory (Düsseldorf). The sequence analysis observed for each expression bands 
(fragments of 848, 778, and 543 bp) of OSTL in the RT-PCR are represented in the table 6.3. 
There are seven splice variant forms of OSTL that transcribe significant OSTL protein as 
observed in table 6.4. The complete map of OSTL with the seven splice variant forms is 
demonstrated in figure 6.7. 
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Table 6.3: Characterization of OSTL splice variants and the corresponding proteins  
OSTL no. Clone/sequence reference Exons Transcribed 
Protein 
1 Mouse BF165105 1, 2, 3, 4, 5, and 6 Ostl no.1 
307 aa 
2 Human AA992964 1b, 1c, 1d, 2, 3, 4, 5, 5b, 
and 6 
OSTL no.2 
275 aa 
3 AW859482 and AA776581 2, 2a, 2b, and 3 OSTL no.3 
~ 91 aa 
4 AA373303 1, and p1a (partial 1a) OSTL no. 4 
~ 99 aa 
5 Fragment from naïve B cells of 
848 bp 
2, 3, 4, 4b, 5, and 6 OSTL no. 5 
~ 256 aa 
6 Fragment from naïve, memory 
and plasma B cell of 778 bp 
2, 3, 4, 5, and 6 OSTL no. 6 
~ 248 aa 
7 Fragement from memory B 
cell of 543 bp 
3, 4, 5, and 6 OSTL no. 7 
~ 205 aa 
 
Table 6.4: OSTL exon names, nucleotide positions in the genomic sequence and splice variants  
Exon 
no. 
Nt from to 
(access no.) 
Splice 
1 
Splice 
2 
Splice 
3 
Splice 
4 
Splice 
5 
Splice 
6 
Splice 
7 
1 95694-95912 
AL355296 
X   X    
p1a 103960-104081 
AL355296 
   X    
1b 138710-138810 
AL355296 
 X      
1c 140938-141125 
AL355296 
 X      
1d 141657-141765 
AL355296 
 X      
2 18684-18917 
AL136128 
X X X  X X  
2a 20080-20134 
AL136128 
  X     
2b 21625-21732 
AL136128 
  X     
3 31415-31579 
AL136128 
X X X  X X X 
4 50130-50331 
AL136128 
X X   X X X 
4b 54568-54637 
AL136128 
    X   
5 54909-54980 
AL136128 
X X   X X X 
5b 55922-56036 
AL136128 
 X   X   
6 56337-57575 
AL136128 
X X   X X X 
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Figure 6.7: Map of OSTL locus showing seven splice variants and their position in the genomic 
sequence. The 6 OSTL exons are represented with pink bars, the splice variants from exon 1 (1pa, 1b, 
1c, and 1d), exon 2 (2a, and 2b), exon 4 (4b), and exon 5 (5b) are represented with red bars. The 
arrows correspond to the seven splice variants of OSTL. The genomic sequences AL355296 and 
AL136128 are indicated with the lower black bars. 
 
6.2. Expression of OSTL at RNA level 
6.2.1. Mouse multiple tissue Northern Blot 
To analyze the expression of Ostl in different mouse tissues, RNA was extracted from heart, 
liver, ovary, spleen, testis, kidney, thymus, bone marrow, and brain (see 5.3.5) from a normal 
4 weeks old BALB/c mouse. A Northern blot with these mouse tissues was hybridized with a 
748 bp OSTL cDNA probe (see 5.3.5), PCR amplified from mouse testis with primers 
OSTLEx1dATGXhoI and OSTL983BPstI (see table 5.1). An Ostl tanscript of 3.5 kbp could 
be clearly detected in liver, ovary and testis RNAs (Figure 6.8). A GAPDH probe was used as 
control for RNA quality (see 5.3.5.4). 
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Figure 6.8: Mouse multiple tissue Northern Blot. mOstl is expressed in liver, ovary and testis. 
 
6.2.2. Human multiple tissue Northern blot 
To analyze the expression of OSTL in different human tissues, a commercial human multiple 
tissues Northern (Clontech) was hybridized with the same OSTL probe as for the mouse 
Northern (see 6.2.1). OSTL transcripts of 9.5, 4.4, and 1.35 kbp were detected in testis and 
OSTL transcripts of 9.5, 4.4, and 2.4 kbp were detected in skeletal muscle (Fig. 6.9). Weak 
OSTL transcripts could be observed in prostate, ovary, heart, placenta, liver, and pancreas. An 
actin was used as control for RNA quality. 
 
Figure 6.9 A and B: Human multiple tissue Northern blot. hOSTL is highly expressed in testis, and 
skeletal muscle; weak expression is observed in prostate, ovary, small intestine, heart, placenta, liver, 
and pancreas. 
Results 
 
106 
6.2.3. Human cells Northern Blot 
To analyze the expression of OSTL in different human cell lines, RNA was extracted from 
BL2, BL41, BL70, DOHH2, Granta 519, Karpas 422, NCEB-1, three transformed 
lymphoblastoid cells from different patients (LCL B, LCL D, and LCL R), and Wsu-NHL 
cells (see 5.2.5 and 5.3.5). The Northern blot from human cell lines was hybridized with the 
same OSTL probe as described before (6.2.1). An OSTL transcript of 5.0 kbp was be detected 
in Karpas and in the three LCL samples (Figure 6.10). An actin probe was used as control for 
RNA quality. 
 
 
Figure 6.10: Human cell line Northern blot. hOSTL is expressed in Karpas 422, and LCLs cells (B, 
D, and R). 
 
6.2.4. RT-PCR with Human cells  
In order to confirm the expression of OSTL observed by the Northern blot in the different 
human cell lines (figure 6.10) we performed RT-PCR on RNA from the above cell lines and 
from two additional lines: SEM and Nalm6 (see 5.2.5). cDNA was synthesized from each cell 
line (see 5.3.6) after treatment of the RNA samples with DNaseI. OSTL primer pairs 5’: 
E06OSTL601T and 3’: E06OSTL761B (see table 5.1) were used for amplification. PCR 
reaction was performed as described in the section 5.3.4.1, using 35 cycles. 
Amplification of a 1.16 kbp fragment was observed in Granta 519, two transformed 
lymphoblastoid patient cells (LCL B, and LCL D) and by SEM cell line. TATA binding 
protein (TBP) primers (see table 5.1) were used as controls for cDNAs quality (figure 6.11). 
Interestingly, the expression pattern observed in the Northern cell lines was not the same as 
the one obtained in the RT-PCR which could be due to the presence of alternatively spliced 
transcripts in the cell lines which can not be amplified with the primers used. 
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Figure 6.11: Human cells RT-PCR. hOSTL is expressed in Granta 519, LCL B and LCL D cells. 
 
6.2.5. RT-PCR with B cells of different developmental stages 
In order to analyze the OSTL expression during B cell development, RT-PCR was performed 
in Markus Müschen's laboratory using B cells from the early developmental stages Pre-B, and 
B1, Naïve, and from B cells from the later stages, plasma B cell and memory B cells. The 
SEM cell line was used as positive control for OSTL expression. GAPDH was used as control 
for cDNAs quality. OSTL primer pairs 5’: OSTLE06205T and 3’: OSTL983BPstI (see table 
5.1) were used for amplification (figure 6.12). 
The PCR reaction was performed as described in section 5.3.4.1, using 30 cycles. As 
observed in the figure 6.12, a 1.1 kbp OSTL fragment could be detected in Pre-B cells; three 
fragments of 1.2, 1.0, and 0.76 kbp were detected in B1; four fragments of 1.3, 0.91, 0.85, and 
0.78 kbp were observed by naïve; four fragments of 0.95, 0.86, 0.78, and 0.54 kbp were 
detected by memory B cell and finally two OSTL fragments of 0.93, and 0.78 kbp were 
observed in plasma B cell. All the fragments were purified from the gel and sequenced. 
Naïve, memory, and plasma B cells fragments (see table 6.3) can encode bigger OSTL 
proteins. 
 
Figure 6.12: RT-PCR with B cells in different developmental stages. OSTL is expressed is all B 
cell stages. SEM cell line was used as positive control for OSTL expression. 
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6.2.6. RT-PCR with leukemic and normal patient bone marrow samples 
In order to analyze the expression of OSTL in different leukemia patient samples, RT-PCRs 
were performed. For OSTL expression the same primer pairs and PCR program as for the 
human cell lines RT-PCR (see 6.2.4) were used. 
For the first RT-PCR (Figure 6.13), three AML samples (AML M1, AML M4, and an AML 
with a CALM-AF10 translocation), and two ALLs (ALL with CALM-AF10 translocation and 
T-ALL with CALM-AF10 translocation) were used. 
A 0.16 kbp fragment was amplified in all leukemia patient cDNAs, as shown in figure 6.13. 
RT-PCR was also performed with normal human bone marrow sample, three pro-B-ALL 
patient samples, one pre-T-ALL, and two pro-T-ALLs as shown in figure 6.14. OSTL 
expression was observed in all the patient cDNAs (human normal BM, pro-B-ALL, pre-T-
ALL, and pro-T-ALL), with a very weak expression in the pro-T-ALL 25 samples (Figure 
6.14).  
 
 
 
Figure 6.13: RT-PCR with leukemia patient cDNAs. 
 
 
 
Figure 6.14: RT-PCR with normal bone marrow, B-ALL and T-ALL leukemia patient cDNAs. 
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6.3. Sub-cellular localization of OSTL 
Cloning 
In order to analyse the sub-cellular localization of OSTL, the OSTL encoding cDNA was 
cloned into pEGFP (Clontech) for the OSTL protein to be expressed as a fusion with the 
enhanced green fluorescent protein.  
The OSTL insert was PCR amplified from the human clone E06, using the primers 5’: 
OSTLEx1dATGXhoI and 3’: OSTL983BPstI (table 5.1).  
The recombinant plasmid was sequenced across the 5’ cloning site with the primer pEGFP-
C11240 (table 5.1) to confirm that the insert was in frame with the GFP open reading frame. 
The pEGFP-C1-OSTL (E06) construct is schematically shown in the figure 6.15. 
 
 
 
Figure 6.15: Schematic representation of the protein encoded by the pEGFP-OSTL construct. 
The human OSTL insert (E06) is shown in blue (Nt 233 – Nt 983). The open reading frame (ATG) and 
stop codon (TAA) of OSTL insert are underlined. The restriction enzymes used to clone OSTL into 
pEGPF vector are shown in red (XhoI and PstI). 
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Transfection and sub-cellular localization experiments 
We analysed the sub-cellular localization of fluorescent protein tagged OSTL protein by 
transiently expressing these proteins in the mouse fibroblast cell line NIH3T3 (see 5.5.1). 
Cells were observed 24 hours after transfection with an inverted epi-fluorescence microscope 
(Zeiss Axiovert 200 M) (see 5.5.3). After formaldehyde fixation, the transfected cells were 
photographed (see 5.5.2 and 5.5.3). OSTL localizes to the cytoplasm of the cells (figure 6.16 
A). The transfected cells were counterstained with DAPI (figure 6.16 B). A merged image the 
GFP and DAPI channel is shown in figure 6.16 C. Figure 6.16 D shows a phase contrast 
picure of the same cell. 
 
 
 
Figure 6.16: Sub-cellular localization of OSTL. A NIH3T3 cell transiently transfected with pEGFP-
OSTL was visualized with a GFP filter, a DAPI filter and in phase contrast. Scale bar = 10 µm. 
 
Protein expression 
In order to confirm the expression of the OSTL protein from our fluorescent construct, we 
over-expressed the protein in the embryonal kidney cell line HEK293T and performed 
Western analysis (see 5.6.). The GFP-OSTL protein was detected with a commercial anti-
GFP antibody (figure 6.17). 
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Figure 6.17: 10% SDS PAGE gel. Western blot of protein extract (10 µg/lane) from HEK 293T cells 
transiently-transfected with pEGFP empty (GFP lane) or pEGFP-OSTL (GFP-OSTL lane). Protein 
extracts were incubated with a rabbit anti-GFP antibody (1:3000) for 1 hour at RT and secondary 
antibody, donkey anti-rabbit HRP-conjugated. Detection was performed using ECL 
chemiluminescence kit, with exposure-time of 3 sec. Bands of 27 and 57 kDa molecular weight, 
correspond to the GFP and to the GFP-OSTL proteins. 
 
6.4. Whole mount in situ hybridization 
In order to analyze the expression pattern of Ostl during mouse embryonic development, we 
performed whole mount in situ hybridization experiments. OSTL RNA samples were prepared 
to hybridize BALB/c mouse embryos from 9.5 days post coitum (d.p.c.) on until 14.5 d.p.c. 
An OSTL insert of 748 bp was PCR amplified (see 5.3.4.1) from mouse testis with primers, 
5’: OSTLEx1dATGXhoI and 3’: OSTL983BPstI (see table 5.1). The insert was gel purified 
and subcloned into pGEMT-easy vector (see 5.2.8.3).  
Ostl showed a distinct expression pattern during mouse embryonal development. Figure 6.18 
shows the expression of Ostl in mouse embryos of 9.5 (A1-4), 10.5 (B1-5), 11.5 (C1-4), and 
12.5 (D1-4) d.p.c. The expression is observed in otic vesicle, optic vesicle, nostrils, prominent 
in somites, first and second limb buds, branchial arches, and closed posterior neuropore.  
Ostl is strongly expressed in limb development (Figure 6.19). 
In the earlier stages, expression is more prominent in the anterior region of the limb buds 
(Figures 6.19 A and B -limb buds of 11.5 d.p.c. embryo). At 12.5 d.p.c. expression divides 
into a proximal domain in the region of the prospective handplate and a distal domain 
including the mesodermal ridge (Figures 6.19 C and D). 
Horizontal, transverse, and sagital sections of whole-mounts stained from 9.5 on until 13.5 
d.p.c. embryos, showed expression of Ostl mainly in the somites and limb buds (figure 6.20). 
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Figure 6.18: (A-D) Whole mount in situ hybridization of Ostl in mouse embryos. (A1) right 
lateral, (A2) left lateral, (A3) caudal lateral, (A4) caudal view of a 9.5 d.p.c. mouse embryo; (B1) right 
lateral, (B2) left lateral, (B3) caudal, (B4) branchial arches, (B5) caudal view of a 10.5 d.p.c. embryo; 
(C1) right lateral, (C2) left lateral, (C3) limb buds, (C4) frontal caudal view of a 11.5 d.p.c. mouse 
embryo; (D1) left lateral, (D2) nostrils, (D3) limb buds, (D4) hind limb bud and caudal view of a 12.5 
d.p.c. embryo. 
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Figure 6.19: (A-D) Ostl expression during limb development. (A) forelimb buds from 11.5 until 
14.5 d.p.c. embryos; (B) hindlimb buds from 11.5 until 14.5 d.p.c. embryos ; (C) limb buds of 12.5 
d.p.c. embryos, and (D) hindlimb buds of 13.5 and 14.5 d.p.c. embryos. 
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Figure 6.20: Ostl expression during mouse embryonic development sections. (A and B) horizontal 
and transverse sections of a whole-mount stained 9.5 d.p.c. embryo, expression is observed in the 
somites; (C) Horizontal section of a whole-mount stained 10.5 d.p.c embryos, Ostl expression is 
detected in the somites; (D-F) Horizontal and sagital sections of a whole-mount stained 11.5 d.p.c. 
embryo, expression is observed in the somites and limb bud; (G and H) sagital sections of a whole-
mount stained 13.5 d.p.c. embryo, Ostl expression is observed in the limb buds (digits). 
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6.5. Preparation and purification of OSTL-GST protein 
Cloning 
In order to produce antibodies against OSTL for the further characterization of the protein, we 
tried to express sufficient quantities of OSTL as a GST fusion protein in bacteria (see 5.7). 
We constructed three plasmids: the first with the full length hOSTL (∼ 275 aa) was cloned 
into pGEX4T-2 vector. The insert was obtained from the plasmid pEGFP-C1-OSTL (see 6.3) 
using the BglII and SalI restriction enzymes and cloned into pGEX4T-2 cut with BamHI and 
XhoI (figure 6.21 A). Two Ostl mutants were constructed: one containing the RING finger 2 
and the C terminus (∼ 127 aa) named Ostl mutant 4 and the other containing only the C 
terminus (∼ 78 aa) called Ostl mutant 6. Both mutants were PCR amplified from the mouse 
J16 clone using the primers J16-836TEcoRI and J16-1218BXhoI (mutant 4) and J16-
982TEcoRI and J16-1218BXhoI (mutant 6) (see table 5.1). The mutants were cloned into the 
EcoRI and XhoI sites of pGEX4T-2 (Figures 3.21 B and C). 
The integrity of all constructs was veryfied by sequencing with primer pGEX 5’ (table 5.1). 
Unfortunately, all three constructs failed to express sufficient amounts of protein. 
 
 
Figure 6.21: Schematic representation of pGEX4T-2-OSTL plasmids. (A) Human full length 
OSTL into pGEX4T-2; (B) Mouse Ostl mutant 4 into pGEXT4-2; (C) Mouse Ostl mutant 6 into 
pGEX4T-2. The diagram indicates the restriction enzyme sites (underlined in red), and the start and 
stop codons (in bold) of OSTL inserts (in blue) for all three constructs. 
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6.6. Identification of OSTL-interacting proteins using the yeast two-hybrid 
system 
To identify OSTL-interacting proteins a yeast two-hybrid protein interaction screen was 
performed. The OSTL protein served as bait and a cDNA Hela S3 library encoding possible 
OSTL-interacting factors supplied the prey (schematically represented in Figures 6.22 A and 
B). 
 
 
 
 
Results 
 
117 
 
 
Figure 6.22: Flow diagrams for the identification of OSTL-interacting proteins. (A) Schematic 
representation of the Hela cDNA library amplification; (B) Schematic representation of the yeast two 
hybrid screening using OSTL as bait gene and the Hela cDNA library as prey.  
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6.6.1. Preparation and test of OSTL as a bait protein 
Cloning 
With standard cloning techniques (see 5.3.4), the OSTL cDNA was inserted into the 
polylinker of the pGBT9 plasmid to produce an in frame GAL4DBD-OSTL fusion protein. 
Briefly, the human OSTL-ORF (E06-ORF) was PCR amplified with the primers 
OSTLEx1dATGXhoI and OSTL983BPstI (table 5.1) and inserted in frame with GAL4-DNA-
BD into the SalI and PstI restriction sites of the pGBT9 vector. The pGBT9-OSTL construct 
is schematically shown in the figure 6.23. 
Using the lithium acetate procedure, the yeast strain CG 1945 (see 5.2.3) was transformed 
with the plasmid pGBT9-OSTL. Since the prey plasmid pGAD-GH and the bait expression 
plasmid pGBT9 harbor the LEU2 and TRP1 genes, respectively (see 5.2.3 and 5.2.8.4), 
transformants which were selected grew in synthetic selective dropout medium lacking 
leucine and tryptophan. To investigate whether OSTL as a bait protein activates transcription 
of the reporter genes in the absence of the “prey” protein, each yeast transformant was diluted 
100 and 1000-fold in sterile water and plated on SD -Trp and SD -Trp, -His plates. The 
growth of the cells was monitored for several days. All yeast clones grew well to a similar 
density on the SD -Trp plates. However, in the presence of histidine the yeast clones did not 
grow. 
These results showed that the binding of the OSTL-GAL4-BD fusion protein upstream of the 
reporter genes HIS3 and lacZ was not enough to activate their transcription. Therefore, it was 
concluded that the OSTL protein is suitable as a bait protein for the yeast two-hybrid assay. 
For the actual yeast two hybrid screen, the OSTL cDNA was inserted into the polylinker of 
the pGBKT7 plasmid to produce an in frame GAL4-BD-OSTL fusion protein. 
The pGBKT7 vector was choose for the further analysis because it carries a kanamycin 
resistence marker and contains a c-Myc epitope, facilitating the selection of OSTL-interactors 
from the library transformants and also the confirmation of positively selected clones through 
in vitro CoIP. The pGBKT7-OSTL construct is schematically shown in figure 6.24. 
To confirm expression of the OSTL protein, the yeast strain harboring the bait plasmid was 
analyzed with a Western blot. 
Results 
 
119 
 
The yeast clone (pGBKT7-OSTL) showed a clear band around 50 kDa on Western analysis 
corresponding to the pGBKT7-OSTL fusion protein. 
 
 
 
Figure 6.23: Diagram of the pGBT9-OSTL plasmid. The restriction enzyme sites from the vector 
and insert are underlined (in red). The human OSTL insert is shown in blue (hOSTL nucleotides are 
indicated). The vertical arrow indicates the plasmid pGBT9-OSTL with start and stop codons of the 
OSTL sequence insert in bold. 
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Figure 6.24: Schematic representation of pGBKT7-OSTL plasmid. The pGBKT7 vector and MCS 
are indicated. The restriction enzyme sites from the vector and insert are underlined (in red). Human 
OSTL insert is represented in blue (hOSTL nucleotides are indicated). The vertical arrow indicates the 
plasmid pGBKT7-OSTL with start and stop codons of OSTL sequence insert in bold. 
 
6.6.2. Screening for OSTL interactors 
The interactor screen was performed in two consecutive large plating steps (see 5.4.5 and 
Figure 6.22 B). First 22 µg and then 33 µg DNA of pGAD-GH plasmid containing the human 
cDNA Hela S3 library (Clontech) were transformed into AH109 cells with the bait plasmid 
(pGBKT7-OSTL) plasmid (see 5.4.5). In order to obtain a high number of primary 
transformants expressing an individual library plasmid, the yeast strain was transformed in 
large scale in 8 different sterile tubes per experiment (2 large scale experiments = 16 tubes). 
For each experiment the transformation efficiency* expressed as colony forming units (cfu) 
per µg of input DNA was around 3x104 (table 6.5). The content of the 8 tubes was pooled, 
and 250 µl of the transformation reaction were plated on thirty 15 cm SD-TRP, -LEU, -HIS, -
ADE plates in the first transformation and on thirty 15 cm SD-TRP, -LEU, -HIS plates in the 
second transformation. 
The plates were incubated at 30°C for 3-7 days until colony growth could be detected. 
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*Transformation efficiency = cfu/ µg transformed DNA 
cfu = colony forming units (into SD/ -TRP-LEU selective yeast medium) 
Number of tested clones = total number of clones per experiment 
 
Table 6.5: Transformation efficiency and number of tested clones 
Experiments Amount of 
transformed DNA in 
µg 
Transformation- 
efficiency in cfu/µg 
Number of 
tested clones 
First 
transformation 
22 29920 660.000 
Second 
transformation 
33 26666 880.000 
 
After seven days, 8 clones from the first experiment and 150 clones from the second 
experiment were detected. The clones from the first experiment were selected on SD –TRP-
LEU-HIS-ADE + X-α-gal master plates (15 cm). The clones from the second experiment 
were selected on SD –TRP-LEU-HIS-ADE and finally on X-α-gal master plate (see 5.4.5.1). 
At this point 8 out of 8 and 39 out of 150 clones grew in the absence of tryptophan, leucine, 
histidine, adenine, and showed X-gal positivity (= blue colonies).  
 
6.6.3. Isolation and classification of library plasmids 
From each of the 8 (first screen) and 39 (second screen) positive yeast clones prey plasmids 
were isolated by performing a rapid yeast plasmid preparation and the isolated DNA was 
transformed into competent XL1 bacteria by electroporation (see 5.4.7 and 5.4.8).  
Seven of 8 and 17 of 39 yeast DNAs were successfully transformed, while the prey clones 
from 23 colonies could not be transformed into XL1 bacteria. From these bacteria, DNA was 
isolated and analyzed by restriction enzyme digestion. Each bacterial miniprep DNA was 
digested with EcoRI and XhoI restriction enzymes to release the insert of the library plasmids. 
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6.6.4. Sequencing of the interaction clones and BLAST analysis 
The 24 clones harboring an EcoRI/XhoI insert in the library plasmid were sequenced with the 
primers Y2H2 and 3’AD (table 5.1). NCBI’s BLAST search (see 5.12) of available sequence 
databases identified the proteins shown in tables 6.6 and 6.7. A brief description of each 
interaction-protein is given in table 6.8.  
As observed in tables 6.6 and 6.7, HAX1 was the most frequent protein found in the two 
screens. Interestingly, not only full length HAX1 protein (represented by clone 5) but also 
eight different fragments of the protein (represented by clones 1 (= 4), 2 (= 104), 3, 6, 15 (= 
41), 79 (= 87), 118, and 127 were found as OSTL interacting proteins (see figure 6.25). 
Only one clone coding for the following proteins was found: SIVA was found in both screens 
as OSTL-interacting protein (represented by clone 7 and as diagram in figure 6.25), Dpy-30 
(clone 19), Luman (clone 21), RPLP1 (clone 27), Metallothionein 2A (clone 43), FLJ31231 
(clone 52), LMS3 (clone 67), a hypothetical protein containing a RING-finger motif (clone 
115). 
PKM2 was found two times in the medium stringency Hela screening as OSTL-interacting 
protein (clones 85 = 107). 
Figure 6.25 schematically shows the full length cDNA and protein sequences of the OSTL 
interacting proteins and their clones found in the HeLa library. 
 
 
Table 6.6: First screening of the Hela-library (SD –T, L, H, A) –  
7 positive clones 
Hela Clones Protein Interaction partners of OSTL 
1, 3 HAX-1 NM_006118.3* 
2 HAX-1 
4, 6 HAX-1 
5 HAX-1 
7 SIVA NM_006427.2* 
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Table 6.7: Second screening of the Hela-library (SD –T, L, H) – 
17 positive clones 
Hela Clones Protein Interaction partners of OSTL 
15, 41 HAX-1 
19 DPY-30 BC_015970.1* 
21 Luman AF_009368* 
27 RPLP1 NM_001003* 
43 Metallothionein 2A BC_007034* 
52 FLJ31231 NM_030919.1* 
67 LSM3 NM_014463.1* 
79, 87 HAX-1 
85, 107 PKM2 NM_002654.1* 
104, 2 HAX-1 
115 MGC 33993 (Hypothetical Protein RING-
Finger motif) 
NM_152737.1* 
118 HAX-1 
127 HAX-1 
*: Genbank accession numbers 
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Table 6.8: Yeast two hybrid OSTL-interacting proteins 
Protein name Cell localization Protein description* 
HAX1 cytoplasm HS1-associated protein X-1, is an anti-apoptotic 
protein, involved in signal transduction in B cells 
SIVA nucleus Intracellular ligand of CD27, is highly expressed in 
lymphoid cells and exhibits pro-apoptotic activity 
DPY-30 nucleus A ubiquitous factor that promote the hermaphrodite-
specific association of DPY-27 with X by affecting 
the activity of a sex-specific dosage compensation 
gene 
Luman cytoplasm Human basic leucine zipper transcription factor, 
requires the host cell factor (HCF) for activity, 
implicated in cell growth 
RPLP1 
 
cytoplasm Homo sapiens ribosomal protein, large, P1 (RPLP1), 
transcript variant 1 
Metallothionein 2A 
(MT2A) 
nucleus Metallothionein (MT) belong to a family of cysteine-
rich, metal-binding intracellular proteins, which are 
encoded by 10 functional MT isoforms, and involved 
in cell proliferation, differentiation and apoptosis 
FLJ31231 or 
chromosome 20 ORF 
129 (C20orf129) 
nucleus Homo sapiens chromosome 20 open reading frame 
129 (C20orf129) 
LSM3 or MDSO17 cytoplasm Homo sapiens LSM3 homolog, U6 small nuclear 
RNA associated S. cerevisiae (LSM3). LSM (1-7) 
proteins form heptameric complexes that are 
involved in various steps of RNA metabolism 
PKM2 cytoplasm Homo sapiens pyruvate kinase, muscle (PKM2) 
MGC33993 
(Hypothetical Protein 
RING-Finger motif) 
 
cytoplasm Homo sapiens ring finger protein 182 (RNF182) 
 
*Literature information 
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Figure 6.25: cDNAs and Open Reading Frames (ORFs) of full length proteins and clones 1-6, 7, 15, 
19, 21, 27, 41, 43, 52, 67, 79 85, 87, 104, 107, 115, 118, and 127 isolated in yeast two hybrid screen as 
OSTL interaction partner. 
 
6.6.5. Confirmation of the interaction between OSTL and HAX1 and OSTL and 
SIVA 
Cotransformation assay in yeast 
For further analysis, we focused on the interaction of OSTL with HAX1 and SIVA. In order 
to perform the first confirmation assay, HAX1 (2, 3, and 5) and SIVA (7) clones obtained 
from a Hela cDNA library were cotransformed with pGBKT7-OSTL into competent yeast 
cells (strain AH109) (see 5.4.3). The cotransformants were plated on highly selective SD 
plates lacking tryptophan, leucine, histidine, and adenine, supplemented with X-α-gal (figure 
6.26). 
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All the tested clones, HAX1 clones 2, 3, and 5 and SIVA clone 7 showed activation of the 
reporter genes indicated by growth on the selective plate and the development of blue 
colonies when cotransformed with pGBKT7-OSTL as shown in figure 6.26. 
 
 
 
Figure 6.26: Highly selective SD plate lacking TRY, LEU, HIS, and ADE supplemented with X-
α-gal. Blue colonies are observed in all library clones (HAX1 2, 3, and 5) and (SIVA 7) 
cotransformed with pGBKT7-OSTL bait plasmid. 
 
Mapping of the HAX1 and SIVA interaction domain with OSTL 
 
Cloning 
In order to analyze which OSTL protein domains are responsible for the interaction with 
HAX1 and SIVA, we constructed several deletion mutants of Ostl. 
For these experiments and further in vitro assays, HAX1 and SIVA cDNAs were cloned into 
pGADT7 (figures 6.27 and 6.28). The full length human HAX1 insert was cut with the 
restriction enzymes EcoRI and BamHI from the plasmid pEYFP-HAX1 (Figure 6.31 A) and 
cloned into a modified pGADT7 vector (cutt with NdeI, blunt ended and religated) (Figure 
6.27). SIVA variant 1 (V1) from Hela library clone 7 was digested with EcoRI and Xho and 
cloned into pGADT7. Unfortunately, plasmid pGADT7-SIVA was out of frame. To correct 
this, the plasmid was cut with NdeI, blunt ended and religated (Figure 6.28). 
Full length mouse Ostl and six mOstl mutants (M1-M6) were cloned into pGBKT7 (Figures 
6.28 and 6.29 B). Mouse Ostl was choose because it has the complete N terminal variant 
RING1, while the human OSTL clone lacks 15 aa of the first RING domain (Figures 6.29 and 
6.30 B lane 8). 
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To construct mouse Ostl deletion mutant expression vectors, the desired sequences were 
amplified from the mOstl coding region by PCR and cloned into NcoI/PstI sites of the 
pGBKT7 vector. 
The forward and reverse primers used to amplify the full-length OSTL were J16-295TNcoI 
and OSTL983BPstI; for Ostl (58 to 307) mutant 1 J16ATG1dNcoI and J16-996BPstI; for Ostl 
(1 to 111) mutant 2 J16-295TNcoI and J16-605BPstI; for Ostl (58 to 187) mutant 3 
J16ATG1dNcoI and J16-855BPstI; for Ostl (166 to 307) mutant 4 J16-838TNcoI and 
OSTL983BPstI; for Ostl (166 to 223) mutant 5 J16-838TNcoI and J16-996BPstI; for Ostl 
(207 to 307) mutant 6 J16-949NcoI and OSTL983BPstI (Figures 6.29 and 6.30 B). All 
constructs were verified by sequencing using primers 5’ Y2H1 for the pGBKT7 vector and 
Y2H3’AD for the pGADT7 vector (see table 5.1 for primer details). 
 
 
 
Figure 6.27: Schematic representation of pGADT7-HAX1 plasmid. The restriction enzyme sites 
from the vector and insert are underlined (in red). Human HAX1 insert is shown in blue (HAX1 Nt 112 
– Nt 1170 are indicated). The vertical arrow indicates the plasmid pGADT7-HAX1 with start and stop 
codons of HAX1 sequence insert in bold. 
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Figure 6.28: Schematic representation of pGADT7-SIVA plasmid. The restriction enzyme sites 
from the vector and insert are underlined (in red). SIVA V1 insert is shown in blue (SIVA Nt 32 – Nt 
565 are indicated). The vertical arrow indicates the plasmid pGADT7-HAX1 with start and stop 
codons of HAX1 sequence insert in bold. 
 
Cotransformation assay in yeast to map the HAX and SIVA interaction domains of 
OSTL 
Cotransformation of pGBKT7-mOstl, hOSTL, and mouse deletion mutant plasmids and 
pGADT7-HAX1 or pGADT7-SIVA were performed using the yeast strain AH109 (as 
described in 5.4.3). Cotransformants were plated into SD lacking TRY and LEU and SD 
lacking TRP, LEU and HIS as shown in figure 6.29 A for HAX1-OSTL cotransformation and 
in figure 6.30 A for SIVA-OSTL cotransformation. 
For each cotransformation reaction, three serial dilutions were performed (1:1000, 1:10000, 
and 1:100000), from 100 µl of total reaction 5 µl were plated on each selection plate (shown 
in A). In B, the lanes 1-9 indicate the Ostl fragments used for the cotransformation. Lane 1 
shows full length mouse Ostl (with all three domains); lane 2: - mutant 1, lacking 15 aa of the 
first RING domain and the C terminus; lane 3: - mutant 2, containing the complete first 
RING; lane 4: - mutant 3, lacking RING 2 and C terminus; lane 5: - mutant 4, RING 2 and C 
terminus; lane 6: - mutant 5, containing only RING 2; lane 7: - mutant 6, C terminus only; 
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lane: - 8 human OSTL (used for the library screening), lacking the first 15 aa of the first 
RING; lane 9: mOstl full length co-transformed with the empty prey plasmid as negative 
control for the growth on SD lacking TRY, LEU and HIS. 
Interaction efficiency are shown in B as +++ or -. As can be seen in fig. 6.29, HAX1 interacts 
with OSTL through its variant RING finger 1. 
For the SIVA-OSTL interaction, shown in figure 6.30, the interaction seems to occur through 
RING finger 1 of OSTL, but here, the C terminus is also involved. 
 
 
 
 
Figure 6.29: Mapping of the HAX1 interaction domain of OSTL. (A) Growth of serially diluted 
yeast colonies (1:100, 1:1000, 1:10000) on SD lacking tryptophan and leucine (SD -TL) or on SD 
lacking tryptophan, leucine and histidine (SD –TLH). The yeast cells AH109 were cotransformed with 
a plasmid expressing a DBD-OSTL or DBD-OSTL deletion mutant proteins (pGBKT7-OSTL) and a 
plasmid expressing an AD-HAX1 fusion (pGADT7-HAX1) shown in lanes 1-8. Lane 9 indicates the 
cotransformation control where the DBD-OSTL protein was co-transformed with the empty prey 
plasmid. (B) First column shows the structure of the DBD-OSTL deletion mutants; the second column 
represent AD fusion, and the third column shows the interaction levels. 
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Figure 6.30: Mapping of the SIVA interaction domain of OSTL. (A) Growth of serially diluted 
yeast colonies (1:100, 1:1000, 1:10000) on SD lacking tryptophan and leucine (SD -TL) or on SD 
lacking tryptophan, leucine and histidine (SD –TLH). The yeast cells AH109 were cotransformed with 
a plasmid expressing a DBD-OSTL or DBD-OSTL deletion mutant proteins (pGBKT7-OSTL) and a 
plasmid expressing an AD-SIVA fusion (pGADT7-SIVA) in lanes 1-8. Lane 9 has the control where 
the DBD-OSTL protein was co-transformed with empty AD in yeast. (B) First column shows DBD-
OSTL deletion mutants; the second column shows the AD fusions, and the third column indicates the 
level of interaction. 
 
Cotransfection assays in mammalian cells 
In order to confirm the OSTL interaction with HAX1 and SIVA through co-localization in 
mammalian cells, we performed cotransfection assays in NIH3T3 cells (see 5.5.1.1). 
 
Cloning 
In order to analyse the sub-cellular localization of OSTL, HAX1 and SIVA, the open-reading 
frame (ORF) of OSTL was cloned in frame with the gene coding for the enhanced cyan 
fluorescent protein (pECFP vector). The ORFs of HAX1 and SIVA were cloned in frame with 
the gene coding for the enhanced yellow fluorescent protein (pEYFP vector). 
Full length human HAX1 was digested from the Hela library clone 5 (Table 6.6 and Figure 
6.25) with the restriction enzymes EcoRI and KpnI and cloned into pEYFP using the same 
enzymes (Figure 6.31 A). The SIVA insert was released from the plasmid pGADT7-SIVA 
(Figure 6.28) using the restriction enzymes EcoRI and XhoI and cloned into pEYFP digested 
with EcoRI and SalI (Figure 6.31 B). Expressing a CFP-OSTL and an YFP-HAX1 or YFP-
SIVA fusion protein in mammalian cells allowed us to colocalize these proteins.  
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Figure 6.31: (A) Schematic representation of pEYFP-C1-hHAX1 and (B) pEYFP-C1-SIVA V1. 
 
Cotransfection and sub-cellular colocalization experiments 
Cells transfected with CFP-OSTL and YFP-HAX1 or CFP-OSTL and YFP-SIVA were 
observed 24 hours after transfection with an inverted epi-fluorescence microscope (see 5.5.3). 
After formaldehyde fixation, the cotransfected cells were photographed using an inverted epi-
fluorescence microscope (see 5.5.2 and 5.5.3). Both OSTL and HAX1 co-localize in the 
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cytoplasm of the cells as shown in figure 6.32 A-D. Figure 6.32 A represented CFP-OSTL in 
the cyan channel, in 6.32 B YFP-HAX1 in the YFP channel, in C the merged image of YFP 
and CFP is shown and in D is phase contrast image of the same cell. 
OSTL and SIVA co-localization was observed in the cytoplasm. As shown in figure 6.33, 
OSTL localization is restricted to the cytoplasm and SIVA, which normally localizes to the 
nucleus, goes also to cytoplasm when OSTL is cotransfected (Figure 6.33 B). In most of the 
examined cells, the pattern observed is the same as shown in figure 6.33. In a few cells (about 
10%) OSTL, when cotransfected with SIVA can also be seen in the nucleus. 
 
 
Figure 6.32: Subcellular localization and colocalization of OSTL and HAX1 in mouse fibroblast 
cells (NIH3T3). (A) CFP-OSTL fusion protein. (B) YFP-HAX1 fusion protein. (C) Merge of CFP-
OSTL and YFP-HAX1. (D) Phase contrast. Scale bar: 10µm 
 
 
 
 
Figure 6.33: Subcellular localization and colocalization of OSTL and SIVA in mouse fibroblast cells 
(NIH3T3). (A) CFP-OSTL fusion protein. (B) YFP-SIVA fusion protein. (C) Merge of CFP-OSTL 
and YFP-SIVA. (D) Phase contrast. Scale bar: 10µm 
 
 
Protein expression 
In order to confirm expression of the OSTL, HAX1, and SIVA proteins in our fluorescent 
constructs, we expressed the proteins in the embryonal kidney cell line HEK293T and 
performed Western analysis (see 5.6). All constructs could be detected in a 10% SDS-PAGE 
gel as shown in figure 6.34. The protein sizes are indicated on the left in kDa. Bands of 27, 
62, 57, and 44 kDa molecular weight correspond to YFP, YFP-HAX1, CFP-OSTL, YFP-
SIVA proteins, respectively.  
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Figure 6.34: Protein expression of the different constructs used in the cotransfection assays. 
Western blot of protein extract (10 µg/lane) from HEK 293T cells transiently transfected with pEYFP 
(first lane) or pEYFP-HAX1 (second lane), pECFP-OSTL (third lane), pEYFP-SIVA (fourth lane), co-
OSTL-HAX1 (fifth lane) and co-OSTL-SIVA (sixth lane). Protein extracts were incubated with a 
rabbit anti-GFP antibody (1:3000) for 1 hour at RT and a secondary donkey anti-rabbit HRP-
conjugated antibody. Exposure time was 3 sec.  
 
 
In vitro coimmunoprecipitation assay 
We were able to confirm the association between OSTL and HAX1 by using the CoiP in vitro 
system from Clontech (see 5.4.8.3). Both proteins were immunoprecipitated using the TNT-
reticulocyte lysate system (Promega) (see 5.4.8.3). The CoiP was performed with mAb c-myc 
Ab against GAL4DBD-OSTL and pAb anti-HA against AD-HAX1. As observed in figure 
6.35 lane 1, both proteins OSTL (30 kDa) and HAX1 (35 kDa) were coimmunoprecipitated 
with the anti-myc Ab. The expression of OSTL and HAX1 can be observed in lanes 2 and 3. 
The negative controls are shown in lanes 4 and 5, where OSTL was immunoprecipitated with 
anti-HA and HAX1 with anti-myc antibodies. 
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Figure 6.35: In vitro coimmunoprecipitation of OSTL and HAX1. OSTL and HAX1 were 
immunoprecipitated with a in vitro transcription/translation coupled reticulocyte lysate system. CoIP 
was performed using a mAb c-myc against GAL4DBD-OSTL. Lane 1 shows the CoIP of OSTL and 
HAX1, lane 2 IP of OSTL identified as a 30 kDa molecular weight band, lane 3 IP of HAX1 identified 
as a 35 kDa molecular weight band, lane 4 IP of OSTL with pAb anti-HA as negative control and lane 
5 IP of HAX1 with mAb anti-myc as negative control. 
 
In vivo coimmunoprecipitation assay 
We were able to confirm the association between OSTL and HAX1 by overexpressing both 
proteins in HEK293T cells and coimmunoprecipitation (see 5.4.8.4). Immunoprecipitation 
was performed using the anti-HAX1 Ab (Clontech) (see 5.2.7.) (Figure 6.36 lower panel). As 
controls, untransfected 293T cells or control goat polyclonal Ab were used (lanes 1 and 3). 
The coprecipitation was performed with anti-GFP Ab (Molecular Probes) (Figure 6.36 upper 
panel). Both proteins CFP-OSTL (57 kDa) and YFP-HAX1 (62 kDa) were 
coimmunoprecipitated with the anti-GFP Ab (lane 2 upper panel). In lanes 4 and 5, 
approximately 10 µg of total cell lysates of untransfected 293T or CFP-OSTL and YFP-HAX1 
cotransfected cells is shown. 
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Figure 6.36: Interaction of OSTL and HAX1 in mammalian cells. Immunoblot detection of 
HEK293T cells cotransfected with CFP-OSTL and YFP-HAX1 proteins was performed. After 24 h, 
cells were lysed (2x106/lane) and analyzed by 10% SDS-PAGE followed by immunoblotting with 
mouse anti-HAX1 Ab (lower panel). Untransfected 293T cells were used as control (lane 1) or control 
mouse polyclonal Ab (lane 3). The same filter was immunoblotted with anti-GFP Ab (upper panel). 
Lane 2, the coprecipitated OSTL and HAX1 fused proteins (upper panel). Lanes 4 and 5, 10 µg of 
total cell lysates of untransfected 293T and cotransfected cells. 
 
The association between OSTL and SIVA could also be confirmed by overexpressing both 
proteins in HEK293T cells (see 5.4.8.4). Immunoprecipitation was performed using a 
polyclonal anti-Siva Ab (Santa Cruz) (see 5.2.7.) (Figure 6.37 lower panel). As controls, 
untransfected 293T cells or control goat polyclonal Ab were used (lanes 1 and 3). The 
coimmunoprecipitation was performed with anti-GFP Ab (Molecular Probes) (Figure 6.37 
upper panel). 
Both proteins CFP-OSTL (57 kDa) and YFP-SIVA (44 kDa) were coimmunoprecipitated 
with the anti-GFP Ab (lane 2 upper panel). In lanes 4 and 5, approximately 10 µg of total cell 
lysates of untransfected 293T or CFP-OSTL and YFP-SIVA cotransfected cells is showed. 
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Figure 6.37: Interaction of OSTL and SIVA in mammalian cells. Immunoblot detection of 
HEK293T cells cotransfected with CFP-OSTL and YFP-SIVA proteins was performed. After 24 h, 
cells were lysed (3x106/lane) and analyzed by 10% SDS-PAGE followed by immunoblotting with goat 
anti-Siva Ab (lower panel). Untransfected 293T cells (lane 1) or control goat polyclonal Ab (lane 3) 
were used as controls. The same filter was immunoblotted with anti-GFP Ab (upper panel). Lane 2, 
the coprecipitated OSTL and SIVA fused proteins (upper panel). Lanes 4 and 5, 10 µg of total cell 
lysates of untransfected 293T and cotransfected cells. 
 
6.7. Ubiquitination assay 
Most RING finger proteins known are ubiquitin ligases (Lorick, et al., 1999). OSTL encodes a 
protein that has a variant RING 1, a DRIL (double RING finger linked) or IBR (in between 
RING fingers) and a RING finger 2 motif (Capili, et al., 2004) (see 6.1.1).  
We have performed experiments to study the involvement of OSTL in the ubiquitin cascade. 
These experiments were done in collaboration with Stefan Müller and Andreas Ledl at the 
Max Planck Institute, Martinsried. We examined whether OSTL plays a role as an E3 ligase 
for HAX1 and or for SIVA, both interaction partners of OSTL (see 6.6.4). We also performed 
a test for ubiquitination of a putative substrate protein (modified from Treier et al., 1994). In 
these experiments, we tested whether OSTL can enhance the ubiquitination of HAX1 and/or 
SIVA (see 5.9). 
We repeated the assays three times and we were unable to show an increased ubiquitination of 
either HAX1 or SIVA in the presence of OSTL (Figures 6.39 and 6.40).  
 
 
 
 
Results 
 
138 
Cloning 
For these experiments the presence of both RING finger domains is essential, therefore we 
cloned the ORF of the whole mouse Ostl gene (J16) in frame with the gene coding for the 
enhanced cyan fluorescent protein (pECFP). mOstl was PCR amplified with the primers 
OSTLj16T302XhoI and OSTLj16B1272XhoI (see table 5.1) and subcloned into pECFP 
vector using the restriction enzyme XhoI. 
The plasmid was sequenced with the primer pEGFP-C11240 (Table 5.1) to confirm that the 
insert was in frame with the cyan fluorescent protein open reading frame. The plasmid is 
schematically shown in figure 6.38. 
 
 
 
Figure 6.38: Schematic representation of the pECFP-mOstl construct. The mouse Ostl insert (J16) 
is represented in blue (Nt 302 – Nt 1218). The open reading frame (ATG) and stop codon (TAA) of 
Ostl insert are underlined. The restriction enzymes used to clone Ostl into pECPF vector are shown in 
red (XhoI and PstI). 
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Western blot analysis of in vitro ubiquitination test using HAX1 and SIVA as candidates 
substrates for Ostl 
 
Figure 6.39: Test of in vitro ubiquitination with cotransfected HEK293 cells in the presence of 
Ostl and HAX1. HEK293 cells were transfected with the indicated combinations of expression 
plasmids. DNA amounts were YFP-HAX1 and/or CFP-Ostl, 3 µg; HA-Ubi and/or His-Ubi, 1µg, per 
35 mm dish. Cells were harvested 48 hr after transfection, and extracts were immunoprecipitated with 
anti-GFP antibody. In the upper panel the protein lysates are shown. Immunoprecipitated material, 
shown in the upper panel, was taken for in vitro ubiquitination reactions in the presence of His-Ubi 
(lanes 3 and 6) or HA-Ubi as negative control (lanes 2 and 5). Reaction products were resolved by 
SDS-PAGE, followed by Western blot analysis with an anti-GFP antibody. Positions of molecular size 
markers are indicated on the right and represented HAX1 + YFP vector (35 kDa+27 kDa). 
 
 
Figure 6.40: Test of in vitro ubiquitination with cotransfected HEK293 cells in the presence of 
OSTL and SIVA. HEK293 cells were transfected with the indicated combinations of expression 
plasmids. Amounts of DNA were SIVA-YFP and/or OSTL-CFP, 3 µg; HA-Ubi and/or His-Ubi, 1µg, 
per 35 mm dish. Cells were harvested 48 hr after transfection, and extracts were immunoprecipitated 
with a SIVA-specific polyclonal antibody. In the upper panel the protein lysates are shown. 
Immunoprecipitated material, shown in the upper panel, was used for in vitro ubiquitination reactions 
in the presence of His-Ubi (lanes 3 and 6) or HA-Ubi as negative control (lanes 2 and 5). Reaction 
products were resolved by SDS-PAGE, followed by Western blot analysis with an anti-GFP antibody. 
Positions of molecular size markers are indicated on the right and represented SIVA+YFP (17 kDa+27 
kDa). 
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6.8. Overexpression of Ostl in primary hematopoietic cells 
To analyze whether the ectopic expression of the Ostl gene is able to transform early murine 
hematopoietic progenitors we expressed Ostl in murine bone marrow cells using a MSCV-
based retroviral construct.  
 
Cloning 
The mouse Ostl cDNA insert was subcloned into the modified MSCV retroviral vector with a 
green fluorescent protein (GFP) selection marker (called MIG). mOstl was PCR amplified 
with the primers OSTLj16T302XhoI and OSTLj16B1272XhoI (see table 5.1 for primer 
informations) and cloned into the XhoI restriction site of MIG. The construct was sequenced 
for us using the primers pMSCV-F and pMSCV-R (see table 5.1) to confirm the correct 
orientation of the insert. Figure 6.41 chematically represent the MIG-Ostl construct. 
 
 
 
Figure 6.41 Schematic diagram of MSCV-mOstl construct. MSCV based retroviral vector were 
used to express whole mouse Ostl in murine Bone marrow. LTR = long terminal repeats; IRES = 
internal ribosomal entry site; GFP = green fluorescente protein.  
 
 
Results of in vitro assays 
 
6.8.1. Ectopic expression of Ostl in vitro is not enough to induce cell proliferation 
or blast colony formation 
We checked the proliferative potential of bone marrow (BM) cells transduced with Ostl in 
vitro by analyzing sorted GFP positive cells (see 5.10.4.1). Expression of Ostl after 2 weeks 
in liquid expansion cultures (supplemented with IL-3, IL-6 and SCF) compared to BM cells 
transduced with GFP as a control did not show any significant (8.8±12.4) proliferation 
advantage (p>0.05) of Ostl-transduced cells (Figure 6.42). 
Cells expressing Ostl were not able to grow in liquid culture supplemented only with IL-3 for 
longer than one week and did not show blast cell morphology. 
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Cytomorphological analysis of the cultured cells showed that BM cells expressing the Ostl 
gene and GFP were able to differentiate to normal terminally differentiated macrophages and 
granulocytes (data not showed). 
 
 
 
Figure 6.42 Ectopic expression of Ostl is not enough to increase the proliferation rate or to block 
cell differentiation. BM cells expressing Ostl did not show a significant proliferative advantage 
compared to GFP transduced cells (N=3) in liquid expansion medium supplemented with cytokines 
(IL-3, IL-6, and SCF). The symbols represent three independent experiments. 
 
 
Results in vivo 
 
6.8.2. Ectopic expression of Ostl in vivo leads to leukemia in transplanted mice 
To analyze whether the ectopic expression of Ostl is able to transform early murine 
hematopoietic progenitors in vivo, total retrovirally transduced murine hematopoietic 
progenitors were injected into lethally irradiated recipient mice without sorting (6 x 105 – 
1.2 x 106 cells/mouse; containing around 4% GFP+ cells). 
Mice transplanted with BM cells expressing Ostl became moribund after a median of 300 
days post transplantation (n=3) (Figure 6.43). Diseased mice were characterized by 
cachexia, shortness of breath and lethargy, at which time they were sacrificed for further 
analysis. All Ostl mice analyzed (n=4) suffered from splenomegaly with an average spleen 
weight of 400 mg (4 fold increase compared to control animals).  
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Immunophenotypic characterization of cells from BM and spleen from the Ostl leukemic 
mice showed predominance of lymphoid CD4+CD8+ cells (∼96% in the BM; 82% in the 
spleen; n=2) compared to the MIG control mice (∼0.1% in the BM; ∼1% in the spleen; n=1) 
(Figure 6.44). 
Unfortunately, the cells obtained from diseased Ostl mice were not GFP positive. To 
confirm the expression of the Ostl gene in these cells, we extracted RNA and we were able 
to show by RT-PCR the Ostl expression, using appropriate controls and primers from OSTL 
gene (E06 OSTL 374T and E06 OSTL 734B) (see table 5.1). RT-PCR was performed using 
normal and leukemic mouse cell subpopulations. In figure 6.45 the lower panel shows the 
mouse GAPDH (mGAPDH) control and the upper panel, lanes 1-6 are show 
subpopulations from normal mice. Ostl expression could be observed in Gr-1+Mac-1+ cells, 
a very weak expression was detected by B220+CD19+ and CD4+CD8+ subpopulations. On 
the other hand, strong expression of Ostl was observed in the T-ALL CD4+CD8+ cell 
subpopulation (Figure 6.45 lane 7). 
 
 
 
Figure 6.43 Survival of transplanted mice. Survival curve of mice transplanted with BM cells 
expressing Ostl (n=3), MIG (n=6), and of secondarily transplanted mice (n=2). 
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Figure 6.44 Ostl expression increases the proportion of early T cells and reduces that of myeloid 
cells. Immnophenotyping of the BM and spleen of Ostl diseased mice showed a predominance of 
lymphoid CD4+, CD8+ cells (n=2). The Gr-1+, Mac-1+ myeloid subpopulations in the BM and spleen 
were greatly reduced compared to MIG control mice. 
 
 
 
 
Figure 6.45 Ostl expression in normal and leukemic mice cell subpopulations. mGAPDH primers 
were used as control in the lower panel, lanes 1-6 represent cell subpopulations from BM and spleen 
of normal C57bl mice and lane 7, CD4+ CD8+ cells from spleen of the T-ALL C57bl mouse. 
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6.8.3. Immunohistochemistry showed blast infiltration in multiple organs 
Histopathology report of one of these diseased Ostl mice (performed at the GSF Institute of 
Pathology by Dr. Leticia Quintanilla-Fend) showed that liver and kidney were diffusely 
infiltrated with neoplastic cells characterized by small to medium-sized cells with open 
blastic chromatin, one small nucleolus and inconspicuous chromatin (Figure 6.46). The 
cells showed a high mitotic index with abundant tingible body macrophages. 
Immunohistochemistry performed with anti-CD3 and Tdt showed positivity for both 
markers (Figure 6.46 E, G, and H). Cells were negative for PAX5 and B220 (Figure 6.46 F 
and I). These findings suggested a diagnosis of a T-cell acute lymphoblastic leukemia (T-
ALL). Wright-Giemsa-stained cytospins of BM and spleen demonstrated the lymphoblastic 
nature of disease (Figure 6.47). 
 
 
 
Figure 6.46 Histological analysis of diseased Ostl (T-ALL mouse) showed multiple organ 
infiltration of blast cell population. Histological analysis of diseased Ostl mouse. A) Liver (H&E 
stainning) immuno-histochemistry showed that the liver is hypercellular (160X); B, C and D) Kidney 
(H&E staining) showed that the kidney is hypercellular (200X and 650X); E) Histology of the kidney 
showed positivity for Tdt (650X); F) negativity for PAX5 (650X) and G and H) positiviy for CD3 
(200X and 650X) and I) negativity for B220 (650x). 
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Figure 6.47: Cytospin of BM and spleen of a diseased mouse (T-ALL) confirmed the 
lymphoblastic phenotype. Cytospin preparations of BM and spleen were analyzed after Giemsa 
staining and photographs were taken with an inverted microscope (Axiovert-135, Zeiss) at 250X. 
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7. Discussion 
 
7.1. Identification and characterization of OSTL gene 
Since the identification of ETV6 about a decade ago it has become increasingly clear that 
ETV6 plays an important role in various forms of leukemia (Golub, 1994a, b; Kobayashi, 
1994; Buijs, 1995; Golub, 1995; Sato, 1995; Papadopoulos, 1995; Romana, 1995a; Shurtleff, 
1995). Recently several studies and reviews have examined the role of ETV6 in hematologic 
malignancies (Belloni, 2004; Tirado, 2005; Vieira, 2005; Bohlander, 2005).  
The mechanism that is used by ETV6 to effect malignant transformation appears to be 
variable. Not only have numerous fusion partners of ETV6 been reported but ETV6 was also 
found to be deleted frequently while the other ETV6 allele was affected by a translocation 
(Raynaud, 1996; Romana, 1996; Bohlander, 2005). The occurrence of this two-hit pattern 
(one allele is rearranged and the other is deleted) is unusual among genes known from 
translocation breakpoints. 
The t(6;12)(q23;p13) translocation involving ETV6 at 12p13 was found in a cell line derived 
from the malignant blasts of a child with B-cell precursor ALL (Suto, 1997). Up to now, this 
is the only ALL or leukemia case with this translocation. However, two cases of a similar 
t(6;12)(q21;p13) were observed in a large series of childhood ALLs; in both cases a pre-B 
immunophenotype was observed (Hayashi, 1990). Although the breakpoints were reported as 
6q21 in this series, it is not clear whether they were really different from the 6q23 case. The 
t(6;12) in the SUB-B2 cell line was only correctly identified after fluorescence in situ 
hybridization (FISH) analysis with probes from 12p. The original karyotype was reported to 
have a t(2;4;12)(q13;q25;p13) and a del(6)(q23q27). It could be that the 6;12 translocation is 
more common than conventional cytogenetic analysis suggests. This was also the case with 
the t(12;21)(p13;q22), which had only been reported in very few cases of childhood ALL by 
traditional cytogenetics (Romana, 1994), but which was found to be the most common 
translocation in childhood ALLs ten years ago (Golub et al., 1995; Romana, 1995b). 
The molecular analysis of the (6;12) translocation in SUB-B2 identified a partner gene of 
ETV6 on chromosome 6 that was named STL (Six twelve Leukemia gene) (Suto, 1997). Like 
with all the previous translocations partners of ETV6 (PDG-FRB, ABL, CBFA2, and MN1), 
was expected to find a gene with a long open-reading frame. Instead, a fusion mRNAs was 
identified that showed no long open-reading frame (ORF) which would continue the ORF of 
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ETV6 either in the ETV6/STL fusion transcript or in the reciprocal STL/ETV6 fusion transcript 
(Figure 4.11 A). 
Suto et al., 1997 tried two different strategies to characterize the STL gene: the first was to 
clone the mouse homologue of STL, to be able to identify human and murine conserved 
sequences. The second strategy was the use of a 3’ probe of STL from the t(6;12) breakpoint, 
but this was also not successfully. A 5’ STL probe was able to identify human and mouse 
homologuous sequences of the STL gene in Genbank. Intriguingly, an EST (Expressed 
Sequence Tag) was identified that belonged to a gene transcribed in the opposite direction to 
the STL gene. This gene was named for us OSTL (opposite STL). 
OSTL shares the first exon with STL but is transcribed in the opposite direction, as shown in 
figure 6.6. The t(6;12) translocation in SUB-B2 interrupts not only STL but might also affect 
the regulation of OSTL (Figure 6.1). 
OSTL was characterized by sequencing using a human and a mouse EST clones (see 6.1). The 
open-reading frame of mouse Ostl encodes a 307 aa protein and of human OSTL a 275 aa 
protein (Table 6.3) with a calculated molecular mass of 30 kDa (Figure 6.17). The OSTL 
protein contains three domains, a N-terminal variant RING finger (variant RING1), a DRIL or 
IBR domain and a C-terminal RING (RING2). These domains are evolutionarily highly 
conserved and have homologies in other genes from human, C.elegans, D. melanogaster, and 
S. cerevisae (Figures 6.4 and 6.5). The variant RING1 in OSTL has the same pattern as the C 
terminal RING (RING2) described in the human homologue of the Drosophila Ariadne gene 
(HHARI) (Capili, 2004). In the OSTL variant RING1 one of the apparently conserved metal 
binding ligand H4 is replaced by a Lys (Figure 7.1). The same situation is found in RNF14, a 
novel RING finger protein (RING finger 14) (Capili, 2004). 
However, in RNF14 and other proteins that belong to the RING-IBR-RING family, such as 
Ariadne-1, Parkin, PARC, UIP28 (Capili, 2004) the amino acid residues show a consensus, 
which is not observed in OSTL (Figure 6.4 and 7.1). 
In OSTL C7 and C8 of variant RING1 are separated by 4 aa residues but only by two aa in 
the other proteins (Figure 7.1).  
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Figure 7.1: Schematic representation of RING finger domain consensus sequence and Variant RING 
1 sequence in OSTL. 
 
Comparison between human and mouse OSTL protein showed a 98% identity and between 
OSTL and puffer fish (Fugu rubripes) protein the identity is about 68% (Figure 6.5), 
suggesting an important, evolutionary conserved cellular function of this protein. 
Sequence analysis of OSTL revealed the presence of six exons and five introns (Tables 6.1 
and 6.2) and several alternatively spliced exons. However, only a minority of the alternatively 
spliced OSTL transcripts would code for longer proteins with functional domains (Table 6.3). 
At least seven “productive” alternatively spliced transcripts of OSTL were identified through 
sequencing and database searches (Table 6.4 and Figure 6.7). 
Our mouse multiple tissues Northern analysis with the mouse 5’ Ostl probe (Figure 6.8) 
revealed that Ostl is not very abundant in any of the tissues and the same was observed when 
human multiple tissue Northern blots were analyzed with a similar probe (Figure 6.9). The 
Ostl transcripts are not restricting to hematopoietic tissues as there is also strong expression in 
muscle tissue. Interestingly, the expression pattern of OSTL was similar to that observed for 
the STL gene, suggesting that these two genes are coregulated (Suto, 1997). Since we were 
not able to obtain the SUP-B2 cell line which was originally characterized by Zhang and 
coworkers in 1993 (it was lost in the freezer thaw of the 1999/2000 transition) we chose other 
B and B-related cell lines to perform the Northern analysis with the human 5’ OSTL probe 
(Figure 6.10). Like in the human multiple tissue Northerns, the OSTL mRNA was not very 
abundant in these cell lines. OSTL transcripts were detected in one B-NHL and three EBV 
transformed B cell lines (Figure 6.10). 
RT-PCR analysis detected expression of OSTL in two patient lymphoblastoid cell lines, a pre-
B cell line, and showed expression in another different B-NHL cell (Figure 6.11). This 
discrepancy could be explained by the presence of different alternatively spliced transcripts in 
these cell lines or variations in the RNA quality. 
Our RT-PCR using B-cells of different developmental stages (Figure 6.12) suggested the 
possible involvement of the gene in the course of B cell development. 
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We were able to show the OSTL expression in several B and also T-ALL samples from 
patients (Figures 6.13 and 6.14), demonstrating the presence of the gene in these types of 
leukemias. 
The OSTL protein is found predominantly in the cytoplasm (Figure 6.16). During mouse 
developmental, Ostl expression was detected in all embryos examined from E9.5 until E14.5 
dpc (Figure 6.18). 
In accordance with the Northern data where OSTL transcripts were observed in skeletal 
muscle and liver, in the mouse embryos, Ostl expression was mainly observed in the somites, 
during limb development and in the branchial arches (Figures 6.18, 6.19 and 6.20). The 
primitive gut and its derivatives (liver, thymus, etc) originate from the branchial arches (from 
the first until the sixth branchial arches).  
We attempted to express an OSTL-GST fusion protein in bacteria (Figure 6.21), which we 
planned to use for immunization to obtain OSTL antibodies, but we failed to obtain 
expression. This was probably due to the high number of cysteines in the OSTL protein. For 
such proteins, it has been reported that the proteins do not fold correctly and may be toxic for 
the bacteria. To circumvent this problem one could express an insoluble OSTL fusion protein 
(e.g. with tiorredoxin or the maltose binding protein). 
7.2. The protein interaction partners of OSTL  
In a yeast two hybrid screen we were able to identify several OSTL-interacting proteins from 
a Hela-cDNA bank (Figure 6.22). Interestingly, two OSTL-interacting proteins are involved 
in B-cell survival and B-cell receptor signaling. 
 
HAX-1 (HS1-associated protein X-1) was first described to interact with HS1 in B-cells 
(Suzuki, 1997). HS1 (hematopoietic lyn substrate 1) is a component of the B-cell receptor 
(BCR) signaling pathway, its expression restricted to hematopoietic cells and it is rapidly 
tyrosine phosphorylated by a variety of non-receptor tyrosine kinases after lymphocytes 
stimulation (Kitamura, 1989; Yamanashi, 1993; Brunati, 1995). The activity of HS1 and 
possibly HAX1 may be important for survival of lymphocytes (Taniuchi, 1995; Suzuki, 
1997). Suzuki and coworkers found that the HAX1 open reading frame encoded a protein 
consisting of 279 amino acids (Figure 7.2 A) with a calculated molecular mass of 35 kDa. 
The HAX1 protein is hydrophilic, but contains a presumptive membrane-spanning 
hydrophobic domain at its carboxy terminus. 
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HAX1 as a whole has no significant homologies to other proteins, but shows some similarity 
to Nip3, which has been reported to interact with the adenovirus E1B and Bcl-2 protein 
(Boyd, 1994). HAX-1 possesses two Bcl-2 homologous domains BH1 and BH2 that are 
conserved among the Bcl-2 family proteins and are known to be critical for the regulation of 
apoptosis (Figure 7.2 A) (Yin, 1994; Suzuki, 1997). HAX1 contains a PEST sequence, 
suggesting that this protein may be degraded rapidly (Rogers, 1986) (Figure 7.2 A). Its 
mRNA is found in all tissues suggesting an essential function of this gene in intracellular 
signaling (Suzuki, 1997). The HAX1 protein has been reported to localize to the 
mitochondria, cytoplasm or plasma membrane (Suzuki, 1997; Gallagher, 2000; Dufva, 2001; 
Sharp, 2002). 
HAX1 interacts with the polycystic kidney disease protein (PKD2) and this interaction 
probably mediates its association with the actin cytoskeleton (Gallagher, 2000). 
Interaction between HAX1 and Epstein-Barr virus nuclear antigen leader protein (EBNA-LP 
or EBNA5) was demonstrated by Kawaguchi, 2000 and by Dufva, 2001 and again suggesting 
a role of HAX1 in apoptosis. 
Recently a model of complex formation was proposed for the EBNA-LP, HAX1 and Bcl-2 
proteins. EBNA-LP interacts with HAX1 via its nuclear localization signal (NLS) and HAX1 
associates with Bcl-2 through its BH2 domain, further supporting the hypothesis that HAX1 
is a regulator of apoptosis (Matsuda, 2003). Yin and coworkers in 2001 reported interaction 
between HAX1 and IL-1α and suggested that HAX1 may modulate multiple facets of the N-
terminal peptide of interleukin-1α (IL-1 NTP) biochemistry. 
Through interaction between HAX1 and Kaposi’s Sarcoma-associated herpesvirus protein 
(K15), Sharp and coworkers in 2002 were able to show that HAX1 is able to block BAX 
induced apoptosis (BAX is a Bcl-2 family member with a strong proapoptotic function). 
HAX1 was found to be upregulated in psoriatic lesions (Mirmohammadsadegh, 2003). 
Mirmohammadsadegh and coworkers analyzed UBV-induced apoptosis in HaCaT 
keratinocytes overexpressing HAX1 mRNA or its antisense and found further evidence for the 
role of HAX1 in antiapoptotic processes.  
HAX1-specific antisense led to a marked increase in caspase-3 mediated apoptosis, strongly 
suggesting an antiapoptotic role for HAX1 (Mirmohammadsadegh, 2003). HAX1 interacts 
with bile salt export protein (BSEP) and regulates its abundance in the apical membrane of 
Madin-Darby canine kidney cells (Ortiz, 2004). A mechanism was proposed suggesting 
HAX1 involvement in clathrin-mediated endocytosis: BSEP and HAX1 are present in 
clathrin-coated vesicles; expression of dominant negative EPS15, which selectively blocks 
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clathrin mediated endocytosis (Benmerah, 1999), doubled the apical membrane concentration 
of BSEP; and expression of dominant negative cortactin also doubled the amount of BSEP in 
the apical membrane. Cortactin, an actin and HAX1-binding protein, participates in clathrin 
endocytosis (Lynch, 2003; Cao, 2003). 
HAX1 interacts with Gα13, the α-subunit of the heterotrimeric G protein G13, this protein has 
been shown to stimulate cell migration in addition to inducing oncogenic transformation 
(Radhika, 2004). 
HAX1 potentiate activation of Rac through Gα13; Rac stimulates the translocation of cortactin 
(Patel, 1998; Weed, 1998); cortactin stimulates actin polymerization leading to lamellipodia 
formation (Weed, 1998; Uruno, 2001; Uruno, 2003); and HAX1 promotes Gα13-mediated cell 
motility, suggesting that Gα13 and HAX1 are part of a signaling complex involved in cell 
motility (Radhika, 2004). 
Finally, HAX1 interacts with Omi/HtrA2, a nuclear-encoded mitochondrial serine protease 
that has a pro-apoptotic function in mammalian cells (Cilenti, 2004). Cilenti and coworkers 
could show that through this interaction, Omi cleaves HAX1 and can initiate apoptosis from 
mitochondria. 
In our work we could show interaction between OSTL and HAX1 and this interaction was 
confirmed by using in vivo and in vitro assays. Interestingly, by using OSTL as bait in a yeast 
two hybrid assay we were able to identify eight different HAX1 clones (Figure 6.25). We 
selected three clones (2, 3, and 5) and confirmed the interaction by cotransformation assay in 
yeast (Figure 6.26). Further assays to confirm the interaction between OSTL and HAX1 were 
performed using HAX1 clone 5, which contains almost the whole HAX1 cDNA (Figure 6.25). 
The interaction was mapped by cotransformation between different Ostl mutants with HAX1 
clone 5 (Figure 6.29). The OSTL variant RING1 (the N terminal RING finger of OSTL) 
seems to be involved in the interaction with HAX1 (Figure 6.29). 
Surprisingly, Ostl mutants 1 and 3 (lanes 2 and 4 in figure 6.29) did not show any interaction 
with HAX1 (any growth in the yeast cotransformation), although they have only one amino 
acid that is different from the Ostl mutant 2 and human OSTL (lanes 3 and 8 in figure 6.29) 
which are capable of interaction with HAX1 (they showed a very nice growth in the yeast 
cotransformation assay). In Ostl mutants 2 and 4 a serine (S) at position 2 is substituted by a 
adenine (A), this substitution might be responsible for the difference observed in the 
interaction assay (Figure 6.29). 
The interaction between OSTL and HAX1 was also confirmed in mammalian cells (NIH3T3) 
by cotransfection assays (Figure 6.32), where we could show colocalization of both proteins 
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in the cytoplasm of the mouse fibroblast cells. Colocalization was also observed in the 
mitochondria (data not showed). 
The in vitro confirmation of interaction was by coimmunoprecipitation using S35 labeled myc-
GAL4DBD-OSTL and HA-GAL4AD-HAX1 proteins. Both proteins could be coprecipitated 
using an anti myc antibody (Figure 6.35). 
CFP-OSTL and YFP-HAX1 overexpressed in 293 cells could be coprecipitated (Figure 6.36). 
This assay confirmed in vivo the association of the two proteins. 
 
 
Figure 7.2: A) Schematic representation of HAX1 amino acid (aa) sequence and domains. BCL-2 
homology domains 1 and 2 (BH1 and -2), a PEST domain, and a transmembrane domain (TMD) are 
indicated (Figure adapted from Sharp, 2002). B) Schematic representation of Siva-1 and Siva-2 aa 
sequences. A death domain homology region (DDHR), and a cysteine-rich domain are represented in 
Siva-1 diagram. Siva-2 lacks the exon 2, corresponding to the 65 aa of the DDHR (Figure adapted 
from Py, 2004). 
 
SIVA (from Shiva, the Hindu god of destruction) was first described to bind to the CD27 
cytoplasmic tail in a yeast two hybrid assay and function as a proapoptotic protein (Prasad, 
1997). The human SIVA protein contains 189 aa (Prasad, 1997), the rat Siva 177 aa. Human 
and rat SIVA are 92% homologous (Padanilam, 1998). Analysis of the primary amino acid 
sequence revealed an amino-terminal region that has a 40% homology to the death domains 
(DDs) of FADD and RIP. The homologies between SIVA and TRADD/Ankyrin DDs is 16% 
and between SIVA and FADD DDs 14% (Yoon, 1999). SIVA has a carboxy-terminal region 
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rich in cystein residues that could form a B-box-like ring finger (Yang, 1997) (Figure 7.2 B). 
The B-box region of SIVA, however, lacks any histidine residues. The amino-terminal RING 
finger and the carboxy-terminal coiled-coil domain, which are characteristic of other B-box-
containing proteins (Yang, 1997), are absent in SIVA. Instead, SIVA has additional cystein 
residues at the carboxy terminus that can potentially form a zinc finger (residues 164-184 in 
the human SIVA). 
Alternatively, the Cys-rich region of SIVA could represent a novel metal binding motif 
involved in either protein-protein or protein-DNA interactions. The architecture of SIVA is 
unlike that of any other protein known to bind to the cytoplasmic tails of TNFR family 
members. The human SIVA mRNA is expressed mainly in thymus and testis, but also in 
spleen, prostate, ovary, small intestine, PB and to a lesser amount in colon. The SIVA 
expression was also observed in some cell lines including HL60, HeLa, Raji, K562, MOLT4, 
SW480, and G361 (Prasad, 1997). In 1997 Prasad and coworkers could demonstrate the 
proapoptotic properties of SIVA in various cell lines (293, Jurkat, Raji, a murine pre-B cell 
(SKW), and Ramos) by transiently expressing SIVA as a GFP fusion protein. 
In 1999, Yoon and coworkers showed that mouse SIVA is 80% homologous to human SIVA. 
The murine Siva mRNA is mainly expressed in testis, muscle, and heart with brain expressing 
the least. Two forms of mouse Siva cDNA were identified by Yoon and coworkers. The 
longer form was named Siva-1 and the shorter form Siva-2 (Yoon et al., 1999) (Figure 7.2 B). 
Part of the amino terminal region and most of the death domain homology region (DDHR) 
including the conserved 13 amino acids stretch is missing in Siva-2. Although Siva-2 lacks the 
major portion of the DDHR, it showed association with the cytoplasmic tail of the CD27 
receptor, as did Siva-1 (Figure 7.2 B). However, murine and human SIVA-2 are much less 
proapoptotic than SIVA-1 (Yoon, 1999). SIVA was also reported to be up-regulated in 
colorectal cancer (Okuno, 2001) and research groups have recently reported the apoptotic 
activity of SIVA (Lin, 1999; Xiao, 2000; Henke, 2000; Cao, 2001; Qin, 2002; Xue, 2002; 
Spinicelli; 2002; Daoud, 2003; Chu, 2004; Seseke, 2004; Py, 2004; Fortin, 2004; Novikowa, 
2005). 
We found interaction between OSTL and the proapoptotic human SIVA-1 in our yeast two 
hybrid assay (Tables 6.6 and 6.8; Figure 6.25; and attachment 4). We were able to confirm the 
interaction through in vivo (Figure 6.33, 6.37) and in vitro assays (Figure 6.26, 6.30). The 
RING finger at the N terminal region of OSTL (variant RING1) and the C terminal region of 
OSTL seems to be involved in the interaction between OSTL and SIVA (Figure 6.30). 
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The mapping of OSTL-SIVA interaction showed the same pattern of yeast growth that was 
observed for the OSTL-HAX1 interaction mapping. The amino acid substitutions (V→Q), is 
probably responsible for the negative interaction results between Ostl mutants 1 and 3 and 
SIVA (Figures 6.29 and 6.30). 
CFP-OSTL and YFP-SIVA overexpressed in 293 cells could be coprecipitated (Figure 6.37). 
This assay confirmed in vivo the association of the two proteins. 
Summarizing our yeast two hybrid data, we propose a functional pathway for OSTL through 
its interaction with HAX1 and SIVA (Figure 7.3). SIVA and HAX1 are involved in pro- and 
antiapoptotic decisions in the cell, respectively.  
 
 
 
Figure 7.3: Hypothetical role of OSTL mediated through its interactions with HAX1 and SIVA. 
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7.3. Functional characterization of Ostl  
Most of RING finger proteins function as E3 ubiquitin protein ligases in the ubiquitin 
conjugation pathway where they catalyze the transfer of an activated ubiquitin from an E2 
ubiquitin conjugating enzyme to a substrate protein (Joazeiro, 2000; Fang, 2003). In our 
work, we performed an ubiquitination assay using HAX1 and SIVA as possible substrates for 
Ostl function as an E3 ubiquitin ligase (Figures 6.39 and 6.40). But neither HAX1 nor SIVA 
showed increased ubiquitination in this assay. However, these results do not completely rule 
out that Ostl functions as an E3 ubiquitin protein ligase. More potential Ostl substrates have 
to be tested.  
In order to investigate the potential of Ostl to transform primary hematopoietic cells, we 
overexpressed Ostl in primary bone marrow cells and assayed the transforming activity in 
various assays.  
In vitro assays, such as liquid culture assays in the presence of myeloid cytokines (IL-3, IL-6, 
and SCF) did not show a significant transformation potential of Ostl, in comparison to GFP 
positive cells (MIG) or to negative cells (Mock) (Figure 6.42). However, when we 
overexpressed Ostl in vivo, injecting lethally irradiated mice with Ostl-positive cells, 
leukemias developed after a median of 300 days (Figure 6.43). The immunophenotypic and 
histopathologic analysis of the leukemic mice revealed a T-ALL (Figures 6.44 and 6.46). The 
BM and spleen cells from such an Ostl-induced T-ALL showed 96% positivity for CD4 and 
CD8 as shown in figure 6.44. The histopathology of one of the mice showed multiple organ 
infiltration with blasts cells, which were positive for CD3 and Tdt (Figure 6.46). Figure 6.47 
shows the microscopic analysis of BM and spleen from an Ostl-induced T-ALL, with a high 
percentage (more than 60% of the cells) of lymphoid cells. The expression of the Ostl gene in 
the leukemic mice was assayed by RT-PCR (Figure 6.45). 
Although the expression of Ostl was observed only in the cell subpopulation of the leukemic 
mice and not in controls cells, the leukemic cells did not show expression of GFP. In order to 
confirm the presence of the OSTL carrying retrovirus in the leukemic cells of these mice we 
are in the process of analyzing the retroviral integration sites in these leukemias. It has been 
reported that retroviral integration by itself will only rarely lead to hematologic malignancies 
(Duesberg, 1987). This information strongly suggests that the expression of OSTL is the 
cause of the leukemias in our model. These OSTL-induced leukemias could be transplanted 
into secondary recipient mice, which also developed leukemia and died four weeks after 
injection of primary leukemic cells (Figure 6.43).  
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In 2005, Schessl and coworkers reported leukemia in mice expressing the AML1-ETO fusion 
gene and a FLT3 length mutation showing a latency period for the leukemia phenotype 
ranging from 100 until more than 600 days after transplantation. The 300 days latency of 
leukemia development observed in our model could be due to the need of secondary in vivo 
genetic events in the animals.  
OSTL was first identified in an B-cell acute lymphoblastic leukemia cell line, which a 
t(6;12)(q23;p13), and in our work its expression was also observed in leukemic cells with 
different immunophenotypes and genetic backgrounds. In our mouse model, Ostl caused a T-
ALL, but the high expression of this gene observed in AML and B-ALL patients might reflect 
the importance of this gene in a wider range of leukemias (Figures 6.13 and 6.14).  
Our data suggest that OSTL is one of the genes on the long arm of chromosome 6 that might 
be important in the development of childhood acute lymphoblastic leukemia (ALL) and 
lymphomas of B and T-cell types (Hayashi, 1990), and adult ALL (Merup, 1998). 
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9. Appendix 
 
1) BLAST search of HAX-1 (Hela clone 2) 
gi|15680006|gb|BC014314.1|   Homo sapiens HS1 binding protein, mRNA (cDNA clone 
MGC:22696 
IMAGE:3931852), complete cds 
Length = 1147 
 
Score =  638 bits (322), Expect = e-180 
Identities = 334/337 (99%), Gaps = 2/337 (0%) 
Strand = Plus / Plus 
 
Query: 49  cccaaccagcaccagactggggctcccagaggccatttcataggtttgatgatgtatggc 108 
           |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 543 cccaaccagcaccagactggggctcccagaggccatttcataggtttgatgatgtatggc 602 
 
Query: 109 ctatggacccccatcctagaaccagagaggacaatgatcttgattcccaggtttcccagg 168 
           |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 603 ctatggacccccatcctagaaccagagaggacaatgatcttgattcccaggtttcccagg 662 
 
Query: 169 agggtcttggcccggttctacagccccagcccaaatcctatttcaagagcatctctgtga 228 
           |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 663 agggtcttggcccggttctacagccccagcccaaatcctatttcaagagcatctctgtga 722 
 
Query: 229 ccaagatcactaaaccagatgggatagtggaggagcgccggactgtgggtgggacagtga 288 
           ||||||||||||||||||||||||||||||||||||||||||||||||   ||||||||| 
Sbjct: 723 ccaagatcactaaaccagatgggatagtggaggagcgccggactgtgg--tggacagtga 780 
 
Query: 289 gggccggacagagactacagtaacccgacacgaagcagatagcagtcctaggggtgatcc 348 
           |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 781 gggccggacagagactacagtaacccgacacgaagcagatagcagtcctaggggtgatcc 840 
 
Query: 349 agaatcaccaagacctccagccctggatgatgccttt 385 
           ||||||||||||||||||||||||||||||||||||| 
Sbjct: 841 agaatcaccaagacctccagccctggatgatgccttt 877 
 
Appendix 1: Genbank nucleotide sequence (156 nucleotides, primer Y2H2) of cDNA 2 (Query) 
 
2) BLAST search of HAX-1 (Hela clone 3) 
gi|15680006|gb|BC014314.1|   Homo sapiens HS1 binding protein, mRNA (cDNA clone 
MGC:22696 
           IMAGE:3931852), complete cds 
          Length = 1147 
 
 Score =  551 bits (278), Expect = e-154 
 Identities = 285/286 (99%), Gaps = 1/286 (0%) 
 Strand = Plus / Plus 
 
Query: 71  gggaacccaaggttccatagtcctcagcacccccctgaggaatttggcttcggcttcagc 130 
           |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 221 gggaacccaaggttccatagtcctcagcacccccctgaggaatttggcttcggcttcagc 280 
 
Query: 131 ttcagcccaggaggagggatacgtttccacgataacttcggctttgatgacctagtacga 190 
           |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 281 ttcagcccaggaggagggatacgtttccacgataacttcggctttgatgacctagtacga 340 
 
Query: 191 gatttcaatagcatcttcagcgatatgggggcctggaccttgccttcccatcctcctgaa 250 
           |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 341 gatttcaatagcatcttcagcgatatgggggcctggaccttgccttcccatcctcctgaa 400 
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Query: 251 cttccaggtcctgagtcagagacacctggtgagagactacgggaggggacagacacttcg 310 
           |||||||||||||||||||||||||||||||||||||||||||| ||||||||||||||| 
Sbjct: 401 cttccaggtcctgagtcagagacacctggtgagagactacggga-gggacagacacttcg 459 
 
Query: 311 ggactcaatgcttaagtatccagatagtcaccagcccaggatcttt 356 
           |||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 460 ggactcaatgcttaagtatccagatagtcaccagcccaggatcttt 505 
 
Appendix 2: Genbank nucleotide sequence (156 nucleotides, primer Y2H2) of cDNA 3 (Query) 
 
3) BLAST search of HAX-1 (Hela clone 5) 
gi|1916621|gb|U68566.1|HSU68566  Human HS1 binding protein HAX-1 mRNA, nuclear gene 
encoding mitochondrial  
            protein, complete cds 
          Length=1196 
 
 Score =  248 bits (125),  Expect = 6e-63 
 Identities = 127/128 (99%), Gaps = 0/128 (0%) 
 Strand=Plus/Plus 
 
Query  125  CTGCGAATGGACCACTGGAGGGGTTCAAAGGTTCGCGTCCCAGTACGGGAATGAGCCTCT  184 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  112  CTGCGAATGGACCACTGGAGGGGTTCAAAGGTTCGCGTCCCAGTACGGGAATGAGCCTCT  171 
 
Query  185  TTGATCTCTTCCGGGGCTTTTTCGGCTTTCCTGGACCTNGGAGCCACAGAGATCCCTTTT  244 
            |||||||||||||||||||||||||||||||||||||| ||||||||||||||||||||| 
Sbjct  172  TTGATCTCTTCCGGGGCTTTTTCGGCTTTCCTGGACCTCGGAGCCACAGAGATCCCTTTT  231 
 
Query  245  TTGGAGGG  252 
            |||||||| 
Sbjct  232  TTGGAGGG  239 
 
Appendix 3: Genbank nucleotide sequence (156 nucleotides, primer Y2H2) of cDNA 5 (Query) 
 
4) BLAST search of SIVA ( Hela clone 7) 
>gi|11277467|ref|NM_006427.2|   Homo sapiens CD27-binding (Siva) protein (SIVA), 
transcript variant 1, mRNA 
Length = 751 
 
Score =  377 bits (190), Expect = e-102 
Identities = 194/196 (98%) 
Strand = Plus / Plus 
 
Query: 78  gcggccatgcccaagcggagctgccccttcgcggacgtggccccgctacagctcaangtc 137 
           |||||||||||||||||||||||||||||||||||||||||||||||||||||||| ||| 
Sbjct: 32  gcggccatgcccaagcggagctgccccttcgcggacgtggccccgctacagctcaaggtc 91 
 
Query: 138 cgcgtgagccaganggagttgagccgcggcgtgtgcgccgagcgctactcgcaggaggtc 197 
           ||||||||||||| |||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 92  cgcgtgagccagagggagttgagccgcggcgtgtgcgccgagcgctactcgcaggaggtc 151 
 
 
Query: 198 ttcgagaagaccaagcgactcctgttcctcggggcccaggcctacctggaccacgtgtgg 257 
           |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 152 ttcgagaagaccaagcgactcctgttcctcggggcccaggcctacctggaccacgtgtgg 211 
 
Query: 258 gatgaaggctgtgccg 273 
           |||||||||||||||| 
Sbjct: 212 gatgaaggctgtgccg 227 
 
Appendix 4: Genbank nucleotide sequence (195 nucleotides, primer Y2H2) of cDNA 7 (Query) 
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